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1. Summary 
 
Personalized therapy is a matter of current discussion in the medical community. It consists of adapting 
the choice of a drug and its posology to the specific profile of a subject (genotype and phenotype) or to 
its disease (i.e. specific cancer biology). Activity of drug metabolizing enzymes depends on the genotype 
and extrinsic factors which together determine the phenotype of a subject. Therefore a precise 
characterization of a patient phenotype will guide the physicians efforts to personalize therapy and thus 
improve efficacy and reduce side effects. This approach requires specific and easy to use diagnostic 
tools that are not yet available in clinical routine. With our work, we explored possible ways to promote 
phenotyping of drug metabolizing enzymes as a valuable tool for personalized medicine. 
In this dissertation we describe the development of a new phenotyping cocktail (Basel cocktail) 
containing caffeine, efavirenz, losartan, omeprazole, metoprolol, and midazolam as probe drugs for 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, respectively. We validated the new 
phenotyping procedure in two clinical studies in healthy volunteers: the Basel cocktail studies I and II. 
With the data acquired in study I, the absence of mutual interactions between the new combinations of 
probe drugs selected for the Basel phenotyping cocktail was established. Furthermore we showed that 
evaluation of the metabolic ratios in plasma at single time-points can replace conventional full AUC 
measurements. Additionally, the use of dried blood spots (DBS) and saliva as minimally or non-invasive 
sampling collection procedures were explored. 
For a comprehensive evaluation of the new phenotyping cocktail, the influence of genetic factors or co-
administration of an enzyme inducer or inhibitor on the metabolic ratios of the Basel cocktail had to be 
assessed. The Basel cocktail study II was performed to characterize the range of the chosen phenotyping 
metrics under conditions of induction and inhibition. Additionally we measured the metabolic ratios in 
saliva and DBS.  
Bioanalysis and genotype determination were key tools for this project. We developed and validated 
bioanalytical methods for simultaneous detection of probe drugs and their main metabolites in different 
human matrices. To maintain clinical applicability, short return times were required. Therefore highly 
sensitive bioanalytical methods with simple sample work-up and short run-times were developed. Study 
subjects providing consent were genotyped for the most relevant single-nucleotide polymorphisms and 
when possible correlations between genotype and phenotype were assessed. 
In the Basel cocktail studies I and II, the lowest commercially available doses and formulations of the 
phenotyping drugs were used. To simplify probe drug administration, a prototype of a combi-pill 
containing all six cocktail probe drugs was developed and tested in a single subject in a clinical pilot 
study. Pharmacokinetic profiles of the new formulation were comparable with the ones obtained after 
intake of the individual probe drugs in the commercial formulations. This new cocktail combi-pill will be 
formally evaluated in a clinical study (Basel cocktail study III) in healthy volunteers.  
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The use of phenotyping information to personalize cancer therapy with tyrosine kinase inhibitors is 
under investigation in an ongoing clinical trial. Individual CYP3A4 and CYP1A2 phenotype will be 
assessed using probe drugs of the Basel cocktail and the correlation of the phenotyping metrics with 
sunitinib, pazopanib or erlotinib exposure will be analyzed. 
Taken together the work performed during this dissertation was important to improve the clinical 
applicability of phenotyping, which is essential to move this important tool for personalized medicine 
closer to the clinical routine. 
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2. Abbreviations 
 
AUC    Area under the curve 
CYP    Cytochrome P450 
Cmax     Peak plasma concentration 
CTC    Common Toxicity Criteria 
DBS    Dried Blood Spot 
DMSO     Dimethyl sulfoxide 
EU    European Union 
FDA    Food and Drug Administration 
HILIC     Hydrophilic Interaction Liquid Chromatography  
HPLC    High Performance Liquid Chromatography 
i.v.    Intravenous 
KTI    Kommission für Technologie und Innovation 
LC-MS/MS   Liquid Chromatography-Triple quadrupole Mass Spectrometry 
MR    Metabolic Ratio 
SPE    Solid Phase Extraction 
tmax    Time corresponding to peak plasma concentration 
t ½    Half-time 
TDM    Therapeutic Drug Monitoring 
UHPLC    Ultra-high Pressure Liquid Chromatography 
UPLC Ultra Performance Liquid Chromatography (Trademark of Waters 
Corporation) 
VAS    Visual Analog Scale 
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3. Introduction 
 
3.1. Phenotyping of Drug Metabolizing Enzymes using a “Cocktail” Approach  
 
Cytochrome P450 (CYP) enzymes, a superfamily of haemoproteins, are the terminal oxidases of the 
mono-oxygenase system. They are involved in the oxidative, reductive and peroxidative metabolism of 
numerous endogenous compounds and xenobiotics [1]. 
The six major human CYP enzymes involved in the metabolism of drugs are (in order of quantitative 
contribution) CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP2E1, and CYP1A2 [2]. CYP2D6, CYP2C9, CYP2C19, 
and CYP1A2 are polymorphically expressed, leading to high interindividual variation in CYP enzyme 
activities [3]. 
In subjects with an increased enzyme activity due to induction or over-expression of the CYP enzyme, 
such as CYP2D6 ultrarapid metabolizers (UMs), a normal therapeutic doses can result in therapeutic 
failure due to decreased systemic exposure [4]. At the other end of the spectrum, reduced activity of 
CYP enzymes due to inhibition of CYP activity or in genetically poor metabolizers (PMs), can result in 
increased systemic exposure of their respective substrates, leading to a pharmacodynamic effect of 
increased intensity and/or duration.  
To optimize therapeutic effect, drug therapy has to be individualized according to a patient’s genotype 
and/or phenotype [5]. Extensive efforts have been directed to develop genotyping methods for 
detecting specific DNA mutations that determine individual drug metabolizing capacity. However, 
genotyping is not able to monitor changes of phenotype caused by non-genetic factors such as e.g. 
drug-drug interactions. Combination drug therapy is common in clinical practice and increases the risk 
for drug–drug interactions (DDIs). Many DDIs occur due to inhibition or induction of the cytochrome 
P450 system. In vitro hepatic microsomal studies can provide preliminary information about the CYP 
isoforms that are likely to be affected clinically. However, the potential to cause relevant DDIs in vivo 
needs to be investigated in clinical studies. In addition to interference with a patient’s phenotype, DDIs 
can cause significant safety problems resulting in delayed drug registration or early withdrawal from the 
market [6]. 
Therefore, there is a need for an easy and reliable phenotyping tool in clinical drug development for 
early identification of clinically relevant DDIs in vivo and in clinical practice to guide dose 
individualization in patient treatment.  
Phenotyping itself involves the administration of an appropriate substrate (i.e. probe drug) that is 
selectively metabolized to a known metabolite by a given CYP isoform. Metabolic ratios, i.e. the ratio of 
the concentration of the substrate to that of a specific metabolite in urine, plasma or saliva produced by 
the CYP isoform of interest are already extensively used as an index of CYP activity [7]. 
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Although many CYP isoforms exhibit overlapping substrate specificity [7], for some substrates a single 
CYP isoform is exclusively or to a major extent involved in a particular pathway of their metabolism [8]. 
For instance, metoprolol α-hydroxylation is mediated by CYP2D6 [7,9] and omeprazole 5-hydroxylation 
by CYP2C19 [10]. 
Phenotyping provides a measure of the activity of a given drug-metabolizing enzyme at a given time-
point, and takes into account not only genetic but also non-genetic and environmental (e.g. DDI) factors 
(Figure 1). 
 
Figure 1. Phenotyping and Genotyping 
When a compound with inhibitory potential is co-administered, the metabolism of the probe drug is 
impaired. When two or more isoforms are involved, several DDI studies may have to be performed to 
understand the full clinical interaction potential. In this case, a ‘cocktail’ approach provides a more 
efficient procedure than the traditional single probe, single study approach.  
The ‘cocktail’ approach involves the simultaneous administration of two or more probe drugs to a single 
subject to assess the activity of several distinct CYP isoforms [5]. By sequential administration of a well-
defined cocktail of probe drugs, the in vivo effect of a test drug (e.g. a new compound in clinical 
development) on clinically relevant CYP isoforms can be established within one clinical study. 
Before a combination of probe drugs can be used as a phenotyping cocktail, it has to be established that 
no pharmacokinetic interactions occur between the probe drugs of the cocktail. Furthermore, 
pharmacodynamic interactions would be of particular concern. Several probe drugs (e.g. losartan, 
metoprolol) can affect blood pressure when applied at therapeutic doses and could influence hepatic 
blood flow and consequently the metabolic clearance of co-administered probe drugs [11]. 
Although several phenotyping cocktails using different combinations of probe drugs have been 
published so far [8, 11-13], none of the proposed cocktails have gained clinical acceptance due to 
several draw-backs such as limited availability of the probe drugs, complicated sampling procedures or 
pharmacodynamic effects due to high doses of the probe drugs [5]. 
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Several improvements such as simplified phenotyping metrics [14], low- or micro-dose approach [15] or 
use of non-invasively accessible biological matrices, as for example oral fluid or dried blood spot (DBS), 
have been shown for midazolam or flurbiprofen [16, 17] but not for most of the other probe drugs. In a 
review paper, Fuhr et al. [18] pointed out the need for optimizing phenotyping procedures. 
Replacement of individual probe drugs, better validated metrics, doses reduction and simplification of 
the sampling procedures are mentioned as possible improvement to promote clinical use of the cocktail 
approach.  
Therefore, the main goal of this project was to develop and validate a new phenotyping cocktail using 
easily available probe drugs at the lowest clinically approved doses. To simplify sampling procedures, an 
appropriate phenotyping metric and optimal time-point for sparse sampling had to be defined. 
Furthermore we wanted to evaluate whether minimally or non-invasive sampling methods such as 
collection of dried blood spots or saliva samples could be used for phenotyping. In the following 
sections, selection and validation criteria of the new probe drug combination are described. The project 
involved the development and validation of two bioanalytical methods, two clinical studies, the Basel 
cocktail basic interaction study and the Basel cocktail induction/inhibition study, and a pilot study with a 
combi-pill containing in a single formulation the phenotyping drugs that constitute the cocktail. Finally 
an application of the phenotyping procedure for optimizing doses of tyrosine kinase inhibitors is 
presented.  
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3.2. Phenotyping cocktail combinations already published 
 
Several different phenotyping cocktails have already been described in literature (Table 1 adapted from 
Ghassbian [19] and Fuhr [18]). The name of the cocktail is often associated with the town where it was 
developed, hence the cocktail we developed is called the “Basel” cocktail. 
Table 1. Summary of published phenotyping cocktails 
Cocktail CYP isoforms Substrates 
Doses 
(mg)  
Availability 
of probe 
drug 
Phenotyping Metric Matrix 
Changsha[13] 1A2 Caffeine 100 ● MR P 6h P, U 
 2C19 Mephenytoin 100 
○ Ae 4'OHM 0-8h  
 2D6 Metoprolol 100 ● MR U 8h  
 2E1 Chlorzoxazone 200 ● MR P 4h  
  3A4 Midazolam 7.5 ● MR P 1h   
Cologne[20-23] 1A2 Caffeine 150 ● MR P 6h P, U 
 2B6 Mephenytoin 50 ● Ae Nirvanol 0-96h  
 2C9 Tolbutamide 125 
○ [Tolbutamide] P 24h  
 2C19 Mephenytoin 50 
○ Ae 4'OHM 0-12h  
 2D6 Dextrometorphan 30 ● MR U 8h  
 3A4 Midazolam 2 (1 i.v.) ● Fi P - CL P 0-12h  
 NAT2 Caffeine  ● MR U 6h  
  P-gp Digoxin 0.5 ● Cmax P 0-12h   
Cooperstown 
5+1[24] 1A2 Caffeine 2 mg/kg ● MR U 0-12h P, U 
 2C9 S-warfarine(+Vit K) 10 ● AUC  0-96h  
 2C19 Omeprazole 40 ● MR P 2h  
 2D6 Dextrometorphan 30 ● MR U 0-12h  
 3A4 Midazolam 
0.025 
mg/kg ● CL P 0-6(-12)h  
 NAT2 Caffeine 2 mg/kg ● MR U 0-12h  
  XO Caffeine 2 mg/kg ● MR U 0-12h   
Darmstadt[25] 1A2 Caffeine  100 ● AUC P 0-24h P, U 
 2C9 Diclofenac 50 ● AUC P 0-24h  
 2C19 Mephenytoin 100 
○ Ae 4'OHMn 0-8h  
 2D6 Metoprolol 100 ● AUC P 0-72h  
  3A4 Midazolam  7.5 ● AUC P 0-24h   
Indianapolis[26, 
27] 1A2 Caffeine 100 ● MR P 6h P, U 
 2C9 Tolbutamide 500 
○ CL/F P 24h  
 2D6 Dextrometorphan 30 ● MR U 24h  
  3A4 Midazolam 
5 (50 
mg/kg 
i.v.) 
● CL/F O 0-12h (CL P 0-12h)   
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Cocktail CYP isoforms Substrates 
Doses 
(mg)  
Availability 
of probe 
drug 
Phenotyping Metric Matrix 
Inje[28] 1A2 Caffeine  93 ● MR P 4h P, U 
 2C9 Losartan 30 ● MR U 8h  
 2C19 Omeprazole 20 ● MR P 4h  
 2D6 Dextrometorphan 30 ● Log MR U 8h  
  3A4 Midazolam 2 ● [Mid] P 4h    
Inje modified  1A2 Caffeine  100 ● MR P 4h P 
by Ghassabian[19] 2C9 Losartan 25 ● AUC R 0-6h  
 2C19 Omeprazole 20 ● MR P 4h or 6h  
 2D6 Dextrometorphan 30 ● AUC R 0-6h  
 3A4 Midazolam 2 ● [Mid] P 4h and AUC R 0-6h  
Jena[29] 1A2 Caffeine 200 ● AUC P 0-12h P, U 
 2D6 Debrisoquine 10 
○ MR U 0-6h  
  NAT2 Sulphamethazine 500 ○ MR U, P 0-6h, 6h   
Karolinska[30] 1A2 Caffeine 100 ● MR P 4h P, U 
 2C9 Losartan 25 ● MR U 0-8h  
 2C19 Omeprazole  20 ● MR P 3h  
 2D6 Debrisoquine  10 
○ MR U 0-8h (*)  
  3A4 Quinidine  250 ○ MR P 16h   
Leiden[31] 2C19 Mephenytoin 100 ○ Ae 4'OHMn 0-8(-48)h P, U 
 2D6 Spartein 25-90 
○ MR U 0-8h  
  3A4 Nifedipine 5-20  ● CL/F 0-8h   
Loughborough[11] 1A2 Caffeine  50 ● MR P 6.5h P, U 
 2C9 Tolbutamide 250 
○ MR U 6-12h  
 2D6 Debrisoquine 5 
○ MR U 0-6h  
 2E1 Chlorzoxazone 250 ● MR P 2.5h  
  3A4 Midazolam 25 mg/kg 
i.v. 
● CL P 0-12h   
Pittsbourgh[32] 1A2 Caffeine 100 ● MR P 8h P, U 
 2C9 Flurbiprofen 50 ● MR U 0-8h  
 2C19 Mephenytoin 100 
○ Ae 4'OHM 0-8h  
 2D6 Debrisoquine 10 
○ MR U 0-8h  
 2E1 Chlorzoxazone 250 ● MR P 4h  
 3A4 Dapsone 100 ○ MR U 0-8h  
  NAT2 Dapsone 100 ○ MR U 0-8h   
Quebec[12] 1A2 Caffeine 100 ● MR U 0-8h U 
 2C9 Tolbutamide 250 
○ MR U 0-8h  
 2D6 Metoprolol 25 ● MR U 0-8h  
 2E1 Chlorzoxazone 250 ● MR U 0-8h  
 3A4 Dapsone 100 ○ MR U 0-8h  
 XO Caffeine  ● MR U 0-8h  
  NAT2 Caffeine   ● MR U 0-8h   
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Cocktail CYP isoforms Substrates 
Doses 
(mg)  
Availability 
of probe 
drug 
Phenotyping Metric Matrix 
Yin[33] 1A2 Caffeine 100 ● MR P 2/3h P, U 
 2C9 Tolbutamide 500 
○ MR U 6-12h  
 2C19 Omeprazole 40 ● MR P  2/3h  
 2D6 Debrisoquine 10 
○ MR U 0-6h  
  3A4 Midazolam 3.75 ● MR P  2/3h   
Basel 1A2 Caffeine 100 ● MR P 8h P 
 2B6 Efavirenz 50 ● MR P 8h  
 2C9 Losartan 12.5 ● MR P 8h  
 2C19 Omeprazole 10 ● MR P 2h  
 2D6 Metoprolol 12.5 ● MR P 8h  
  3A4 Midazolam 2 ● MR P 2h   
(*) Interference observed  
Ae Amount excreted 
AUC R Area under the curve ratio 
CL Clearance  
F bioavailability 
Fi intestinal bioavailability 
MR Metabolic ratio 
P Plasma  
U Urine  
4'OHM 4'hydroxy-mephenytoin 
● Widely available (Switzerland or European Union) 
○ Not available (Switzerland or European Union) 
 
None of the proposed cocktails have so far gained sufficient acceptance to be used as a tool to 
phenotype patients in clinical practice. 
Currently available cocktails have several limitations, such as limited availability of probe drugs, 
complicated sampling procedures, and/or insufficiently validated phenotyping metrics. 
Several drugs such as mephenitoine, tolbutamide, debrisoquine, and sparteine are specific CYP 
substrates and are no longer available on the Swiss market or no longer used in clinics and therefore 
difficult to obtain. This makes their use for phenotyping more complicated.  
Only one matrix, urine or plasma, is used in the Quebec cocktail and modified Inje cocktail respectively. 
All the other cocktails recommend metrics in plasma and urine. The use of only one matrix would 
facilitate sampling procedures.  
In the modified Inje cocktail, plasma AUC of dextromethorphan is used as CYP2D6 metric. Validation 
data are reported for dextromethorphan in urine, but not in plasma. 
Based on this analysis of strengths and weaknesses of published phenotyping procedures our goal was 
to select the most promising probe drugs and make a new phenotyping cocktail.  
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3.3. Specific CYP substrates used in the Basel Cocktail study I – selections 
criteria 
The selection of caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam for 
phenotyping of CYP 1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4, respectively, is the 
result of an extensive evaluation. The criteria that guided our choices are described in the following 
paragraphs. 
 
3.3.1. Selection criteria of Caffeine as a specific substrate for CYP1A2  
Caffeine is a natural product present in coffee, tea, soft drinks and chocolate. It is a bronchial smooth 
muscle relaxant, a CNS stimulant, a cardiac muscle stimulant, and a diuretic.  
Despite several alternative substrates being available, caffeine is the most commonly used substrate for 
CYP1A2 and arylamine N-acetyltransferase 2 (NAT2) phenotyping. The first step in its metabolism is 
almost exclusively mediated by CYP1A2, while NAT2 is mainly responsible for the formation of 5-
acetylamino-6-formylamino-3-methyluracil (AFMU), one of the final metabolites of caffeine (Figure 
2)[34]. 
 
 
Figure 2. Main pathway of caffeine metabolism in human healthy subjects and enzymes involved [35]. 
Caffeine 
Paraxanthine 
 
1,7-Dimethyluric acid 
5-Acetylamino-6-formylamino-3-methyluracil 
 
1-Methylxanthine 1-Methyluric acid 
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The major primary metabolite is paraxanthine; other primary metabolites are theobromine and 
theophylline. The dimethylxanthines are pharmacologically active and may contribute to the effects of 
caffeine. Sequential metabolic steps include acetylation, 8-hydroxylation, and metabolism by xanthine 
oxidase.  
Caffeine is well tolerated and easily available therefore several studies have been performed and 
extensive validation data are available.  
Caffeine is completely absorbed from caffeinated beverages and reaches peak concentrations in blood 
in about 30-60 min. The rate of metabolism is variable, with a half-life ranging from 2 to 12 hours in 
healthy adults. On average, the half-life is 4-6 hours, with shorter half-life in smokers and longer half-life 
in people with chronic liver disease or in pregnant women. Plasma caffeine concentrations in the 
general population have not been well characterized. In a group of 600 medical outpatients, plasma 
caffeine averaged 2.1 mg/L (range 0.2-13.1 mg/L). In an experimental study of 17 health care personnel 
who were all moderate to heavy coffee drinkers, plasma caffeine averaged (24-h mean) 4.4 mg/L (range 
1.2-9.7) [36]. 
Theophylline, tizanidine and melatonin are also specific substrates of CYP1A2. Even if they are valuable 
alternatives for phenotyping, their application is much less common. Validation data are lacking, 
theophylline has a narrow therapeutic range, and melatonin is not available in Switzerland. 
Duloxetine, another specific substrate of CYP1A2, is also a moderate inhibitor of CYP2D6, therefore 
cannot be used in phenotyping cocktail approach. 
 
3.3.2. Selection criteria of Efavirenz as a specific substrate for CYP2B6  
Efavirenz (Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of 
highly active antiretroviral therapy (HAART) for the treatment of HIV type 1.  
Efavirenz has never been tested as part of a phenotyping cocktail. It is an established probe for 
determining CYP2B6 activity [37] and its use is recommended by the FDA for this purpose [38]. CYP2B6 
is responsible for the formation of the main metabolite 8-hydroxy-efavirenz and subsequently 8,14-
dihydroxy-efavirenz. Phase II reactions mediated by UGT produce the glucuronide derivative of the two 
metabolites (Figure 3). 
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Figure 3. Metabolism of efavirenz as proposed by Jiang al [39]. EFV, Efavirenz; EFG(-G), EFV-glucuronide; 7-OH-EFV, 7-
hydroxyefavirenz; 7-OH-EFV(-G), 7-hydroxyefavirenz-glucuronide; 8-OH-EFV, 8-hydroxyefavirenz; 8-OH-EFV(-G), 8-
hydroxyefavirenz-glucuronide; 8, 14-OH-EFV, 8,14-hydroxyefavirenz;  8, 14-OH-EFV(-G), 8,14-hydroxyefavirenz-glucuronide 
 
After repeated dosing it is a moderate inducer of CYP3A4 [40] and there are no published in vivo data 
available about CYP inhibition by efavirenz. The only retrievable data show in vitro inhibition of several 
CYP isoforms (CYP1A2, 2C9, 2C19, 2D6 and 3A4). When the study was planned, pharmacokinetic data 
after administration of 50 mg efavirenz were not available. We expected plasma concentrations would 
be reached in vivo after oral administration of 50 mg efavirenz of the drug to be much lower than the in 
vitro IC50 reported for 1A2, 2C9, 2C19, 2D6 and 3A4 [41]. On the basis of in vitro data (and assuming no 
relevant accumulation of efavirenz into hepatocytes), we expected plasma concentrations at least 
twenty times lower than the lowest IC50 (20 μM for 2C9, 2C19 and 3A4). Based on these considerations, 
we hypothesized that after low-dose efavirenz, relevant in vivo inhibition will not occur.  
The elimination half-life of efavirenz is 52-76 h (after single dose) and 40-55 h (after multiple dose), 
making longer sampling intervals and washout periods necessary. The usual adult dose is 600 mg once a 
day. In our studies we used single doses of 50 mg efavirenz separated by sufficiently long wash-out 
periods to ensure that no accumulation occurs. As known from Marzolini et al. CNS symptoms occur 
more frequently at higher plasma concentrations [42]. So we expect that a dose of 50 mg will cause 
fewer and/or milder adverse effects.  
The use of alternative substrates has been evaluated. Bupropion is also a specific substrate of CYP2B6. 
However, bupropion inhibits CYP2D6 and the only formulation available is a slow release tablet, 
therefore it was not suitable for the cocktail approach planned in this study. Propofol, ketamine or 
prasugrel were not selected due to lack of an oral formulation, inhibition of 2C9 and 3A4, or insufficient 
selectivity. 
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3.3.3. Selection criteria of Losartan as specific substrate for CYP2C9  
Losartan is an angiotensin II receptor (type AT1) antagonist. It is mainly indicated for the treatment of 
hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular 
hypertrophy. 
Oxidation of Losartan to its metabolite E-3174 is primarily mediated by CYP2C9. The elimination half-life 
of losartan is 1.5-2 h, and for E3147 4-9 h. 
CYP3A4 appears to play a very minor role at the concentrations corresponding to therapeutic plasma 
levels. Losartan has already been used in several phenotyping cocktails [28, 30] and recent 
investigations have concluded that it may be a useful CYP2C9 phenotypic probe in humans. The ratio of 
losartan plasma AUCtotal to the E-3174 plasma AUCtotal was used by Yasar et al. [43] to characterize poor 
and enhanced CYP2C9 metabolizers. The ratio was about 30-fold higher in poor compared to enhanced 
metabolizers. The same trend was expected for the ratio between the plasma concentration of losartan 
and E-3174 four hours postdose. 
Tolbutamide, warfarin, flurbiprofen, and losartan have already been used as probe drugs for CYP2C9 in 
cocktail combinations. Tolbutamide is an oral hypoglycemic drug no longer available in Switzerland and 
in several European Union (EU) countries. Tolbutamide plasma clearance and plasma concentrations 24 
hours after administration were shown to correlate to CYP2C9 phenotype [20]. Warfarine is an 
anticoagulant metabolized by CYP2C9. The pharmacological effect of warfarine is a limitation to its 
phenotyping application. It was included in phenotyping cocktail in association with vitamin K. 
Flurbiprofen is also a specific substrate of CYP2C9. Zgheib et al. have evaluated flurbiprofen urinary 
ratios as phenotyping indices for CYP2C9 activity [32, 44]. Warfarine is no longer available in 
Switzerland. Flurbiprofen was not considered for the Basel cocktail because when the first study was 
planned, validation data were only available in urine.  Recently, Daali et al. [17] described CYP2C9 
phenotyping using 4'-hydroxy-flurbiprofen/flurbiprofen metabolic ratio in plasma and dried blood spot 2 
hours after administration of 50 mg flurbiprofen. According to these data, flurbiprofen seems to be a 
valuable alternative to losartan. 
 
3.3.4. Selection criteria of Omeprazole as specific substrate for CYP2C19  
Omeprazole is indicated for treatment of peptic ulcer disease in adults.  
CYP2C19 and CYP3A4 exhibit stereoselective metabolism of omeprazole. 5-hydroxylation of R-
Omeprazole is exclusively mediated by CYP2C19, while S-isomer is metabolized by CYP3A4 to sulphone 
and by CYP2C19 to 5-O-desmethyl-omeprazole and only 27% to 5-hydroxy-omeprazole (Figure 4) [45, 
46]. 
 Page 23 
 
 
Figure 4. Stereoselective metabolism of omeprazole [47].  
 
The plasma elimination half-life is very short (0.5-1 h), which requires sampling within a few hours after 
administration. 
The reference compound for CYP2C19 phenotyping is mephenytoin. Since mephenytoin is no longer 
available, omeprazole is often used instead. According to Tamminga et al, all correlations between AUC 
0-12 hours and individual metabolic ratios at 3 hours postdose were significant. The ratio between the 
plasma concentration of omeprazole and 5-hydroxyomeprazole 3 hours postdose was assumed to be a 
good measure for the activity of CYP2C19 [9]. Omeprazole has already been applied in several cocktails 
[28, 30, 48] and was also selected for our cocktail. 
 
3.3.5. Selection criteria of Metoprolol as specific substrate for CYP2D6  
Metoprolol is a selective β1-adrenoreceptor antagonist. It is indicated for the treatment of hypertension, 
for the long-term treatment of angina pectoris and in the treatment of hemodynamically stable patients 
with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. The only 
formulation available in Europe is the sustained release formulation. 
Metoprolol is a specific and extensively validated substrate of CYP2D6. The measure of plasma AUC or 
the metabolic ratios between metoprolol and OH-metoprolol in urine have already been used as 
phenotyping index in several cocktails, while the use of metabolic ratio in plasma has never been 
evaluated [13, 25]. In the Basel cocktail, the plasma metabolic ratio has been evaluated for the first 
time.  
Absorption of metoprolol in man is rapid and complete. Plasma concentrations following oral 
administration, however, approximate 50% of levels following intravenous administration, indicating 
about 50% first-pass metabolism. Plasma concentrations achieved are highly variable after oral 
administration. Only a small fraction of the drug (about 12%) is bound to human serum albumin. 
Metoprolol is a racemic mixture of R- and S-enantiomers. Less than 5% of an oral dose is recovered 
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unchanged in the urine, the rest is excreted by the kidneys as metabolites that appear to have no clinical 
significance. 
There are marked ethnic differences in the prevalence of the CYP2D6 poor metabolizers (PM) 
phenotype. Approximately 7% of Caucasians and less than 1% Asians are poor metabolizers. Poor 
CYP2D6 metabolizers exhibit several-fold higher plasma concentrations of metoprolol than extensive 
metabolizers with normal CYP2D6 activity [9]. The elimination half-life of metoprolol is about 7.5 hours 
in poor metabolizers and 2.8 hours in extensive metabolizers. None of the metabolites of metoprolol 
contribute significantly to its beta-blocking effect. The estimation of the ratio between the plasma 
concentrations of metoprolol and OH-metoprolol in poor and extensive metabolizers four hours 
postdose shows a bimodal distribution. 
Dextromethorphan, sparteine, debrisoquine and metoprolol have been described as probe drugs for 
CYP2D6 [9]. 
Sparteine and debrisoquine are not widely available, therefore their use is no longer possible.  
The molar ratio of dextromethorphan over dextrorphan in urine collected 0-8 h postdose has been 
extensively validated. When the same ratio is measured in plasma the concentrations of parent 
compound are extremely low, especially in extensive metabolizers, making detection of 
dextromethorphan difficult. In this study we planned to analyze phenotyping indexes in plasma, blood, 
and oral fluid, but not in urine, therefore dextromethorphan was not selected for our cocktail.  
 
3.3.6. Selection criteria of Chlorzoxazone as specific substrate for 
CYP2E1 
Chlorzoxazone is a centrally-acting agent for painful musculoskeletal conditions with an elimination half-
life of 1.1 h. The clearance of chlorzoxazone and the ratio 6-hydroxy-chlorzoxazone over chlorzoxazone 
in plasma 2 to 4 h after oral administration of a 250-500 mg dose are validated CYP2E1 markers. 
However, in vivo inhibition of CYP3A4 by chlorzoxazone has been documented, but the available data 
are not conclusive. Palmer et al. have reported an interaction between chlorzoxazone at the dose of 250 
mg and midazolam [49], while according to Zhu et al. when chlorzoxazone was administered in 
combination with midazolam at the dose of 200 mg no significant interactions were observed [13]. 
In order to minimize inhibition of CYP3A4 a dose of 125 mg was applied.  
Felbamate and theophylline were reviewed as alternative probe drugs for CYP2E1. 85% of felbamate is 
unchanged in plasma and it is metabolized only to a minor extent by CYP2E1 and CYP3A4 [50]. 
Theophylline is also metabolized by CYP3A4 and CYP1A2[50]. No other suitable probe drugs for CYP2E1 
apart from chlorzoxazone could be identified. 
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3.3.7. Selection criteria of Midazolam as specific substrate for CYP3A4  
Midazolam was introduced in the late 1970s as short-acting benzodiazepine. It has potent anxiolytic, 
anesthetic, hypnotic, anticonvulsant, skeletal muscle relaxant, and sedative properties. It is used in 
many countries as a premedication before surgery or for sedation before short minor procedures such 
as dental extraction. Midazolam is one of the most extensively validated and specific CYP3A4 substrates 
and its application has already been described in several cocktails [25, 28]. The broad experience of our 
group using midazolam for phenotyping guided our choice to this substrate [16]. 
The usual oral dose for insomnia treatment is 7.5-15 mg. The effect usually begins after 10-20 min, 
reaches the peak after 30-60 min and reduces after 1-2 h. The elimination half-life is 1.8-6.4 h. For our 
studies we used a formulation containing a lower dose of 2 mg of midazolam to minimize unwanted 
sedative effects. Feasibility of using low- or micro doses of midazolam for phenotyping has already been 
shown by another group [15].  
The erythromycin breath test [51] has been used to characterize CYP3A4 phenotypes. A 3 μCi 14C-N-
methyl-erythromycin dose is administered i.v. CYP3A4 is responsible of the N-demethylation of the 
labeled methyl group. The reaction produces formaldehyde that is excreted as carbon dioxide in the 
breath. The 14CO2 concentration detected in breath 20 minutes after dosing correlates with the subject 
phenotype. The i.v. administration of a labeled compound was probably an obstacle to the clinical 
acceptance of this procedure, not routinely applied nowadays. 
Quinine is mentioned in FDA guidelines as specific CYP3A4 with a narrow therapeutic range. A cocktail 
approach including quinidine was not explored because of CYP2D6 quinidine inhibition [52]. 
Dapsone is also a well-accepted CYP3A4 specific substrate. Its use was not considered because 
according to Gass et al dapsone recovery in urine is not sensitive to inhibition [53]. 
 
3.4. How to study the possible interactions between the seven components 
of the Basel cocktail? 
The fundamental requirement of cocktail combinations is that no mutual interactions between 
substrates occur. Potential interactions are estimated measuring AUC of the substance of interest alone 
and co-administered with other components of the cocktail.  
To systematically verify the interactions between seven substrates would have required testing of 21 
possible combinations, an approach not feasible for a clinical study. To simplify the procedure, we used 
information already available in literature (drug-drug interaction studies or substrates already validated 
in a cocktail mix). In order to visualize the interactions, green lines were used to link substrates where 
no interactions have previously been reported. Interactions that were already reported in literature 
were linked with red lines and where there was contradictory or missing data, links were grey. 
In Figure 5 interactions of each probe drug with the other substrates of Basel cocktail are shown. 
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Caffeine Efavirenz 
  
Losartan Omeprazole 
  
Metoprolol Chlorzoxazone 
 
 
Midazolam  
 
Figure 5. Visualization of interactions for each component of the Basel cocktail. CAF, caffeine; EFA, efavirenz; LOSA, losartan; 
OME, omeprazole; METO, metoprolol; MDZ, midazolam. 
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Figure 6 combines all the information reported in Figure 5 and summarizes all the possible interactions 
between the Basel cocktail substrates. 
 
Figure 6. Visualization of all the possible interactions 
 
To evaluate the interactions using a minimum number of study days, we grouped substrates for which 
no interactions have been documented into “safe” 3-drug combinations to acquire reference 
pharmacokinetic profiles for each substrate. For the 3-drug combination A (Figure 7) which included 
losartan, omeprazole and midazolam, only green arrows are visualized, therefore these three probe 
drugs could be combined without mutual interactions. 
 
Figure 7. Treatment A: Losartan, omeprazole and midazolam 
 
Treatment B (Figure 8) consisted of metoprolol, caffeine, and chlorzoxazone. Also for this combination 
no interactions have previously been documented. 
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Figure 8. Treatment B: Metoprolol, caffeine, and chlorzoxazone 
 
Treatment C (Figure 9) was used to explore interactions between losartan, metoprolol, chlorzoxazone, 
and midazolam and to test whether a reduction of the chlorzoxazone dose would allow minimizing or 
avoiding the possible interaction between midazolam and high dose chlorzoxazone. As mentioned 
above, contradictory information about the interaction between chlorzoxazone and its inhibitory effect 
on CYP3A4 are available. Chlorzoxazone has already been used in combination with midazolam in the 
Changsa cocktail. To evaluate this possible interaction, an ad-interim analysis of the data after 
treatment C was planned with the option of removing chlorzoxazone from the final cocktail. 
 
 
Figure 9. Treatment C: Midazolam, chlorzoxazone, losartan, caffeine, metoprolol and omeprazole 
 
Since efavirenz has never been used as part of a phenotyping cocktail and no pharmacokinetic data for 
the 50 mg dose in healthy volunteers were available, efavirenz was given alone in treatment D (Figure 
10). 
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Figure 10. Treatment D: Efavirenz alone 
 
According to the results of the ad-interim analysis, treatment E (Figure 11) or Ebis (Figure 12) was 
applied.  
 
 
Figure 11. Basel cocktail, treatment E including chlorzoxazone, depending on the result of the inter-analysis after treatment C. 
 
 
Figure 12. Basel cocktail, treatment Ebis. 
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3.5. Drugs used as inhibitors and inducers in Basel cocktail study II 
The effects of inducers and inhibitors on the Basel cocktail substrates was evaluated in a clinical study 
using specific drugs selected according to the criteria described in the following paragraphs. 
3.5.1. Selection criteria of Ciprofloxacin 
Ciprofloxacin is a fluorochinolone with a broad antibacterial spectrum and is used in numerous infection 
diseases. 
After administration of a single-dose of 250 mg, 500 mg, 750 mg and 1’000 mg, ciprofloxacin peak 
concentrations of 0.94-1.53 mg/L (2.84-4.62 µM), 2-2.9 mg/L (6.04-8.75 µM), 2.6-4.3 mg/L (7.85-12.98 
µM) and 5.4 mg/L  (16.3 µM), respectively, were reached after 1-2 h. The elimination half-life was 3-6 h 
[54] i.e. >90% of the steady state concentration is achieved after 10-20 h. 
According the FDA-Guidance ciprofloxacin is a moderate inhibitor of CYP1A2 [38]. In vitro and in vivo 
data suggest that ciprofloxacin does not inhibit other cytochromes than CYP1A2 [55]. 
An interaction study with ciprofloxacin and caffeine in ten healthy volunteers showed a significant 
increase of the half-life of caffeine (from 5.2 ± 1.2 to 8.2 ± 2.5 h) and the caffeine AUC (from 16.3 ± 6.6 
to 25.9 ± 7.8 mg·h/L) while a decrease of the total body clearance (from 106 ± 41.6 to 58.2 ± 28.8 
mL/min per 1.73 m2) was observed. In addition, the rate of conversion of caffeine to paraxanthine was 
significantly delayed [56]. 
In another study in 12 healthy volunteers a two fold increase of the area under the plasma 
concentration-time curve (77.8 vs. 31.8 mg·h/L) and terminal-phase half-life (9.7 vs. 4.5 h) of caffeine 
was observed in the presence of ciprofloxacin [57]. In both studies ciprofloxacin was administered in a 
dose of 750 mg twice daily. 
Based on these data ciprofloxacin was administered as an inhibitor of CYP1A2 in the Basel cocktail II 
study at a dose of 750 mg, 24 h, 12 h and 1 h before administering the Basel cocktail. 
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3.5.2. Selection criteria of Fluconazole 
Fluconazole is a triazole antifungal, which is used in various infections with Candida species and 
Cryptococcus neoformans.  
Following oral administration of a single-dose of 400 mg of fluconazole in fasted healthy volunteers, the 
Cmax was 6.72 mg/L (range 4.12-8.08 mg/L) after 1-2 h. Fluconazole has a high oral bioavailability (90 %) 
and a half-life of 30 h, therefore the steady state is reached after 5-10 days [54]. 
According to the FDA-Guidance fluconazole is a moderate inhibitor of CYP2C9 [38].  
In addition to the inhibition of CYP2C9, fluconazole was also shown to be a strong inhibitor of CYP2C19 
and CYP3A4, whereas in vitro data suggest only minor effects on CYP1A2, CYP2B6 and CYP2D6 activity 
[55].  
In a study with 12 volunteers receiving fluconazole and midazolam, a single dose of fluconazole 
increased the area under the oral midazolam concentration-time curve (AUC0-∞) 3.5-fold (p < 0.001) and 
the peak concentration 2-fold (P < 0.05) compared to placebo. On the sixth day the AUC0-∞ of oral 
midazolam was 3.6 times higher with fluconazole (P < 0.001) than without the antimycotic. The 
psychomotor effects of midazolam were also profoundly increased (P < 0.001) [58]. 
Another study investigated the interaction of fluconazole and omeprazole in 18 healthy male 
volunteers. After inhibition with fluconazole, the area under the plasma concentration-time curve of 
omeprazole from time zero to time infinity (AUC0-∞) increased significantly (3090 vs 491 µg h/L), 
terminal half-life of omeprazole was prolonged (2.59 vs. 0.85 h), and peak plasma concentration of 
omeprazole (Cmax) was higher (746 vs. 311 µg/L) [59]. 
Based on these data, fluconazole was used to inhibit CYP2C9, CYP2C19 and CYP3A4. The inhibitory effect 
on CYP1A2, CYP2B6, and CYP2D6 was expected to be minimal. 
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3.5.3. Selection criteria of Paroxetine 
Paroxetine is a phenylpiperidine antidepressant agent which selectively inhibits serotonin reuptake. 
Paroxetine was developed as an alternative to tricyclic antidepressants that interfere with the reuptake 
of both serotonin and other neurotransmitters [54]. Paroxetine is approved for the treatment of 
depression, panic, and generalized anxiety disorders as well as social phobias [50].  
After oral administration of 20 mg paroxetine, mean peak serum concentration was 10.7 µg/L (range 
0.8-32.5 µg/L). With oral doses of 30 and 40 mg, mean peak concentrations were 17.6 µg/L and 26.6 
µg/L after 3 and 8 h respectively [54]. 
According to FDA-Guidance paroxetine is a strong inhibitor of CYP2D6 [38]. 
An interaction study with metoprolol and paroxetine in eight healthy male volunteers showed a 
significant increase of the mean area under the plasma concentration-time curve extrapolated to infinity 
(AUC0-∞) of R- and S-metoprolol (169 vs. 1340 µg·h/L [P < 0.001] and 279 vs. 1418 µg·h/L [P < 0.001], 
respectively), with an approximately 2-fold increase in both maximum plasma concentration and 
terminal elimination half-life. The mean metoprolol metabolic ratio (metoprolol / 5-OH-metoprolol) was 
significantly increased from 0.17 to 5.69 (P < 0.05) [60].  
In another study, 17 depressed patients with acute myocardial infarction received metoprolol as a 
routine part of their therapy (mean dose 75 ± 39 mg/day). Paroxetine 20 mg daily was then 
administered. Mean metoprolol areas under the concentration-time curve (AUC) increased 4-fold (1064 
± 1213 to 4476 ± 2821 nM·h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 ± 872 to 
348 ± 279 nM·h/mg per kg, P < 0.0001), with an increase of metabolic ratios (0.9 ± 1.3 to 26 ± 29; P < 
0.0001). A reduction of metoprolol dose was required in two patients due to excessive bradycardia and 
severe orthostatic hypotension. No other adverse effects of the drugs were identified [61]. 
In contrast to CYP2D6, little is known about the effects of paroxetine on the activity of CYP1A2, CYP2B6, 
CYP2C9, CYP2C19 and CYP3A4. 
In an in vivo single-dose study, 24 young, healthy men received increasing doses (10, 20, 40 and 80 mg) 
of paroxetine, fluoxetine, fluvoxamine and citalopram. The subjects were phenotyped for CYP2D6, 
CYP2C19 and CYP1A2 by co-administration of spartein, mephenytoin and caffeine. Potent inhibition of 
CYP2D6 and moderate inhibition of CYP2C19 was observed after administration of paroxetine and 
fluoxetine. Fluvoxamine showed an inhibitory effect on CYP1A2 [62]. 
In vitro data suggest no effect of paroxetine on CYP3A4 [55] and CYP2C9 [63].  
In summary, paroxetine is a strong inhibitor of CYP2D6 with no effects on CYP1A2, CYP2C9, CYP2C19 
and CYP3A4. The initial therapeutic dose is 20 mg daily. The dose may be increased of 10 mg/day at 
intervals of at least 1 week. Paroxetine has an elimination half-life of 15-22 h, therefore 90% of the 
steady state concentration is reached after 50-72 h. Using loading doses in the therapy with paroxetine 
is unusual because higher doses in previously untreated patients lead to more adverse effects. For these 
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reasons paroxetine was administered in a dose of 20 mg daily up to 72 h before applying the cocktail 
drugs (i.e. 72 h, 48 h, 24 h, and 1 h). 
 
3.5.4. Selection criteria of Rifampicin 
Rifampicin is a semi-synthetic antibiotic derived from a fermentation product of Nocardia Mediterranei. 
The drug has a wide antibacterial spectrum and is approved for the treatment of several infectious 
diseases, especially tuberculosis.  
Rifampicin is one of the stronger inducers of cytochromes and therefore recommended by the FDA for 
induction studies [38].  
A mean Cmax of 10.54 mg/L following 600 mg oral doses was found in 14 healthy adult volunteers. Time 
to peak concentration observed after oral administration was 1-4 h. A high oral bioavailability, 90 to 95 
% and a half-life of 1.5-5 h [54] was reported. 
Rifampicin is a known inducer of CYP3A4 and CYP2C9 in vivo [64, 65]. It has also been reported that 
rifampicin is an inducer of CYP1A2 (only weak effect), CYP2C8 and CYP2C19 [66-68].  
Kanebratt et al. investigated the inducing effect of rifampicin on the cytochromes CYP1A2, CYP2C9, 
CYP2C19 and CYP3A4 using the Karolinska Cocktail. Caffeine (CYP1A2), losartan (CYP2C9), omeprazole 
(CYP2C19), quinine (CYP3A4) and 4β-hydroxycholesterol (as an endogenous CYP3A4 marker) were used 
as specific phenotyping substrates. After administration of Rifampicin (20, 100 or 500 mg daily) for 14 
days to eight healthy subjects a four-fold induction of CYP3A4 was observed at the highest dose by both 
quinine/3′-hydroxyquinine and 4β-hydroxycholesterol measurements (P < 0.001). CYP3A4 induction was 
also observed at lower doses of rifampicin. CYP1A2, CYP2C9 and CYP2C19 were induced after daily 
treatment with 500 mg rifampicin (1.2-fold, P < 0.05; 1.4-fold, P < 0.05; and 4.2-fold, P < 0.01, 
respectively) [69]. 
In contrast to CYP1A2, CYP2C9, CYP2C19 and CYP3A4, cytochrome CYP2D6 does not seem to be 
inducible. To date no CYP2D6-inducer has been identified.  
The effect of rifampicin on the metabolism of efavirenz was published by Yenny et al. [70]. Co-
administration of a single dose of Efavirenz 600 mg after 1-week rifampicin treatment (450 mg/day) 
significantly reduced efavirenz bioavailability in healthy volunteers. 
In the Sustiva® medication instruction sheet a rifampicin related reduction of efavirenz Cmax and AUC by 
20 % (11-28%) and by 26% (15-36%), respectively is reported. 
In summary, rifampicin is a strong inducer of CYP3A4 and especially CYP2C19 and a weak inducer of 
CYP1A2 and CYP2C9. Data published on CYP2B6 induction are contradictory and no effect on CYP2D6 
has been observed. FDA-Guidance recommends a rifampicin dose of 600 mg daily for multiple days. The 
time required to achieve a complete induction depends on the cytochrome [71]. On average 1 week 
seems to be enough for a sufficient induction. On the other hand, the baseline activity after 
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discontinuing rifampicin treatment would be attained in about 2 weeks. The uncertainty of the time 
period required for complete induction is reflected in the numerous dosing regimens used in other 
studies [15, 69, 70, 72-76]. On average most studies used a dose of 600 mg rifampicin daily for 7 days. 
FDA guidelines suggest evaluating the effect of CYP1A2-induction by comparative PK studies in smokers 
vs. non-smokers. This procedure would have required a different study design, not appropriate for other 
CYP450 isoforms monitored in our study. On the basis of these considerations rifampicin was 
administered in a dose of 600 mg for 7 days before applying the cocktail drugs. 
 
  
 Page 35 
 
3.6. Genotyping of Drug Metabolizing Enzymes  
 
In the Basel cocktail I and II studies the most relevant single-nucleotide polymorphisms (SNP) associated 
with altered enzyme function were determined. Genetic polymorphism of CYP1A2, CYP2D6, CYP2C9 and 
CYP2C19 have been shown to impact the pharmacokinetics of drugs metabolized by these isoforms [77]. 
While genotyping only detects genetic variations, phenotyping provides a measure of the activity of a 
drug-metabolizing enzyme at a given point in time, and reflects all relevant factors that influence drug 
metabolism (e.g. genetic variations, drug-drug interactions, hormonal and environmental influences). 
Genotyping of enzymes responsible for drug metabolism has become more important but is still 
reserved to a few specific applications. One example is thiopurine S-methyl-transferase (TPMT), a 
polymorphic enzyme responsible for S-methylation of azathioprine (AZA), 6-mercaptopurine (6-MP) and 
thioguanine (TG). Since there is a significant correlation between TPMT genotype and TPMT activity the 
Clinical Pharmacogenetics Implementation Consortium provided dosing recommendation for AZA, 6-MP 
and TG based on TPMT genotype [78]. Similarly, guidelines for CYP2D6 and CYP2C19 genotypes and 
dosing of tricyclic antidepressant [79], or for CYP2C19 genotyping and clopidogrel therapy [80] have 
been published.  
From the technical perspective, automation of genotype testing has been implemented. The Roche 
AmpliChip® CYP450 test delivers information on CYP2D6 and CYP2C19 polymorphisms in the form of a 
genotype and predicted metabolizer status. Despite approval of this test by the FDA in 2005, CYP2D6 
and CYP2C19 genotyping is not yet commonly used in clinical practice. 
 
3.7. Minimally-invasive and non-invasive sample collection: dried blood 
spot technique and saliva sampling as tools for easier phenotyping 
 
Introduction of new diagnostic procedures such as phenotyping into clinical practice may encounter 
resistance, especially if complicated and invasive sampling is required. The easier a procedure, the more 
likely it will be accepted and used in daily practice. For this reason we explored the possibility of 
minimizing the number of samples to be collected as well as invasiveness, using single time point saliva 
or dried blood spot sampling instead of collecting full 24 h pharmacokinetic plasma profiles. 
 
3.7.1. Dried blood spot technique 
DBS collection technique due its popularity to the neonatal screening application introduced by Guthrie 
in 1963 [81]. Few applications for quantitation of drugs in DBS were reported in the literature between 
1980 and 2000. The main limitation to its application was the high sensitivity required to accurately 
quantify drugs or biomarkers in a single drop of a complex matrix such as blood. With the sensitivity 
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increase of LC-MS/MS instruments, these limitations have been overtaken and an increased interest of 
hospitals, academia and pharmaceutical industries has appeared (Figure 13).  
19
80
19
83
19
85
19
88
19
90
19
93
19
95
19
98
20
00
20
03
20
05
20
08
20
10
20
13
0
20
40
60
80
100
N
um
be
r o
f p
ub
lic
at
io
ns
Years  
Figure 13. Number of publications per year about DBS in Pubmed (1980-2012) using the search term “dried blood spot” in the 
title. 
 
DBS sampling involves collection of a few drops of blood either by heel prick (in newborns) or by finger 
prick on special blood collection cards. After drying for 2 hours the blood spots are ready for analysis or 
storage.  
The main advantages of this approach are a less invasive and easier blood collection. If correctly 
instructed, the patient can perform finger prick and collect DBS without the support of medical staff. If 
the dugs of interest are stable at room temperature, DBS samples can be shipped easily by normal mail. 
DBS have been proposed also as solution to stability issues. The removal of water can stabilize the 
sample as described by Heinig et al [82]. The advantages mentioned would also support the choice of 
DBS when a clinical study is performed in regions with limited logistics support [83]. 
Since DBS are obtained by prick of the finger, the collected blood is capillary blood. For classic diagnostic 
purposes blood is collected from a forearm or cubital vein. Before replacing conventional sampling with 
DBS, it is necessary to demonstrate that the sampling site does not influence the measurement. This 
approach is the “clinical validation” and consists in collecting at the same time venous and capillary 
blood, compare the measurement, and establish to what extent venous and capillary blood 
concentration correlates. 
Our interest for DBS in phenotyping is related to the low invasiveness of this technique. In chapters 6, 7, 
and particularly in chapter 8.2 the results of DBS applications are described. 
From a technical perspective, analysis of DBS is a challenging task. Each DBS is manually processed. A 
manual puncher is used to cut out a disc with 3 or 6 mm diameter, transferred in a test tube, extracted 
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with a suitable solvent, and analyzed by LC-MS. Handling of a high number of DBS cards following the 
manual procedure is time consuming and could generate errors. A technical solution has been proposed 
by Camag that has developed and now commercializes the DBS 500, an online DBS extraction system. In 
the framework of a KTI project, we established collaboration with Camag to develop DBS analysis for 
phenotyping and TDM of tyrosine kinase inhibitors. The technical details are reported in chapter 8.2. 
 
3.7.2. Oral fluid sampling 
If DBS is an easy and low invasive sampling approach, collection of oral fluid is even easier and non-
invasive. 
Saliva has been used for monitoring of drugs of abuse, while TDM applications are less common [84]. 
Quantification of midazolam in oral fluid for phenotyping purpose has already been described by Link et 
al. The possibility to extend it to other phenotyping substrates has been explored in the two Basel 
cocktail studies (chapters 6 and 7) 
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4. Aims of the thesis 
 
The overall objective of this thesis was to develop and characterize a new phenotyping procedure with 
the potential to be used not only in the classical phase I research setting but also for clinical 
applications.  
To reach this goal, the work was divided into three projects: 
(A) Bioanalytical method development (Chapter 5) 
(B) Clinical trial to rule out mutual interactions between phenotyping probe drugs (Basel cocktail 
study I, Chapter 6) 
(C) Characterization of phenotyping metrics under conditions of induction and inhibition (Basel 
cocktail study II, Chapter 7) 
The objective of the first project was to develop and validate bioanalytical methods for simultaneous 
detection of probe drugs and their main metabolites in different human matrices. To limit side effects, it 
was planned to use the lowest commercially available doses of probe drugs. It was anticipated that 
under induction or inhibition very low concentrations of either parent or metabolite would occur 
compared to baseline conditions. To maintain clinical applicability, short return times are required. 
Therefore highly sensitive bioanalytical methods with simple sample work-up and short run-times had 
to be developed. 
Clinical validation of the new phenotyping procedure involved two clinical studies in healthy volunteers: 
the Basel cocktail studies I and II. The objective of the second project (Basel cocktail study I) was to 
prove the absence of interactions between the new combination of probe drugs selected for the Basel 
phenotyping cocktail. Furthermore the possibility of using metabolic ratios in single time-point plasma 
measurements to replace the full AUC measurements was tested. Additionally, the use of DBS and saliva 
as minimally or non-invasive sampling collection procedures was explored. 
The goal of the third project (Basel cocktail study II) was to characterize the range of the chosen 
phenotyping metrics under conditions of induction and inhibition. For a comprehensive evaluation of 
the new phenotyping cocktail, the influence of genetic factors or co-administration of an enzyme 
inducer or inhibitor on the metabolic ratios of the Basel cocktail had to be assessed. Additionally, the 
measurements of metabolic ratio in saliva and DBS were repeated to evaluate whether oral fluid or DBS 
sampling could also be used to phenotype individuals in situations where very low concentrations of 
either parent or metabolite are expected. 
In the last part of the thesis an outlook on planned phenotyping projects is provided. In the Basel 
cocktail studies I and II, the commercially available formulations of the phenotyping drugs were used. To 
simplify probe drug administration, a prototype of a combi-pill containing all six cocktail probe drugs 
was developed, and tested in a single subject in a clinical pilot study. Pharmacokinetic profiles of the 
new formulation were comparable with the ones obtained after intake of the individual probe drugs in 
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the commercial formulations. This new cocktail combi-pill will be formally evaluated in a clinical study 
(Basel cocktail study III) in healthy volunteers.  
The use of phenotying information to personalize cancer therapy with tyrosine kinase inhibitors is under 
investigation in an ongoing clinical trial. Individual CYP3A4 and CYP1A2 phenotype will be assessed using 
probe drugs of the Basel cocktail and the correlation of obtained phenotyping metrics with sunitinib, 
pazopanib or erlotinib exposure will be analyzed. 
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5. Development and validation of a bioanalytical method for 
simultaneous quantification of the BASEL phenotyping cocktail probe 
drugs and metabolites in plasma, saliva and dried blood spots  
 
Massimiliano Donzelli1, Stephan Krähenbühl1, Manuel Haschke1  
 
1 Division of Clinical Pharmacology & Toxicology and Department of Biomedicine, University Hospital 
Basel, Switzerland 
 
5.1. Introduction 
 
The first and fundamental step in developing a new phenotyping cocktail is to have the analytical tools 
that reliably quantify low concentrations of the phenotyping dugs and their metabolites. To limit side 
effects, the lowest possible doses of probe drugs should be applied. Furthermore, under induction or 
inhibition very low concentrations of either parent or metabolite compared to baseline conditions are to 
be expected. To maintain clinical applicability, short return times of the results are required. Therefore 
high sensitivity, a simple sample work-up effective for all the analytes, and short run-times were the 
prerequisites for developing the analytical method to be used for the samples of the Basel cocktail 
studies. 
The analytical methods for the analysis of already published phenotyping cocktails are quite diverse. The 
probe drug combination we selected was new and therefore already published methods could not be 
used. The most recent methods are summarized below. All these authors tried to achieve our objectives 
in terms of sensitivity and speed, reducing sample pretreatment with online solid phase extraction 
(SPE), improving chromatographic separation with UHPLC, and increasing sensitivity with high end mass 
spectrometry detection.  
Lin et al. [85] recently published a cocktail method with online SPE-HPLC separation and diode array 
detection. The limit of quantitation (LOQ) achieved (50 ng/mL for omeprazole, 200 ng/mL for 
metoprolol) clearly support the need for a more sensitive detection mode such as MS/MS if sub-
therapeutic doses are administered. Ghassabian et al. [86] presented a method to quantify the Injie 
cocktail drugs using liquid-liquid extraction for caffeine and paraxanthine and SPE for all the other 
analytes, followed by a 6 min LC-MS/MS run. An 8 min UHPLC-MS/MS method was proposed by Stewart 
et al [87] for the quantification of the 6 probe drugs and metabolites of the Pittsburg cocktail. Petsalo et 
al [88] have developed a sensitive cocktail method to quantify 12 CYP-specific probe metabolites and 
their nine parent drugs in urine, using a sub 2 μm particle size column and a 5 min LC-MS/MS run.  This 
method was developed for urine and detected only few of the drugs used in the Basel cocktail.  
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Within the Basel cocktail study I and II the application of less invasive sampling techniques was explored. 
Quantification of low concentrations of drugs in plasma, blood and especially in saliva and DBS, is a 
challenging process. Use of DBS for caffeine determination in preterm infants [89] or for quantification 
of  midazolam for CYP3A4 phenotyping [90] has already been reported. Daali et al [17] have 
demonstrated the possibility of using flurbiprofen quantitation in DBS for phenotyping of CYP2C9.  
Saliva or oral fluid is a matrix much less used. Phenotyping of CYP1A2 measuring caffeine and its 
metabolites in saliva has already been reported by Perera et al [91], while determination of midazolam 
in saliva to phenotype CYP3A4 has been explored by Link et al [16].  
The optimization and partial validation of two analytical methods, the first developed in 2010 for the 
analysis of the first Basel cocktail (study I) and a second optimized method (higher sensitivity, shorter 
runtime) developed in 2011 for the analysis of the second Basel cocktail (study II) are described in the 
following chapters.  
 
5.2. Material and Methods 
5.2.1. Chemicals and reagents 
Caffeine-d9, chlorzoxazone, 6-hydroxy chlorzoxazone, chlorzoxazone-d3, 8-hydroxy efavirenz, efavirenz-
d4, losartan, losartan carboxylic acid, losartan-d4, hydroxy-metoprolol, metoprolol-d7, omeprazole, 5-
hydroxy omeprazole, omeprazole-d3, were purchased from TRC (Toronto, Canada). 1’-hydroxy-
midazolam and midazolam-d6 were from Lipomed (Arlesheim, Switzerland). Metoprolol and 
paraxanthine were obtained from Sigma-Aldrich (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). 
Midazolam (Hoffmann-La Roche, Basel, Switzerland) and efavirenz (Merck, NJ, USA) were kindly 
provided by the producer. 
Formic acid, HPLC-grade methanol, and water were purchased from Merck (Darmstadt, Germany). 
Schleicher & Schuell #903® filter paper was purchased from Schleicher & Schuell GmbH (Dassel, 
Germany). Manual hole punchers with a diameter of 3mm, Harris punch and cutting mats were from 
Whatman (Sanford, USA). 
5.2.2. Stock solutions, standard solutions and quality controls 
Fresh stock solutions containing caffeine, paraxanthine, chlorzoxazone, 6-hydroxy-chlorzoxazone, 
efavirenz, 8-hydroxy-efavirenz, losartan, losartan carboxylic acid, metoprolol, hydroxy-metoprolol, 
midazolam, 1’-hydroxy-midazolam, omeprazole, and 5-hydroxy-omeprazol were prepared in dimethyl 
sulfoxide (DMSO) at a concentration of 2 mg/mL. Calibration spiking solutions containing the cocktail 
components at concentrations of 100, 50, 25, 10, 5, 2.5, 1, 0.5, 0.25, 0.1 and 0.05 μg/mL and quality 
controls (QC) at concentrations of 50, 5, and 0.5 μg/mL were prepared from the concentrated DMSO 
solutions. Calibration standards ranging from 0.5 to 1000 ng/mL and quality controls at 5, 50, and 500 
ng/mL were prepared by enriching caffeine free blank human plasma, blood and saliva using the 
corresponding spiking solutions. 50 μL aliquots of plasma, blood and saliva were stored frozen at -20 °C 
until use. 
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DBS calibration and quality control samples were prepared by transferring 15 μL of enriched blood on 
filter paper.  
Stock solutions containing metoprolol-d7, omeprazole-d3, losartan-d4, midazolam-d6, caffeine-d9, 
efavirenz-d4, and chlorzoxazone-d3 were prepared in DMSO at a concentration of 2 mg/mL. An internal 
standard (ISTD) solution containing the deuterated compounds mentioned above at a concentration of 
0.1 μg/mL was prepared in methanol and used for the analysis of samples from study I. A 10 ng/mL 
solution of the same deuterium labeled compound was used for the analysis of samples from the study 
II. For the extraction of DBS the same concentration of deuterated compounds was spiked in 
methanol/water (1/1, v/v). 
5.2.3. Preparation of plasma, blood and saliva samples 
Sample work up was carried out with aliquots of 50 μL human plasma, blood or saliva. 50 μL aliquots 
were mixed with 150 μL ISTD solution. After vortex mixing for at least 30 s and centrifugation (3220 g, 
30 min, 10°C), samples were analyzed by LC-MS/MS. 
5.2.4. Treatment of plasma and saliva samples with glucuronidase 
Plasma and saliva samples collected during the Basel cocktail study II were treated with glucuronidase. 
50 μL of plasma or saliva were incubated with ≥ 500 units of β-glucuronidase Type HP 2 (Sigma G7017, 
Sigma-Aldrich, Buchs, Switzerland) at 37°C for 16h. Sample processing was as described above for 
plasma and saliva samples. 
5.2.5. Preparation of dried blood spot samples 
A disc with a diameter of 3 mm was cut out of the center of the dried blood spots into a clean tube using 
a manual hole punching device. 200 μL of ISTD solution were added to each tube, containing one blood 
spot. The vials were vortex-mixed for 10 min and centrifuged (3220 g, 30 min, 10 °C).  
5.2.6. LC-MS/MS instrumentation and conditions used in study I - (BC-
LCMS-01) 
Chromatographic separation was performed on a Shimadzu HPLC system (Shimadzu AG, Reinach, 
Switzerland). Samples were eluted on an Atlantis T3 column (2.1X50 mm, 3 μm, Waters, Baden-Dättwil, 
Switzerland). The injection volume was 10 μL and total run time was 5.5 min. The following gradient was 
applied: from 0 to 0.5 min 100% solvent A (0.1% formic acid in water), from 0.5 to 4.3 min the 
proportion of solvent B (0.1% formic acid in methanol) linearly increased from 0 to 70%, at 4.31 the 
percentage of B was increased to 95% and maintained for 0.7 min. At 5.0 min the initial conditions were 
re-established. The flow rate was 0.35 mL/min, the column was placed in a column oven at 40°C and the 
samples were stored in the autosampler at 10°C. 
The LC system was interfaced with a triple quadrupole mass spectrometer (API4000, AB/MDS Sciex, 
Concord, Canada) equipped with an ESI source. Positive ESI was applied for the first 4.25 min (ion spray 
voltage 5500 eV). Polarity was then switched to negative mode (ion spray voltage -4500 eV) for the 
detection of efavirenz and 8-hydroxy-efavirenz. The probe temperature was 350°C. The selected mass-
to-charge (m/z) ratio transitions of the analytes and internal standards used in selective reaction 
monitoring mode are reported in Table 2. Efavirenz probes were reanalyzed using an optimized method 
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to improve the detection of efavirenz and 8-hydroxy-efavirenz. The same gradient was applied but only 
the negative mode transitions were monitored. 
Table 2. Multiple reaction monitoring (MRM) transitions monitored in the analytical method used to quantify the samples of 
Basel cocktail study I 
Analyte Precursor (m/z) Product (m/z) Ionization mode 
Metoprolol 268 116 ESI+ 
1-Hydroxy-metoprolol 284 116 ESI+ 
Metoprolol-d7 275 123 ESI+ 
Omeprazole 346 198 ESI+ 
3-Hydroxy-omeprazole 362 214 ESI+ 
Omeprazole-d3 349 198 ESI+ 
Losartan 423 405 ESI+ 
E-3174 437 235 ESI+ 
Losartan-d4 427 409 ESI+ 
Midazolam 326 291 ESI+ 
1'-Hydroxy-midazolam 342 324 ESI+ 
Midazolam-d6 332 297 ESI+ 
Caffeine 195 138 ESI+ 
Paraxanthine 181 124 ESI+ 
Caffeine-d9 204 144 ESI+ 
Efavirenz  314 244 ESI- 
8- Hydroxy -efavirenz 330 258 ESI- 
Efavirenz-d4 318 69 ESI- 
 
5.2.7. LC-MS/MS instrumentation and conditions used in study II (BC-
LCMS-02) 
The analytical method applied for the analysis of the Basel cocktail study I, was adapted to additionally 
monitor the concentrations of the inhibitors ciprofloxacin, fluconazole, paroxetine, and the inducer 
rifampicin, as well as the metabolite 8,14-dihydroxy-efavirenz. 
Chromatographic separation was performed using a Shimadzu HPLC system (Shimadzu AG, Reinach, 
Switzerland). 
Samples were eluted on an Atlantis T3 column (2.1X50 mm, 3 μm, Waters, Baden-Dättwil, Switzerland). 
The injection volume was 10 μL and total run time was 2.5 min. The following gradient was applied: 
from 0 to 0.5 min 100% solvent A (0.1% formic acid in water), from 0.5 to 2 min the proportion of 
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solvent B (0.1% formic acid in methanol) linearly increased from 50 to 70%, at 2.01 the percentage of B 
was increased to 95% and maintained for 0.5 min. At 2.5 min the initial conditions were re-established. 
The flow rate was 0.8 mL/min, the column was placed in a column oven at 60°C and the samples were 
stored in the autosampler at 10°C. 
The LC system was interfaced with a triple quadrupole mass spectrometer (API4000, AB/MDS Sciex, 
Concord, Canada) equipped with an ESI source. Positive ESI was applied for the first 1.8 min (ion spray 
voltage 5500 eV). Polarity was then switched to negative mode (ion spray voltage -4500 eV) for the 
detection of EFA, OH EFA and 8,14 di OHEFA. The probe temperature was 450°C. 
The selected mass-to-charge (m/z) ratio transitions of the analytes and internal standards used in 
selective reaction monitoring mode were already reported in Table 2. The MRM transitions added to the 
present method are reported in Table 3. 
Table 3. MRM transitions additionally monitored in the Basel cocktail II analytical method 
Analyte Precursor (m/z) Product (m/z) Ionization mode 
Ciprofloxacin 332 288 ESI+ 
Fluconazole 307 238 ESI+ 
Paroxetine 330 192 ESI+ 
Rifampicin 823 791 ESI+ 
8,14-Dihydroxy-efavirenz 346 262 ESI- 
 
Efavirenz probes were reanalyzed using an optimized method to monitor 8,14-dihydroxy-efavirenz. The 
same gradient was applied but only the negative mode transitions were monitored. 
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5.3. Results 
 
Two bioanalytical methods were used for the analysis of the samples collected in two Basel cocktail 
studies. The second method was developed to monitor the concentrations of the compounds used for 
inhibition and induction as well as an additional efavirenz metabolite. 
 
5.3.1. Performance of the analytical method used to quantify plasma, 
blood, saliva and DBS samples of study I 
The first LC-MS/MS method, BC-LCMS-01, was developed and partially validated for the quantification 
of metoprolol, OH-metoprolol, caffeine, paraxanthine, omeprazole, 5-OH-omeprazole, midazolam, 1’-
OH-midazolam, losartan, E-3174, efavirenz, and 8-OH-efavirenz. 
A representative chromatogram is reported in Figure 14. 
 
 
Figure 14. Representative chromatogram of a calibration sample containing 1000 ng/mL of each analyte in human plasma. OH-
metoprolol (1), Metoprolol (2), Paraxanthine (3), Caffeine (4), Midazolam (5), 5-OH-omeprazole (6), Omeprazole (7), 1’-OH-
midazolam (8), Losartan (9), E-3174 (10), 8-OH-efavirenz (11), Efavirenz (12). 
 
The lower limits of quantification (LLOQ) achieved in plasma, saliva, blood and DBS are reported in Table 
4. 
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Table 4. LLOQ in plasma, saliva, blood, and DBS (Basel cocktail study I). 
Analyte 
LLOQ plasma LLOQ saliva LLOQ blood LLOQ DBS 
(ng/mL) (ng/mL) (ng/mL) (ng/mL) 
Metoprolol 1 0.5 0.5 2.5 
OH-metoprolol 0.5 2.5 1 25 
Omeprazole 0.5 0.5 0.5 1 
5-OH-omeprazole 0.5 0.5 0.5 5 
Losartan 1 0.5 1 10 
E3174 1 0.5 1 10 
Midazolam 0.5 0.5 0.5 2.5 
1'-OH-midazolam 0.5 0.5 0.5 5 
Caffeine 10 5 5 25 
Paraxanthine 2.5 2.5 2.5 25 
Efavirenz 1 2.5 2.5 10 
8-OH-efavirenz 1 2.5 2.5 25 
 
The performance of the method was monitored using quality control (QC) samples at low, medium and 
high concentrations. 
In plasma, inter-assay accuracy (determined as the percent bias) for QC samples ranged from -4.7 to 
11.6 and inter-assay precision (determined as the relative standard deviation) was lower than 10.3 for 
all the analytes (Table 5). 
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Table 5. Inter-assay accuracy and precision for QC plasma samples (Basel cocktail study I).  
nominal concentrations QC1 = 5 ng/mL QC2 = 50 ng/mL QC3 = 500 ng/mL 
Metoprolol Overall Mean (n) 5.58 (18) 49.9 (21) 494 (21) 
 Accuracy (Bias%) 11.6 -0.26 -1.25 
 Precision (CV %) 2.09 4.00 3.69 
OH-metoprolol Overall Mean (n) 5.15 (18) 49.8 (21) 476 (21) 
 Accuracy (Bias%) 2.94 -0.37 -4.68 
 Precision (CV %) 7.53 7.57 6.17 
Omeprazole Overall Mean (n) 5.11 (21) 50.4 (21) 484 (21) 
 Accuracy (Bias%) 2.17 0.881 -3.30 
 Precision (CV %) 2.44 2.38 1.83 
5-OH-omeprazole Overall Mean (n) 4.97 (21) 49.7 (21) 499 (21) 
 Accuracy (Bias%) -0.686 -0.719 -0.133 
 Precision (CV %) 4.48 3.38 2.36 
Losartan Overall Mean (n) 5.05 (21) 50.1 (21) 493 (21) 
 Accuracy (Bias%) 0.910 0.324 -1.33 
 Precision (CV %) 4.39 2.11 2.26 
E-3174 Overall Mean (n) 4.97 (21) 50 (21) 494 (21) 
 Accuracy (Bias%) -0.624 -0.100 -1.30 
 Precision (CV %) 5.60 3.52 2.94 
Midazolam Overall Mean (n) 4.9 (21) 49.3 (21) 494 (21) 
 Accuracy (Bias%) -2.02 -1.38 -1.20 
 Precision (CV %) 3.70 3.92 3.08 
1'-OH-midazolam Overall Mean (n) 4.82 (21) 48.3 (21) 498 (21) 
 Accuracy (Bias%) -3.68 -3.44 -0.457 
 Precision (CV %) 5.79 4.38 3.90 
Caffeine Overall Mean (n) not measured 51.8 (21) 500 (21) 
 Accuracy (Bias%)  3.68 -0.062 
 Precision (CV %)  5.17 2.10 
Paraxanthine Overall Mean (n) 5.12 (19) 50.4 (21) 496 (21) 
 Accuracy (Bias%) 2.41 0.819 -0.762 
 Precision (CV %) 8.52 3.85 2.51 
Efavirenz Overall Mean (n) 4.94 (19) 51.3 (21) 501 (21) 
 Accuracy (Bias%) -1.17 2.74 0.167 
 Precision (CV %) 10.30 5.08 2.67 
8-OH-efavirenz Overall Mean (n) 4.89 (21) 50.1 (21) 486 (21) 
 Accuracy (Bias%) -2.16 0.229 -2.78 
  Precision (CV %) 7.46 4.00 3.40 
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In saliva, inter-assay accuracy (determined as the percent bias) for QC samples ranged from -6.81 to 
10.4 and inter-assay precision (determined as the relative standard deviation) was lower than 7.52 for 
all the analytes (Table 6). 
 
Table 6. Inter-assay accuracy and precision for QC saliva samples (Basel cocktail study I). 
nominal concentrations 
  
QC1 = 5 ng/mL QC2 = 50 ng/mL QC3 = 500 ng/mL 
Metoprolol Overall Mean (n) 4.82(21) 50(21) 511(21) 
 Accuracy (Bias%) -3.5 0.02 2.25 
 Precision (CV %) 4.97 1.62 3.82 
OH-metoprolol Overall Mean (n) 4.69(16) 50(21) 552(17) 
 Accuracy (Bias%) -6.18 -0.25 10.4 
 Precision (CV %) 7.52 5.65 5.03 
Omeprazole Overall Mean (n) 4.79(21) 50(21) 487(21) 
 Accuracy (Bias%) -4.11 0.11 -2.58 
 Precision (CV %) 2.13 1.97 4.03 
5-OH-omeprazole Overall Mean (n) 4.78(21) 50.3(21) 534(20) 
 Accuracy (Bias%) -4.46 0.67 7.22 
 Precision (CV %) 3.51 3.10 4.54 
Losartan Overall Mean (n) 4.81(21) 49.1(21) 509(21) 
 Accuracy (Bias%) -3.90 -1.83 1.85 
 Precision (CV %) 6.02 2.75 4.88 
E-3174 Overall Mean (n) 4.86(21) 50.6(20) 541(21) 
 Accuracy (Bias%) -2.90 1.20 8.11 
 Precision (CV %) 4.21 4.31 4.84 
Midazolam Overall Mean (n) 4.76(21) 49.7(21) 513(21) 
 Accuracy (Bias%) -4.76 -0.73 2.69 
 Precision (CV %) 4.38 2.13 4.92 
1'-OH-midazolam Overall Mean (n) 4.76(21) 49.5(21) 477(19) 
 Accuracy (Bias%) -4.92 -1.03 -4.60 
 Precision (CV %) 5.56 4.29 7.52 
Caffeine Overall Mean (n)  not measured 49.1(21) 514(21) 
 Accuracy (Bias%)  -1.86 2.70 
 Precision (CV %)   3.87 4.71 
Paraxanthine Overall Mean (n)  not measured 49.6(21) 506(21) 
 Accuracy (Bias%)  -0.88 1.17 
 Precision (CV %)   3.12 4.53 
Efavirenz Overall Mean (n) 4.99(21) 50.1(21) 524(21) 
 Accuracy (Bias%) -0.08 0.11 4.80 
 Precision (CV %) 6.57 7.42 4.95 
8-OH-efavirenz Overall Mean (n) 4.99(20) 50.1(21) 500(21) 
 Accuracy (Bias%) -0.09 0.19 0.00 
  Precision (CV %) 6.66 5.91 4.46 
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In DBS, inter-assay accuracy (determined as the percent bias) for QC samples ranged from -8.5 to 1.0 
and inter-assay precision (determined as the relative standard deviation) was lower than 10.6 for 
omeprazole, 5-OH-omeprazole, caffeine, and paraxanthine. For the other analytes LLOQ was too high to 
quantify study samples, therefore performance of the method was not reported (Table 7). 
 
Table 7. Inter-assay accuracy and precision for QC DBS samples (Basel cocktail study I). 
nominal concentrations 
  
QC1 = 5 ng/mL QC2 = 50 ng/mL QC3 = 500 ng/mL 
Omeprazole Overall Mean (n) 4.58(20) 48.4(20) 476(20) 
 Accuracy (Bias%) -8.53 -3.19 -4.76 
 Precision (CV %) 7.04 4.38 7.30 
5-OH-omeprazole Overall Mean (n) 5.02(16) 47.8(18) 470(20) 
 Accuracy (Bias%) 0.38 -4.43 -5.96 
 Precision (CV %) 9.22 8.54 5.14 
Caffeine Overall Mean (n) not measured 50.5(18) 474(21) 
 Accuracy (Bias%)  1.02 -5.32 
 Precision (CV %)   10.6 7.60 
Paraxanthine Overall Mean (n) not measured 48.8(19) 494(21) 
 Accuracy (Bias%)  -2.40 -1.29 
  Precision (CV %)   10.33 4.88 
 
Clinical validation data for caffeine and paraxanthine 6 hours after administration of a caffeinated drink 
had already been acquired by Berger et al (Poster 2, page 145). Caffeine and paraxanthine concentration 
in DBS were highly correlated with venous concentrations. Efavirenz concentrations in DBS were 
measured using a prototype of an online extraction system and as well after manual preparation. With 
both methods comparable results were obtained (Poster 3, page 147). Further comparison between 
caffeine and efavirenz PK profiles in venous and capillary (DBS) was performed for the Basel cocktail 
study I and results are summarized in Poster 4 (page 149). Overall correlation between concentrations 
of caffeine and efavirenz in DBS and venous blood was good (R2 0.881 and 0.908, respectively). During 
the absorption phase, higher concentrations were observed in DBS compared to venous blood samples, 
while in the elimination phase (after Tmax) the correlation for both caffeine and efavirenz improved (R2 
0.969 and 0.942, respectively).  
 
5.3.2. Performance of the analytical method used to quantify plasma, 
blood, saliva and DBS samples of study II 
Samples collected in the Basel cocktail study II were analyzed with a different method, BC-LCMS-02. 
Representative chromatograms are reported in Figure 15, Figure 16, and Figure 17. In addition to the 
probe drugs and metabolites already analyzed with the previous method, fluconazole, ciprofloxacin, 
paroxetine, rifampicin, and 8,14-diOH-efavirenz were included. 
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Figure 15. Representative chromatogram of a calibration sample containing 1000 ng/mL of each phenotyping analyte in human 
plasma. OH-metoprolol (1), Metoprolol (2), Paraxanthine (3), Caffeine (4), Midazolam (5), 5-OH-omeprazole (6), Omeprazole 
(7), 1’-OH-midazolam (8), Losartan (9), E-3174 (10), 8-OH-efavirenz (11), Efavirenz (12). 
 
 
Figure 16. Representative chromatogram of a calibration sample containing 1000 ng/mL of inhibitors and inducer in human 
plasma. Fluconazole (13), Ciprofloxacin (14), Paroxetine (15), Rifampicin (16). Negative mode MRM window not reported. 
 
 
Figure 17. Representative chromatogram of a calibration sample containing 1000 ng/mL of 8,14-diOH-efavirenz (17), 8-OH-
efavirenz (11), Efavirenz (12) in human plasma.  
 
The lower limits of quantification (LLOQ) achieved in plasma, saliva, and blood are reported in Table 8. 
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Table 8. LLOQ in plasma, saliva and blood (Basel cocktail study II). 
Analyte 
LLOQ plasma LLOQ saliva LLOQ blood LLOQ DBS 
(ng/mL) (ng/mL) (ng/mL) (ng/mL) 
Metoprolol 1 0.5 0.5 1 
OH-metoprolol 0.5 2.5 1 1 
Omeprazole 0.5 0.5 0.5 1 
5-OH-omeprazole 0.5 0.5 0.5 1 
Losartan 1 0.5 1 25 
E3174 1 0.5 1 25 
Midazolam 0.5 0.5 0.5 1.0 
1'-OH-midazolam 0.5 0.5 0.5 2.5 
Caffeine 10 10 10 50 
Paraxanthine 10 10 10 10 
Efavirenz 1 0.5 1 5 
8-OH-efavirenz 1 0.5 1 25 
8,14-(OH)2-
efavirenz 
0.50    
 
The performance of the method was monitored using quality control (QC) samples at low, medium and 
high concentrations. 
In plasma, inter-assay accuracy (determined as the percent bias) for QC samples ranged from -11.6 to 
10.2 and inter-assay precision (determined as the relative standard deviation) was lower than 10.4 for 
all the analytes (Table 9). 
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Table 9. Inter-assay accuracy and precision for QC plasma samples (Basel cocktail study II).  
nominal concentrations QC1 = 5 ng/mL QC2 = 50 ng/mL QC3 = 500 ng/mL 
Metoprolol Overall Mean (n) 5.51 (9) 50.9 (9) 454 (9) 
 Accuracy (Bias%) 10.2 1.74 -9.11 
 Precision (CV %) 3.55 3.19 3.70 
OH-metoprolol Overall Mean (n) 5.36(8) 49.9 (9) 488 (9) 
 Accuracy (Bias%) 7.10 -0.76 -2.36 
 Precision (CV %) 8.49 8.67 5.42 
Omeprazole Overall Mean (n) 5.06 (9) 50.6 (9) 457 (9) 
 Accuracy (Bias%) 1.36 1.02 -8.62 
 Precision (CV %) 4.84 3.15 2.48 
5-OH-omeprazole Overall Mean (n) 5.05 (9) 50.3 (9) 442 (9) 
 Accuracy (Bias%) 0.860 0.670 -11.6 
 Precision (CV %) 5.20 5.33 3.28 
Losartan Overall Mean (n) 5.24 (9) 51.4 (9) not measured 
 Accuracy (Bias%) 4.80 6.68  
 Precision (CV %) 8.10 6.68   
E-3174 Overall Mean (n) 5.28 (9) 52.4 (9) 460 (9) 
 Accuracy (Bias%) 5.57 4.76 -8.04 
 Precision (CV %) 8.24 5.70 4.58 
Midazolam Overall Mean (n) 5.41 (6) 49.9 (9) not measured 
 Accuracy (Bias%) 8.12 -0.18  
 Precision (CV %) 6.20 6.98   
1'-OH-midazolam Overall Mean (n) 5.11 (8) 49.3 (8) 486 (9) 
 Accuracy (Bias%) 2.16 -1.49 -2.90 
 Precision (CV %) 9.11 4.29 2.64 
Caffeine Overall Mean (n) not measured 50.8(9) 506(9) 
 Accuracy (Bias%)  1.64 1.28 
 Precision (CV %)   10.4 6.22 
Paraxanthine Overall Mean (n) not measured 50.7 (9) 505 (9) 
 Accuracy (Bias%)  1.37 1.01 
 Precision (CV %)   8.27 5.06 
Efavirenz Overall Mean (n) 5.05 (9) 48.6 (9) 480 (9) 
 Accuracy (Bias%) 0.88 -2.86 -3.99 
 Precision (CV %) 5.59 2.66 1.89 
8-OH-efavirenz Overall Mean (n) 5.31 (9) 50.0 (9) 445 (9) 
 Accuracy (Bias%) 6.10 0 -10.9 
  Precision (CV %) 4.58 5.00 2.35 
 
In saliva, inter-assay accuracy (determined as the percent bias) for QC samples ranged from -7.3 to 10.2 
and inter-assay precision (determined as the relative standard deviation) was lower than 12.1 for all the 
analytes (Table 10). 
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Table 10. Inter-assay accuracy and precision for QC saliva samples (Basel cocktail study II).  
nominal concentrations QC1 = 5 ng/mL QC2 = 50 ng/mL QC3 = 500 ng/mL 
Metoprolol Overall Mean (n) 5.52(9) 51.6(9) not measured 
 Accuracy (Bias%) 10.2 3.30  
 Precision (CV %) 3.15 3.75   
OH-metoprolol Overall Mean (n) 4.99(8) 51.2(9) not measured  
 Accuracy (Bias%) -0.3 2.56  
 Precision (CV %) 11.4 7.32   
Omeprazole Overall Mean (n) 5.37(9) 50.2(9) not measured  
 Accuracy (Bias%) 7.22 0.4  
 Precision (CV %) 4.81 3.34   
5-OH-omeprazole Overall Mean (n) 5.38(9) 51.3(9) not measured  
 Accuracy (Bias%) 7.63 2.52  
 Precision (CV %) 5.14 4.96   
Losartan Overall Mean (n) 5.27(8) 50.8(9) not measured  
 Accuracy (Bias%) 5.39 1.70  
 Precision (CV %) 4.82 3.45   
E-3174 Overall Mean (n) 5.47(9) 51.2(9) not measured  
 Accuracy (Bias%) 9.38 2.33  
 Precision (CV %) 4.60 2.76   
Midazolam Overall Mean (n) 5.44(9) 52.6(9) not measured  
 Accuracy (Bias%) 8.78 5.13  
 Precision (CV %) 3.55 5.40   
1'-OH-midazolam Overall Mean (n) 5.29(7) 51.1(8) not measured 
 Accuracy (Bias%) 5.86 2.29  
 Precision (CV %) 4.45 6.50   
Caffeine Overall Mean (n) not measured 53.7(9) 467(9) 
 Accuracy (Bias%)  
7.56 -6.58 
 Precision (CV %)  
3.27 6.25 
Paraxanthine Overall Mean (n) not measured  52.9 (9) 463(9) 
 Accuracy (Bias%)  
5.67 -7.30 
 Precision (CV %) 
  3.16 6.93 
Efavirenz Overall Mean (n) 5.35(9) 52.9(9) 478(9) 
 Accuracy (Bias%) 
6.89 5.91 -4.33 
 Precision (CV %) 
6.86 5.12 12.1 
8-OH-efavirenz Overall Mean (n) 5.49(8) 53.3(9) not measured 
 Accuracy (Bias%) 
9.88 6.57 
 
 Precision (CV %) 
2.37 4.70   
 
Rifampicin, fluconazole, ciprofloxacin and paroxetine were measured to verify treatment adherence and 
to estimate the extent of exposure. Accuracy and precision were not evaluated. 
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5.4. Discussion 
 
The substances used in the Basel Cocktail have quite diverse physical and chemical properties. Our aim 
was to quantify the parent compound and the phase I metabolites expected to be more hydrophilic than 
the parent compound with a single method. The selection of the column chemistry was mainly based on 
LogP values of the analytes that had to be analyzed. A LogP value above 0 indicates a more hydrophobic 
molecule, usually better retained and separated by a reversed phase (RP) chromatography column. LogP 
values below 0 indicate a more hydrophilic analyte that will be better analyzed using a column with 
hydrophilic interaction liquid chromatography (HILIC) chemistry. Paraxanthine and caffeine have LogP 
values of -0.94 and -0.13 respectively, while efavirenz at the other end of the spectrum has a LogP of 
3.03. To retain and separate a mixture characterized by such a broad polarity range, several RP column 
chemistries (C8, C18, and pentafluorophenyl) were tested. A C18 column with special affinity for 
hydrophilic compounds, the Atlantis T3 column, exhibited the best separation performance for the 
components of the Basel cocktail and the metabolites generated in vivo. 
To improve sample clean up and to increase the amount of sample injected and consequently the 
sensitivity of the analytical method, we explored the application of online solid phase extraction (SPE). 
Several trapping columns were tested (Oasis HLB, Clipeus, Halo EXP). The most promising results were 
observed with the Halo EXP trap. Very hydrophilic compounds such as metoprolol and OH-metoprolol 
were retained by the trapping column, while efavirenz and OH-efavirenz were not retained.  
For the analysis of DBS, online extraction with online dilution using a 20 μL mixing chamber to improve 
sample and mobile phase mixing was evaluated. Sensitivity slightly increased but only for a few of the 
analytes. Therefore online extraction was abandoned and the method was optimized and validated 
using the Atlantis T3 analytical column. To increase sample throughput, analysis time was considerably 
reduced from 5.5 min in BC-LCMS-01 to 2.5 min in BC-LCMS-02 by increasing mobile phase flow and 
column oven temperature (Table 11). 
Table 11. Comparison between relevant parameters in analytical method BC-LCMS-01 and BC-LCMS-02.  
Analytical 
method 
Flow 
(mL/min) 
T 
(°C) 
Total run time 
(min) 
N° of samples 
analyzed 
BC-LCMS-01 0.35 40 5.5 circa 9000 
BC-LCMS-02 0.8 60 2.5 circa 4300 
 
Over the past few years, there has been increasing interest in using very high pressure conditions 
(namely UHPLC, for ultra-high pressure liquid chromatography) with columns packed with porous sub-
2μm particles. This approach increases the resolving power and speeds up the analytical separation 
process, therefore the transfer of the HPLC method to UHPLC conditions was also evaluated. Although 
Waters, the supplier of the Atlantis T3 column, claims the HSS T3 to be an equivalent UHPLC column, 
our tests of UHPLC conditions were not successful for this application. The hydrophilic compounds 
paraxanthine and OH-metoprolol for example were not retained by the HSS T3 column under UHPLC 
conditions. 
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All the analytes with the exception of efavirenz and its metabolites were detected in positive ion mode. 
E-3174, detected in positive mode, was eluted shortly before OH-efavirenz and efavirenz, the only two 
analytes detected in negative mode. Fast polarity switching is one of the options of the API4000 that 
could have been used for these analyses. The disadvantage is that for each cycle a pause time is 
necessary between the positive and negative mode detection, resulting in a lower sensitivity. This kind 
of approach is necessary when the components detectable with different polarity co-elute. For this 
application, compounds detected in positive mode were separated by analytes detectable in negative 
mode. We therefore used within the same method a positive MRM window followed by a negative 
MRM window. This implied a fine tuning of the switching time. Just after the elution of the E3174 peak, 
polarity was switched to negative and efavirenz and its metabolites were acquired. 
Due to the low absolute amount of analyte contained in a DBS, sensitivity of the DBS method was the 
limiting factor for using DBS instead of venous blood sampling. Therefore, clinical validation of DBS with 
the Basel cocktail study I samples could only be performed for caffeine and efavirenz. The high LLOQ, 
particularly for losartan and E-3174, did not allow quantification of these analytes in DBS and the 
comparison with venous blood concentration was not possible. Another limitation of using DBS is the 
extensive sample work-up requiring manual punching, transfer of the DBS to a test tube and offline 
extraction of the paper disc with a suitable solvent. A set of operations that for 96 samples took 2 to 3 
hours. An automated online extraction system, the CAMAG DBS-MS 500 was tested for analysis of 
efavirenz (Poster 3, page 147
 Page 57 
 
Poster 3) and a more extensive validation was performed for the analysis of TKIs in DBS (Poster 6, page 
153). Use of such automated systems reduces manual workload and increases sample throughput. 
While chromatographic separation is performed, the DBS-MS 500 prepares for the extraction of the 
subsequent sample, minimizing the delay between sample analyses. On-line extraction takes 2 minutes 
per sample and can be performed in parallel with the chromatographic separation. However such 
systems are not yet available in clinical routine and were also not available long enough to analyze the 
samples from the two Basel cocktail studies. 
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5.5. Conclusions 
 
For the development of the new phenotyping cocktail fast, sensitive and robust bioanalytical methods 
were required. Both developed methods proofed to be valuable tools, capable of analyzing thousands of 
study samples in diverse matrices from the two Basel cocktail studies and the combi-pill pilot study. 
Both methods fulfilled requirements of accuracy, precision and robustness. The second method was 
faster, allowing shorter return times if phenotyping is used in clinical applications. DBS as a less invasive 
sampling method is currently only feasible for selected analytes. Sensitivity needs considerable 
improvements and the observed difference between capillary and venous concentrations during 
absorption phase should be further investigated. A more efficient and automated extraction system 
such as the CAMAG DBS-MS 500 autosampler will allow a reduction of the manual workload and speed 
up sample processing times. 
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6.1. Introduction 
 
The advantages of the cocktail approach have already been mentioned in the introduction section and 
are summarized in brief here. Phenotyping cocktails enable the simultaneous characterization of 
cytochrome P450 enzymes using a combination of specific substrates. Many phenotyping cocktails have 
already been published and are used to investigate drug interactions in early clinical drug development. 
The cocktail approach could also be applied to predict drug exposure of a patient before administering a 
medication personalizing the therapy and avoiding exposure to potential risk, particularly when the 
treatment consists of a drug with narrow therapeutic range. 
None of the published cocktails have so far gained sufficient acceptance to be used as a tool to 
phenotype patients in clinical practice. Currently available cocktails have several limitations. Some of the 
probe drugs used in many of these cocktails, such as tolbutamide, mephenytoin, or debrisoquine are no 
longer available as licensed drugs in most countries [18]. Another limitation is complicated sampling 
procedures, requiring collection of multiple plasma samples at appropriate timepoints for specific CYP 
isoforms or for the determination of AUCs. Insufficiently validated phenotyping metrics (e.g. dapsone 
for CYP3A4) and/or complicated bioanalytical procedures (e.g. off-line sample purification, multiple 
methods for different analytes or biological matrices) are further limitations. 
To improve clinical applicability of CYP phenotyping, our primary objective was to develop a new 
cocktail (Basel cocktail) based on probe drugs that are widely used in clinical practice and therefore 
easily available. To minimize probe drug exposure and adverse effects, the lowest commercially 
available doses were chosen. A secondary objective was to test whether alternative minimally or non-
invasive sampling methods (dried blood spots or saliva samples) could be used to simplify the sampling 
process.  
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6.2. Material and Methods 
6.2.1. Clinical study  
All subjects signed informed consent prior to any study-mandated procedure. Screening consisted of 
medical history, physical examination, including heart rate, systolic and diastolic blood pressure, 
standard 12-lead electrocardiogram, routine blood tests and urine drug screen. Exclusion criteria 
included any clinically relevant abnormality identified at the physical examination or laboratory 
screening, positive results from urine drug test (amphetamines/methamphetamines, cocaine, opiates, 
phencyclidine, tetrahydrocannabinol, acetaminophen, barbiturates, benzodiazepines, methadone, 
propoxyphene and tricyclic antidepressants), smoking within the last 3 months prior to screening, 
history or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening, 
consumption of alcohol within 14 days before the first drug administration, consumption of more than 
800 mg caffeine daily, previous treatment with any prescribed or over the counter (OTC) medications 
within 2 weeks prior to screening, treatment with another investigational drug within 30 days prior to 
screening. 
A single-center, randomized, five-way crossover study was performed at the Phase I Research Center, 
University Hospital Basel, Basel, Switzerland (ClinicalTrials.gov  Identifier: NCT01187862).  
6.2.2. Experimental procedures 
Each subject first received the treatments A, B, C and D in a randomized order: 4 subjects received the 
sequence ABCD, 4 subjects the sequence BCDA, 4 subjects the sequence CDAB, and 4 subjects the 
sequence DABC. The allocation to one of the groups was drawn by lot. Single doses of 12.5 mg losartan 
(Cosaar®) for CYP2C9, 10 mg omeprazole (Antramups®) for CYP2C19, 2 mg midazolam (Midazolam oral 
solution 2mg/ml) for CYP3A4, 100 mg caffeine (Coffeinum® N 0.2) for CYP1A2, 12.5 mg metoprolol 
(Belok ZOK®) for CYP2D6, 125 mg chlorzoxazone (Paraflex®) for CYP2E1and 50 mg efavirenz (Stocrin®) 
for CYP2B6 were administered in different combinations: 
Treatment A:   Losartan-Omeprazole-Midazolam 
Treatment B:   Caffeine-Metoprolol-Chlorzoxazone  
Treatment C:  Losartan-Omeprazole-Midazolam-Caffeine-Metoprolol-Chlorzoxazone (A+B) 
Treatment D:  Efavirenz 
Treatment E: Losartan-Omeprazole-Midazolam-Caffeine-Metoprolol-Efavirenz (Basel Cocktail) 
After the first 10 subjects had completed treatments A and C, an ad interim analysis was performed to 
evaluate a possible interaction of chlorzoxazone on probe drugs of treatment A. Interactions between 
chlorzoxazone and midazolam were observed and therefore chlorzoxazone was excluded from the final 
cocktail (Treatment E). 
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On study days, the subjects remained fasted from at least 10 hours prior to and up to 4 hours after 
study drug intake. No food was allowed for at least 4 hours postdose. Water was allowed as desired 
except for one hour before and after drug administration. The drugs were administered with 240 ml of 
tap water. On the day of drug administration, subjects received standardized meals: lunch 
approximately 4 hours after drug administration (after blood sampling), and snack approximately 8 
hours after drug administration. Drinking of alcoholic beverages or xanthine-containing food or 
beverages was not permitted during the time in the clinic. No concomitant medications were allowed, 
except for the treatment of adverse events (AE). Use of herbal medicines, OTC medications or food 
products known to be inducers or inhibitors of CYP450 (e.g. grapefruit juice) was forbidden during the 
entire study. Consumption of alcoholic beverages was not allowed for 2 weeks prior to first dosing until 
after the end of the study to avoid induction of CYP2E1. Caffeine-containing beverages were not allowed 
for 48h prior to dosing until after the last sampling time-point of the study period. The washout time 
between different study periods was 14 days. 
6.2.3. Pharmacokinetic sampling 
Blood samples for pharmacokinetic analysis were taken before and 0.25, 0.50, 0.75, 1, 2, 3, 4, 6, 8, 12, 
24, 48, and 72 h after drug administration (72 h only treatment D and E). About 2.7 ml blood were 
collected by direct venous puncture (for 24, 48 and 72 h samples) or via an i.v. catheter placed in an 
antecubital vein in the arm in Monovette® tubes containing EDTA. The indwelling catheter was inserted 
in the arm at a maximum of 1 hour before the start of blood sampling. In order to keep the catheter 
patent, 0.9% sodium chloride i.v. drip at a very slow rate, i.e. one drop every 2 to 3 seconds was infused. 
To avoid any dilution artifacts the i.v. drip was stopped and 1-2 ml of blood was drawn through the 
catheter and wasted prior to collection of the blood sample. Immediately following collection of the 
required blood volume, the Monovettes® were slowly tilted backwards and forwards (no shaking) to 
bring the anti-coagulant into solution, and immediately cooled on ice. Within 30 minutes of collection, 
an aliquot of 1 ml of blood was transferred in a labeled tube. The Monovettes® containing the remaining 
blood were centrifuged at approximately 1’500 g for 10 minutes at 4°C. The plasma was transferred into 
one labeled polypropylene tube to avoid carry-over of erythrocytes. All samples were stored in an 
upright position at -80°C. 
Dried blood spot (DBS) and oral fluid samples were collected before dosing and 0.5, 1, 2, 4, 8, 12 and 
24 h (plus 48 and 72h for treatments containing efavirenz) after study drug administration. DBS samples 
were collected via capillary puncture of the fingertip using a finger pricker (Accu-Check Softclix Pro, 
Roche, Basel, Switzerland). A drop of blood (approximately 20 μL) was transferred on filter paper 
(Schleicher & Schuell GmbH ,Dassel, Germany). After drying for at least 2 h at room temperature the 
DBS samples were stored at -80°C until analysis. Oral fluid (5 mL) was collected in polypropylene tubes. 
To avoid contamination, subjects were asked to rinse their mouth before sampling. After centrifugation 
(1500 g for 10 min at 4°C) the supernatant was stored at -80°C until analysis.  
6.2.4. Pharmacodynamic measurements and adverse events 
Pharmacodynamic assessments (heart rate, blood pressure, sedation score) were performed at baseline 
(up to 30 min before drug intake) and 1, 2, 4, 6, and 12 h after drug administration. Subjects rated their 
level of sedation on a visual analog scale (VAS) ranging from 0, “not tired” to 10, “very tired”. 
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All AEs, regardless of severity or relationship to the study drug were recorded. 
6.2.5. Study drugs 
The following study drugs were purchased through the University Hospital Pharmacy, Basel, 
Switzerland:  
• Caffeine (Coffeinum N 0.2g, Mylan Dura GmbH, Darmstadt, Germany) 
• Efavirenz  (Stocrin®, Merck Sharp & Dohme-Chibret AG, Opfikon, Switzerland) 
• Losartan (Cosaar®, Merck Sharp & Dohme-Chibret AG, Opfikon, Switzerland) 
• Metoprolol (Belok ZOK®, AstraZeneca AG, Zug, Switzerland) 
• Omeprazole (Antramups®,  AstraZeneca AG, Zug, Switzerland) 
• Chlorzoxazone (Paraflex®, BioPhausia AB, Stockholm, Sweden) 
• Midazolam (midazolam oral solution, 2 mg/ml, in-house formulation University Hospital 
Pharmacy, Basel, Switzerland)  
6.2.6.  Bioanalytical analysis 
The bioanalytical method used for the analysis of the plasma, saliva, blood and DBS samples is described 
in chapter 5. 
6.2.7. Data Analysis  
Area under concentration time curve from time zero to 24 hours (AUC) after dosing and half-life were 
estimated using non-compartmental methods, maximal concentrations (Cmax) and time to reach Cmax 
(tmax) were directly taken from observed data. AUC was estimated using the linear trapezoidal method. 
Bioequivalence (BE) tests were performed with a linear mixed effects model using WinNonlin (Pharsight, 
Mountain View, CA). Results are represented as geometric mean and 90% confidence intervals. To 
determine the appropriate BE acceptance limits, within-subject coefficients of variation (CV%) for the 
AUCs were calculated using the root mean square approach. For not highly variable drugs with a within-
subject CV% below 30%, the BE acceptance limits of 0.8 and 1.25 had to be met by the point estimate 
and both 90% confidence intervals. After the first four treatment sequences (treatments A to D) a 
preplanned interim analysis was performed to detect a possible interaction of chlorzoxazone with 
CYP3A4. A bioequivalence test was performed using the midazolam AUCs of treatment A (no 
interaction) and treatment C (midazolam in combination with chlorzoxazone). To conclude absence of a 
relevant interaction, point estimate and 90% confidence intervals were required to fall completely 
within the BE limits stated above. Correlations between single time point concentration ratios and AUC 
ratios were tested using linear regression analysis. Concentration ratios of different genotype groups 
were compared using the nonparametric Kruskal-Wallis test. 
 
6.2.8. Genotype analysis 
DNA was isolated from 400 μL EDTA-blood on an m2000sp instrument (Abbott Molecular, De Plaines, IL, 
USA) following the manufacturer’s protocol. Final elution volume was 100 microliter. Specific single 
nucleotide polymorphisms in the genes encoding CYP1A2 (alleles *1A, *1F), CYP2B6 (allele *6), CYP2C9 
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(alleles *2, *3) and CYP2C19 (alleles *1, *2, *3) were detected using primer / probe real time PCR 
reagent (Lightmix, TIB MOLBIOL, Berlin, Germany) on a Lightcycler 1.5 instrument (Roche Diagnostics, 
Rotkreuz, Switzerland). For detection of CYP2C19 (*2, *3, *4, *6, *7, *8, *9, *10, *17), CYP2D6 (*2, *3, 
*4, *5, *6, *7, *8, *9, *10, *12, *14, *17, *28, *41, *XN) and CYP3A4 (alleles *1B, *2, *3, *12, *17) 
hybridization of amplified products was performed using the Infiniti chip technology (Autogenomics, 
Carlsbad, USA) according to the manufacturer’s instructions. 
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6.3. Results 
6.3.1. Pharmacodynamics and adverse events 
Sixteen healthy male volunteers (mean age 26 years, range 18-45 years, mean BMI 23.4 kg/m2, range 
20.6-26.3 kg/m2) completed the study according to the protocol. All subjects were with no history of 
relevant disease and no history of drug or substance abuse. All study subjects were of Caucasian 
ethnicity, with normal findings on physical exam, screening laboratory (including drugs of abuse screen), 
and ECG. Simultaneous administration of all probe drugs was well tolerated. No clinically significant 
adverse effects and no relevant changes in heart rate, blood pressure or sedation score (Figure 18) were 
observed. 
                                              A 
 
                                             B 
 
                                             C 
 
                                              D 
 
Figure 18. Changes of heart rate (Figure 18A), systolic and diastolic blood pressure (Figure 18 B and C) and sedation scores 
(Figure 18D) were compared after administration of efavirenz (treatment D, white boxes) and after administration of the final 
6-drug cocktail (treatment E, grey boxes). Treatment D was chosen as “negative control”, as there are no relevant effects of 
efavirenz on heart rate, blood pressure or alertness at the low dose of 50mg used in this study. The whiskers represent the 
range with minimum and maximum. The boxes represent the 25.-75. percentile and the median. 
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6.3.2. Pharmacokinetic interactions and bioequivalence testing 
Bioequivalence tests based on full pharmacokinetic profiles of the probe drugs were performed to test 
for mutual interactions. In a pre-planned interim analysis, chlorzoxazone, the probe drug for CYP2E1, 
was found to cause a significant increase of midazolam AUC (geometric mean AUC ratio 1.77, 90%CI 
1.57-1.99, Figure 19) and had to be excluded from the final cocktail. 
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Figure 19. Comparison of plasma concentration time-profile of midazolam obtained after application in a safe 3-drug 
combination (together with two other probe drugs with documented lack of interaction, treatment A) and in a combination 
containing chlorzoxazone (treatment C) 
 
For the remaining six probe drugs of the final cocktail there was no evidence for pharmacokinetic 
interactions (Figure 20). Pharmacokinetic profiles of the probe drugs in the final six drug combination 
were almost identical with profiles obtained when the probe drug of interest was administered in 
combination with two other, not-interacting probe drugs (“safe” 3-drug combination, see methods 
section for further details).  
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Figure 20. Comparison of plasma concentration time-profiles of cocktail probe drugs obtained after application in a safe 3-drug 
combination (together with two other probe drugs with documented lack of interaction) and in the final 6-drug cocktail. 
Concentration-time profiles are shown for parent drugs and corresponding metabolites for CYP1A2 (A), CYP2B6 (B), CYP2C9 (C), 
CYP2C19 (D), CYP2D6 (E) and CYP3A4 (F). For all concentration-time profiles no significant difference between application in the 
3-drug combination and in the final 6-drug cocktail is observed.  
 
All within-subject coefficients of variation (CV%) for the AUCs were below 30%, hence the 
bioequivalence (BE) acceptance limits were set to 0.8 and 1.25. The point estimates and the 90% 
confidence intervals for the AUC ratios (AUC of probe drug in final cocktail vs. AUC of probe drug in 
combination with two known, non-interfering probe drugs) were all within the chosen BE acceptance 
limits (Table 12 and Figure 21). 
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Table 12. Geometric mean and 90% confidence interval for AUC ratios of probe drugs in final 6-drug cocktail compared to 3-
drug cocktail  
 
 
 
 
AUC, area under the curve; CI, confidence interval; CV, coefficient of variation; 3-drug cocktail, probe drug of interest 
combined with two other, non-interacting probe drugs  
 
 
Figure 21. Point estimate and 90% confidence interval of geometric mean of AUC ratios of probe drug in final 6-drug cocktail 
compared to 3-drug cocktail (probe drug combined with two other, non-interfering probe drugs, e.g. for CYP3A4 midazolam 
combined with omeprazole and losartan). Dotted lines represent bioequivalence acceptance limits of 0.8 and 1.25.  
 
 
6.3.3. Single sampling for phenotyping applications 
In a next step, limited sampling procedures were evaluated. Parent drug concentrations measured at a 
single time-point during the first 12 hours after dosing were correlated with full pharmacokinetic 
profiles of the parent drug (AUCparent). 
For all final cocktail probe drugs, correlations of single point parent concentrations with the respective 
AUCparent were higher for samples taken during the elimination phase compared to earlier time-points 
(Table 13). Since CYP activity is not only reflected in changes of the parent, but also of the metabolite 
concentration, we also tested the correlation of parent drug to metabolite concentration ratios 
(metabolic ratio) measured at a single time-point with the corresponding AUC ratios (i.e. AUCparent to 
AUCmetabolite).  
 
Cytochrome Probe drug n 
geometric 
mean AUC 
ratio 
90% CI 
lower 
90% CI 
upper 
within 
subject 
CV% 
CYP1A2 caffeine 16 1.04 0.94 1.15 15.5 
CYP2B6 efavirenz 16 1.01 0.96 1.05 6.9 
CYP2C9 losartan 16 0.99 0.90 1.10 13.7 
CYP2C19 omeprazole 16 1.06 0.92 1.23 24.5 
CYP2D6 metoprolol 16 0.97 0.89 1.05 12.6 
CYP3A4 midazolam 16 0.98 0.89 1.07 14.4 
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Table 13. Correlation of single point measurements with AUC in plasma 
  coefficient of determination (R
2) 
 time (h) CYP1A2 CYP2B6 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
pa
re
nt
 c
on
ce
nt
ra
tio
n 
 
vs
 A
U
C
 
1      0.886 
2    0.290  0.910 
3    0.577  0.955 
4 0.863 0.269 0.431 0.590 0.527 0.929 
6 0.949 0.484 0.620  0.771  
8 0.865 0.591 0.681  0.829  
12 0.915 0.863   0.867  
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vs
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/A
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tio
 1      0.944 
2    0.892  0.959 
3    0.903  0.950 
4 0.844 0.817 0.197 0.936 0.888 0.894 
6 0.927 0.897 0.409  0.904  
8 0.910 0.888 0.592  0.808  
12 0.967 0.954   0.987  
 
 
For all cocktail probe drugs, correlations of parent concentrations with AUC were higher for samples 
taken during the elimination phase compared to earlier time-points. For caffeine and midazolam, 
correlations between parent concentration and AUC were comparable with correlations between 
metabolic ratios (i.e. single point parent to metabolite concentration ratio and AUCparent to AUCmetabolite 
ratio). For efavirenz, omeprazole and metoprolol, on the other hand, a better correlation was found 
between metabolic ratios than with single point parent concentration and AUCparent. Therefore 
metabolic ratios were used as simplified phenotyping metric for the final cocktail. Due to large 
pharmacokinetic differences between the probe drugs, two sampling time-points (2h and 8h after 
dosing) were necessary to obtain sufficiently high correlations between single point concentration ratios 
and AUC ratios. Correlations of individual single point concentration ratios with the corresponding AUC 
ratios for the two selected time-points (2h after dosing for omeprazole and midazolam and 8h after 
dosing for caffeine, efavirenz, losartan and metoprolol) are shown in Figure 22. The coefficient of 
determination R2 was >0.8 for all correlations except for losartan with an R2 of 0.59. 
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Figure 22. Correlations of individual single point concentration ratios with the corresponding AUC ratios 2h after dosing for 
omeprazole(D) and midazolam (F) and 8h after dosing for caffeine (A), efavirenz (B), losartan (C) and metoprolol (E). 
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6.3.4. Genotyping 
 
All study participants were genotyped for altered function alleles. CYP2D6 genotyping identified one 
poor, one intermediate, 14 extensive and no ultrarapid metabolizers. The poor metabolizer was 
compound heterozygous for two loss-of-function alleles (CYP2D6*3/*4). In this subject no OH-
metoprolol could be detected and no metabolic ratio could be calculated. The intermediate metabolizer 
had a combination of a loss-of-function and a diminished-function allele (CYP2D6*4/*41). This subject 
showed the highest metabolic ratio at 8h (Figure 22E). For CYP2B6, CYP2C9 and CYP2C19 no poor 
metabolizers were identified. Six subjects were heterozygous for diminished-function alleles of CYP2B6 
(CYP2B6*6, n=6) and/or CYP2C9 (CYP2C9*2, n=2 and CYP2C9*3, n=4). The metabolic ratios of the four 
subjects heterozygous for the CYP2C9*3 allele were not significantly higher (p=0.074) compared to 
subjects with *1 or *2 alleles. One subject was heterozygous for the loss-of-function allele CYP2C19*2 
and 8 subjects for the enhanced function allele CYP2C19*17. Genotyping of CYP1A2 identified 11 
subjects homozygous and four subjects heterozygous for the *1F allele, which is associated with 
increased inducibility (Fehler! Verweisquelle konnte nicht gefunden werden.).  
Metabolic ratios for heterozygous carriers of altered function alleles did not show significant differences 
compared to non-carriers (Figure 22, p>0.05 for all correlations between genotype and AUC ratios). 
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Table 14 (subject 1-8). Results of genotyping analysis (Basel cocktail study I). WT, wildtype; HT, heterozygous; HO, homozygous; 
neg, gene deletion or duplication not observed. 
 
 
  
CYP Allele Subject      1
Subject      
2
Subject      
3
Subject      
4
Subject      
5
Subject      
6
Subject      
7
Subject      
8
1A2 CYP1A2*1F HO HT HO HO HO HO HO HO
2B6 CYP2B6*6 WT HT WT WT HT WT WT WT
2C9 CYP2C9*2 WT WT WT WT WT HT WT WT
CYP2C9*3 WT WT WT WT WT WT HT WT
2C19 CYP2C19*2 WT HT WT WT WT WT WT WT
CYP2C19*3 WT WT WT WT WT WT WT WT
CYP2C19*4 WT WT WT WT WT WT WT WT
CYP2C19*6 WT WT WT WT WT WT WT WT
CYP2C19*7 WT WT WT WT WT WT WT WT
CYP2C19*8 WT WT WT WT WT WT WT WT
CYP2C19*9 WT WT WT WT WT WT WT WT
CYP2C19*10 WT WT WT WT WT WT WT WT
CYP2C19*17 HT WT WT WT WT HT WT WT
2D6 CYP2D6*2 HT HT HT HT WT WT HO HT
CYP2D6*3 WT WT WT WT WT WT WT WT
CYP2D6*4 WT WT HT HT HT WT WT WT
CYP2D6*5 neg neg neg neg neg neg neg neg
CYP2D6*6 WT WT WT WT WT WT WT WT
CYP2D6*7 WT WT WT WT WT WT WT WT
CYP2D6*8 WT WT WT WT WT WT WT WT
CYP2D6*9 WT WT WT WT WT WT WT WT
CYP2D6*10 WT WT HT HT HT WT WT WT
CYP2D6*12 WT WT WT WT WT WT WT WT
CYP2D6*14 WT WT WT WT WT WT WT WT
CYP2D6*17 WT WT WT WT WT WT WT WT
CYP2D6*29 WT WT WT WT WT WT WT WT
CYP2D6*41 WT WT WT WT WT WT WT HT
CYP2D6*XN neg neg neg neg neg neg neg neg
3A4 CYP3A4*1B WT WT WT WT WT WT WT WT
CYP3A4*2 WT WT WT WT WT WT WT WT
CYP3A4*3 WT WT WT WT WT WT WT WT
CYP3A4*12 WT WT WT WT WT WT WT WT
CYP3A4*17 WT WT WT WT WT WT WT WT
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Table 14 (Subject 9-16). Results of genotyping analysis (Basel cocktail study I). WT, wildtype; HT, heterozygous; HO, 
homozygous; neg, gene deletion or duplication not observed. 
 
 
  
CYP Allele Subject      9
Subject      
10
Subject      
11
Subject      
12
Subject      
13
Subject      
14
Subject      
15
Subject      
16
1A2 CYP1A2*1F HO HT HO HO HO HT HT WT
2B6 CYP2B6*6 HT WT WT HT HT HT WT WT
2C9 CYP2C9*2 WT WT WT HT WT WT WT WT
CYP2C9*3 HT WT WT WT WT HT HT WT
2C19 CYP2C19*2 WT WT WT WT WT WT WT WT
CYP2C19*3 WT WT WT WT WT WT WT WT
CYP2C19*4 WT WT WT WT WT WT WT WT
CYP2C19*6 WT WT WT WT WT WT WT WT
CYP2C19*7 WT WT WT WT WT WT WT WT
CYP2C19*8 WT WT WT WT WT WT WT WT
CYP2C19*9 WT WT WT WT WT WT WT WT
CYP2C19*10 WT WT WT WT WT WT WT WT
CYP2C19*17 HT WT HT HT HT WT HT HT
2D6 CYP2D6*2 HT WT HT HT HT HT WT WT
CYP2D6*3 WT WT WT WT WT WT WT HT
CYP2D6*4 HT HT WT WT WT HT HT HT
CYP2D6*5 neg neg neg neg neg neg neg neg
CYP2D6*6 WT WT WT WT WT WT WT WT
CYP2D6*7 WT WT WT WT WT WT WT WT
CYP2D6*8 WT WT WT WT WT WT WT WT
CYP2D6*9 WT WT WT WT HT WT WT WT
CYP2D6*10 HT HT WT WT WT HT HT HT
CYP2D6*12 WT WT WT WT WT WT WT WT
CYP2D6*14 WT WT WT WT WT WT WT WT
CYP2D6*17 WT WT WT WT WT WT WT WT
CYP2D6*29 WT WT WT WT WT WT WT WT
CYP2D6*41 HT WT WT WT WT WT WT WT
CYP2D6*XN neg neg neg neg neg neg neg neg
3A4 CYP3A4*1B WT WT WT WT WT HT WT WT
CYP3A4*2 WT WT WT HT WT WT WT WT
CYP3A4*3 WT WT WT WT WT WT WT WT
CYP3A4*12 WT WT WT WT WT WT WT WT
CYP3A4*17 WT WT WT WT WT WT WT WT
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6.3.5. DBS as a minimally invasive sampling procedure for phenotyping 
In DBS only caffeine, paraxanthine, omeprazole, 5-OH-omeprazole, efavirenz and midazolam could be 
quantified. The concentrations of the metabolites of efavirenz and midazolam as well as losartan and 
metoprolol (and their respective metabolites) were below the limit of quantification in DBS at the time 
points 2 and 8 h. The correlation of single point concentration ratios in DBS for CYP1A2 at 8h and for 
CYP2C19 at 2h with the corresponding AUC ratios in plasma were good (R2 >0.8 for both, Figure 23A and 
B) and comparable to correlations between single point concentration ratios and AUC ratios determined 
in plasma.  
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Figure 23. Correlations of individual single point concentration ratios in DBS with the corresponding AUC ratios 2h after dosing 
for omeprazole (B) and 8h after dosing for caffeine (A). 
 
Efavirenz concentrations at 8h or 12h and midazolam concentrations at 1h or 2h in DBS showed only 
moderate correlation (R2 of 0.44 to 0.57) with the corresponding AUCs in plasma (Table 15). 
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Table 15. Correlation of single point DBS measurements with AUC in plasma 
  coefficient of determination (R
2) 
 time (h) CYP1A2 CYP2B6 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
pa
re
nt
 c
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nt
ra
tio
n 
in
 D
B
S 
vs
 A
U
C
 
1    0.011  0.442 
2    0.436  0.571 
3       
4 0.937 0.091     
6       
8 0.926 0.443     
12 0.936 0.522     
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 1    0.484   
2    0.800   
3       
4 0.925      
6       
8 0.877      
12 0.787      
 
6.3.6. Oral fluid as a non-invasive sampling procedure for phenotyping 
In saliva the concentrations of all analytes except caffeine, paraxanthine, omeprazole, 5-hydroxy-
omeprazole and metoprolol were too low to allow reliable quantification (LLOQ between 0.5 and 
5ng/ml, Table 4). The correlation of metabolic ratios for CYP1A2 in saliva at 8h with the corresponding 
AUC ratios in plasma was good (Figure 24A), whereas the metabolic ratios for CYP2C19 in saliva at 2h 
only showed moderate correlation to the corresponding AUC ratios in plasma (Figure 24B). 
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Figure 24. Correlations of individual single point concentration ratios in saliva with the corresponding AUC ratios 2h after 
dosing for omeprazole (B) and 8h after dosing for caffeine (A). 
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Table 16.Correlation of single point saliva measurements with AUC in plasma. 
  coefficient of determination (R2) 
 time (h) CYP1A2 CYP2B6 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
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1    0.959   
2    0.63   
3       
4 0.873   0.201   
6       
8 0.883    0.306  
12 0.894    0.279  
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 1    0.905   
2    0.473   
3       
4 0.918   0.544   
6       
8 0.812    0.192  
12 0.719    0.008  
 
Since OH-metoprolol could not be quantified in saliva only data for metoprolol could be examined. In 
contrast to plasma, metoprolol concentrations at 8h and metoprolol AUC0-24h in saliva in the 
intermediate and poor metabolizers were significantly higher (p≤0.01) compared to extensive 
metabolizers. Within the extensive metabolizer group the same was observed for subjects heterozygous 
for a diminished- or a loss-of-function allele (*4, *9, *41) compared to subjects with two normal 
function (*1 or *2) alleles (p<0.05 for AUC and 8h concentration, respectively, Figure 25C and Figure 
25D). In plasma, however, only metoprolol AUC0-24h, but not 8h concentrations were higher for 
intermediate and poor metabolizers compared to extensive metabolizers with two normal function 
alleles (Figure 25 A and B). No significant difference between extensive metabolizers with two and those 
with only one normal function allele was found. 
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Figure 25. Metoprolol AUC in plasma and saliva versus CYP2D6 genotype (A and C), metoprolol concentration in plasma and 
saliva versus CYP2D6 genotype (B and D). 
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6.4. Discussion 
 
In our study we investigated a new combination of probe drugs for simultaneous phenotyping of six 
major human cytochromes in plasma, saliva and dried blood spots. Limited availability and tolerability of 
specific probe drugs are major limitations of many published cocktails, preventing more widespread use 
of this phenotyping tool [18]. One of our main goals was to develop a phenotyping cocktail that causes 
minimal pharmacodynamic effects and thus could also be applied to patients. In contrast to many 
existing cocktails, all probe drugs of our cocktail are approved for clinical use and commercially available 
in many countries. They were administered at the lowest approved oral dose and the selected 
combination proved to be safe and did not cause any relevant effects on vital signs or vigilance in our 
study subjects.  
After excluding chlorzoxazone from the initial drug combination, we did not find evidence for mutual 
pharmacokinetic interactions between the final six cocktail probe drugs. In contrast to many published 
phenotyping cocktails which used changes in phenotyping metrics as an indicator for pharmacokinetic 
interactions [8, 11-13, 24, 30], we performed bioequivalence tests based on full pharmacokinetic 
profiles of all our cocktail probe drugs. All intra-subject CV% were lower than 30%, hence the standard 
bioequivalence limits for low-variability drugs of 0.8-1.25 were applied and met by all six probe drugs 
[92]. 
Another draw-back of many available phenotyping methods are complicated sampling procedures 
requiring collection of more than one sample matrix at multiple time-points after dosing. We present 
one of the first phenotyping cocktails that is completely based on plasma as single sample matrix. Apart 
from the Quebec cocktail, which only uses urine samples [12], most other cocktails are based on at least 
two different matrices, usually plasma and urine. Use of a single matrix not only offers the advantage of 
easier sample processing, but also reduces the complexity of bioanalytical method validation and pre-
analytical sample work-up. 
To promote clinical application of phenotyping procedures, a single sampling time-point as early as 
possible after dosing would be ideal. With our cocktail a single plasma sample 4 hours after dosing could 
be proposed for five of the six CYP isoforms (CYP1A2, 2B6, 2C19, 2D6 and 3A4) with good correlations 
(R2 >0.82) between concentration ratios and AUC ratios (Table 13). The only exception is CYP2C9, where 
the correlation between losartan metabolic ratios and AUC ratios at 4h was poor and a later time point 
was needed for better correlation. On the other hand, at time-points later than 4 hours, midazolam and 
omeprazole could not be reliably quantified due to their short plasma half-lifes. Therefore two sampling 
time points, the first 2 hours and the second 8 hours after dosing are proposed to obtain reasonable 
correlations for all six CYP isoforms of the cocktail.  
Efavirenz is a specific substrate for CYP2B6 in vitro [37] and CYP2B6 poor metabolizer genotypes are 
associated with elevated efavirenz exposure in vivo [93, 94]. Efavirenz is listed as a sensitive CYP2B6 
substrate in the FDA/CDER draft guidance on drug interaction studies but has so far not been used as 
part of a phenotyping cocktail [92]. Therapeutic doses of efavirenz are associated with side effects such 
as vivid and unpleasant dreams which typically occur after the first one or two doses. In our cocktail 
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efavirenz was used at a dose of 50mg, which is more than ten times lower than the recommended 
therapeutic dose. At this low dose it was well tolerated without causing any relevant side effects. 
Efavirenz can thus be safely used as part of a phenotyping cocktail without interfering with phenotyping 
metrics of other CYP isoforms. 
Metoprolol is an established probe drug for CYP2D6, which is mainly responsible for α-hydroxylation of 
metoprolol [95]. Urinary metoprolol/α-hydroxymetoprolol concentration ratios show a bimodal 
distribution corresponding to extensive and poor metabolizer subgroups and they are highly correlated 
with urinary debrisoquine/4-hydroxydebrisoquine ratios [96]. In contrast to metoprolol concentration 
ratios in urine, which have previously been used as phenotyping metric [12, 13], metoprolol metabolic 
ratios in plasma have so far not been used in phenotyping cocktails.  
Our data showed a high correlation between metoprolol metabolic ratio in plasma at 8h and plasma 
AUC ratios for extensive metabolizers.  
The only intermediate metabolizer in the sample had a distinctly higher metabolic ratio of 8.3 compared 
to the extensive metabolizers, while for the poor metabolizer no ratio could be calculated due to 
undetectable hydroxymetoprolol. For the poor metabolizer subject no metabolic ratio could be 
calculated due to undetectable hydroxymetoprolol. In such cases an alternative metabolic ratio could be 
obtained by substituting the lower limit of quantification of the bioanalytical method for the non-
detectable metabolite concentration. For our subject this would have resulted in a ratio of 29. Although 
not a “true” metabolic ratio, this alternative ratio clearly indicates poor metabolic activity and could be 
useful to detect poor CYP2D6 metabolizers. The proposed procedure should to be tested in a larger 
sample with a sufficient number of poor metabolizer subjects. 
Our observations are in line with data published on metoprolol metabolic ratios in plasma. In a study 
with healthy Asian subjects, the 3h metoprolol/hydroxymetoprolol concentration ratios in plasma 
correlated with 0-8h urinary metabolic ratios and were distinctly higher for poor compared to extensive 
metabolizers [97]. In another study hydroxymetoprolol could not be detected in poor metabolizers, due 
to insufficient sensitivity of the analytical method (lower limit of quantification 5ng/ml) [9]. In a 
prospective clinical study with primary care patients treated with metoprolol, concentrations ratios 
taken at the end of the dose interval were higher for poor metabolizers compared to intermediate and 
extensive metabolizers, without an overlap between the ratios of intermediate and poor metabolizers 
[98].  
Losartan has so far been used as a probe drug for CYP2C9 in two phenotyping cocktails. In both cocktails 
the 0-8h urinary losartan/E-3174 ratio was used [28, 30]. Although less well validated than tolbutamide, 
the urinary losartan/E-3174 ratios have been shown to be significantly higher in subjects carrying a 
CYP2C9*3 diminished-function allele compared to subjects with wild-type alleles [43, 99, 100] and 
plasma AUClosartan/AUCE-3174 ratios were highly correlated with the corresponding urinary ratios [43]. 
Furthermore, the plasma AUClosartan/AUCE-3174 ratio is also significantly altered by the CYP2C9 inhibitor 
fluconazole [101]. In our study we found a reasonable correlation between the plasma losartan/E-3174 
metabolic ratios at 8h with the plasma AUClosartan/AUCE-3174 ratios. A possible explanation for the lower 
correlation with plasma AUC ratios compared to the other probe drugs of the cocktail could be the fact 
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that losartan undergoes enterohepatic circulation which increases variability of concentrations around 
4-8 hours after dosing [102].  
Availability of minimally or non-invasive sampling procedures such as DBS or saliva would further 
increase attractiveness of phenotyping outside of clinical research settings. However, the low systemic 
drug exposures reached with our low-dose cocktail pose bioanalytical challenges when using alternative 
matrices. In DBS reliable single point concentration ratios could only be obtained for the probe drugs of 
CYP1A2 and 2C19. Feasibility of using DBS for phenotyping of CYP3A4 has been shown by another group 
using a higher midazolam dose (7.5mg) together with extensive pre-analytical sample work-up and 
detection with a UPLC-LCMS system [90]. For CYP2C9, DBS has recently been evaluated using 
flurbiprofen as probe drug [17].  
In saliva, a useful correlation between single point concentration ratios and AUC ratios was only found 
for CYP1A2, whereas the correlation for CYP2C19 was moderate. Using a higher midazolam dose of 
7.5mg we have previously shown the usefulness of saliva for non-invasive phenotyping of CYP3A4 [16], 
again emphasizing the need for ultrasensitive bioanalytical methods before alternative matrices such as 
DBS or saliva can be used for the phenotyping of all major CYP isoforms. Although we were not able to 
quantify OH-metoprolol in saliva, inspection of the metoprolol data in saliva showed that in contrast to 
the corresponding plasma values, both metoprolol AUC and metoprolol concentrations at 8h were able 
to distinguish intermediate and poor metabolizers from extensive metabolizers. The reason for this 
finding is not clear, however, if confirmed in a larger sample, this would be an attractive alternative for 
non-invasive CYP2D6 phenotyping. 
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6.5. Conclusions 
 
We have validated a new phenotyping cocktail that offers several improvements compared to 
established procedures. The required probe drugs are all approved for clinical use, commercially 
available in many countries and well tolerated at the low doses used. For the first time low-dose 
efavirenz has been included in a cocktail and correlation of metabolic ratios with AUC ratios in plasma 
has been evaluated for losartan and metoprolol. With the exception of losartan, all probe drugs are 
listed as sensitive in vivo CYP substrates by the FDA. Collection of a single plasma sample 4 hours after 
dosing for simultaneous assessment of five CYP isoforms, or two plasma samples 2 hours and 8 hours 
after dosing for the assessment of six major CYP isoforms are proposed and should be further evaluated. 
To assess validity of this approach, additional studies in subjects with altered CYP activity (either 
genetically or due to CYP induction or inhibition) are required. Use of DBS or saliva samples seems 
feasible for phenotyping of selected CYP isoforms at present. With more sensitive analytical methods in 
the future, minimally or non-invasive phenotyping procedures can be expected to become available for 
other major CYP isoforms. 
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7. Effects of induction and inhibition on the Basel Phenotyping Cocktail  
 
Adrian Derungs1, Massimiliano Donzelli1, Maria-Giovanna Serratore2, Christoph Noppen2, Stephan 
Krähenbühl1, Manuel Haschke1  
 
1 Division of Clinical Pharmacology & Toxicology and Department of Biomedicine, University Hospital 
Basel, Switzerland 
2 Viollier AG (MGS, CN), Allschwil, Switzerland 
 
7.1. Introduction 
 
In the “Basel” Phenotyping Cocktail Study we showed that caffeine, midazolam, losartan, omeprazole 
and efavirenz do not interfere with each other and can be safely administered together as phenotyping 
probe drugs. We also collected information about the variation of the metabolic ratios in a small 
population of healthy subjects that, with the only exception of an intermediate and a poor metabolizer 
for CYP2D6, did not show altered metabolism.  
One of the classic applications of phenotyping cocktails is the identification of inhibiting or inducing 
effects of new investigational drugs on cytochromes during drug development. Changes of the 
metabolic ratios of the cocktail probe substrates after exposure to the investigational drug compared 
with the metabolic ratios under baseline conditions reliably indicates whether the investigational drug 
inhibits or induces a certain cytochrome [103].  
After excluding mutual interactions between the chosen combination of probe drugs as a first validation 
step of our cocktail, we wanted to know how co-administration of an inducer or an inhibitor and genetic 
factors (poor or extensive metabolizers) would influence the metabolic ratios of the Basel cocktail.  
With these objectives, we tested the Basel cocktail alone, in combination with the known inhibitors 
ciprofloxacin, fluconazole and paroxetine and with the known inducer rifampicin in a three way 
crossover design. These drugs were selected, with the only exception of losartan, on the basis of the 
FDA “Guidance for Industry for Drug interactions Studies” [38] and/or available clinical data indicating 
that the compound could be used as a specific probe drug. 
A second aim of the “Basel” Phenotyping Cocktail Study was to evaluate whether minimally or non-
invasive sampling techniques such as collection of saliva or dried blood spots could be used instead of 
the more invasive venous blood sampling.  In the first Basel Phenotyping Cocktail Study the correlation 
between probe substrates and their metabolites measured in saliva and DBS with the corresponding 
metabolic ratios measured in plasma was evaluated. In the second study, these measurements were 
repeated to evaluate whether DBS or oral fluid sampling could also be used under conditions of 
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induction or inhibition where very low concentrations of either metabolite or parent compound will 
occur. 
7.2. Material and Methods 
7.2.1. Clinical study  
A single-center, randomized, three-way crossover study was performed at the Phase I Research Center, 
University Hospital Basel, Basel, Switzerland (ClinicalTrials.gov  Identifier: NCT01386593). Screening 
procedures and exclusion criteria were the same as used in the 1st Basel cocktail study (6.2.1).  
Single doses of caffeine, efavirenz, losartan, omeprazole, metoprolol and midazolam were administered 
together as a cocktail with and without preliminary inhibition with fluconazole, ciprofloxacin and 
paroxetine or induction with rifampicin. Each treatment was investigated in the same group of 16 
healthy male subjects. The study was divided in three treatment arms A, B, and C (Figure 26, Table 17). 
 
 
Figure 26. Study Design 
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Table 17. Study drug administration plan 
 
 
All the subjects received the Basel Cocktail (treatment A) to establish the baseline pharmacokinetic 
profile: 
• Treatment A: single oral dose of 100 mg caffeine, 50 mg efavirenz, 12.5 mg losartan, 10 mg 
omeprazole, 12.5 mg metoprolol and 2 mg midazolam. 
 
After treatment A, one group received treatment B and then treatment C, while the other group 
received first treatment C and then treatment B: 
• Treatment B (Inhibitors and Basel cocktail): 
• Day -3, morning: fluconazole 400 mg and paroxetine 20 mg. 
• Day -2, morning: fluconazole 100 mg and paroxetine 20 mg. 
• Day -1, morning: fluconazole 100 mg, paroxetine 20 mg, ciprofloxacin 750 mg. 
• Day -1, evening: ciprofloxacin 750 mg. 
• Day 1, 1 h before administration of the Basel Cocktail: fluconazole 100 mg, paroxetine 20 mg, 
ciprofloxacin 750. 
 
• Treatment C (Inducer and Basel cocktail): 
• Day -7 to -1, daily: rifampicin 600 mg. 
• Day 1 Basel Cocktail. 
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7.2.2. Pharmacokinetic sampling 
Pharmacokinetic sampling was performed as described for the 1st Basel cocktail (see 6.2.3).  
7.2.3. Pharmacodynamic measurements and adverse events 
Pharmacodynamic assessment (heart rate, blood pressure, sedation) was performed as described for 
the 1st Basel cocktail study (see 6.2.4). 
7.2.4. Study drugs 
The Basel cocktail drugs (see paragraph 6.2.5), ciprofloxacin (Ciproxin®, 750 mg, Bayer), fluconazole 
(Diflucan®,200 mg, Pfizer), paroxetine (Deroxat®, 20 mg, GlaxoSmithKline), and rifampicin (Rimactan®, 
600 mg, Sandoz) were purchased through the University Hospital Pharmacy, Basel, Switzerland.  
7.2.5.  Bioanalytical analysis 
The bioanalytical method used for the analysis of the plasma, saliva, blood and DBS samples is described 
in chapter 5. 
7.2.6. Genotype analysis 
DNA was isolated from 400 μL EDTA-blood on an m2000sp instrument (Abbott Molecular, De Plaines, IL, 
USA) following the manufacturer’s protocol. Final elution volume was 100 μL. Specific single nucleotide 
polymorphisms in the genes encoding CYP1A2 (alleles *1A, *1F), CYP2B6 (alleles *1, *6), CYP2C9 (alleles 
*1, *2, *3), CYP2C19 (alleles *1, *2, *3) and CYP2D6 (*1, *2, *3, *4, *5, *6, *XN) were detected using 
primer/probe real time PCR reagent (Lightmix, TIB MOLBIOL, Berlin, Germany) on a Lightcycler 1.5 
instrument (Roche Diagnostics, Rotkreuz, Switzerland). Detection of hybridization of amplified products 
was performed using the Infiniti chip technology (Autogenomics, Carlsbad, USA) according to the 
manufacturer’s instructions. 
Subjects with SNPs responsible for relevant altered CYP activity were not included in the phenotyping 
data evaluation. 
 
7.2.7. Data analysis 
The pharmacokinetics parameters (AUC, half-life, Cmax, and tmax) were calculated as already described 
in paragraph 6.2.7. Analysis of variance (ANOVA) was performed to test for overall differences between 
the MRs in the different treatments. Post-hoc analysis using the Dunnet test was used to test for 
between group differences. All statistical analyses were done using GraphPad Prism version 6.02 
(GraphPad Software Inc., La Jolla, CA). 
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7.3. Results 
7.3.1. Pharmacodynamic effects and adverse events 
Sixteen healthy male volunteers (mean age 23.8 years, range 20-35 years, mean BMI 23.5 kg/m2, range 
20.6-27.5 kg/m2) completed the study according to the protocol. The simultaneous administration of all 
probe drugs, inhibitors as well as the inducer was well tolerated. No serious adverse events (CTC grade 3 
or higher) were observed and no relevant changes in heart rate (Figure 27 A), blood pressure (Figure 27 
B and C) or sedation score (Figure 27 D) were observed. 
 
                                        A 
 
                                        B 
 
 
 
Figure 27 (A, B). Changes of heart rate (A) and systolic blood pressure (B) were compared after administration of Basel cocktail 
(treatment A, white boxes), after administration of Basel cocktail and inhibitors (treatment B, dotted boxes) and after 
administration of Basel cocktail and inducer (treatment C, grey boxes). The whiskers represent the range with minimum and 
maximum. The boxes represent the 25.-75. percentile and the median. 
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                                        C 
 
                                          D 
 
 
Figure 27 (C, D). Changes of diastolic blood pressure (C) and sedation scores (D) were compared after administration of Basel 
cocktail (treatment A, white boxes), after administration of Basel cocktail and inhibitors (treatment B, dotted boxes) and after 
administration of Basel cocktail and inducer (treatment C, grey boxes). The whiskers represent the range with minimum and 
maximum. The boxes represent the 25.-75. percentile and the median. 
 
7.3.2. Effects of induction and inhibition on the pharmacokinetics of the 
cocktail probe drugs 
Each subject received the Basel cocktail, the Basel cocktail in concomitance with specific inhibitors 
(ciprofloxacin, fluconazole and paroxetine) and the Basel cocktail after one week pretreatment with the 
CYP inducer rifampicin. The pharmacokinetic profiles in plasma (Figure 28), saliva, blood and DBS of the 
probe drugs and of their respective metabolites were measured for the three treatments. 1'-OH-
midazolam glucuronide and 8-OH-efavirenz glucuronide were indirectly quantified in plasma and saliva 
after incubating the samples with β-glucuronidase. The pharmacokinetic profiles of the metabolites 
before and after treatment of the plasma samples with the enzyme are reported in Figure 29 and Figure 
30. 
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Figure 28. Comparison of plasma concentration time-profiles of cocktail probe drugs obtained after application of the 6-drug 
cocktail alone (blue curves), in presence of the inhibitors paroxetine, ciprofloxacin, and fluconazole (red curves) as well as in 
presence of the inducer rifampicin (green curves). Concentration-time profiles are shown for parent drugs and their 
corresponding metabolites for CYP1A2 (A), CYP2B6 (B), CYP2C9 (C), CYP2C19 (D), CYP2D6 (E) and CYP3A4 (F). 
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Figure 29. Comparison of plasma concentration time-profiles of 8-OH-efavirenz obtained after application of the 6-drug cocktail 
alone (blue curves), in presence of the inhibitors paroxetine, ciprofloxacin, and fluconazole (red curves) as well as in presence 
of the inducer rifampicin (green curves). Concentration-time profiles before (A) and after (B) treatment with β-glucuronidase. 
 
 
Figure 30. Comparison of plasma concentration time-profiles of 1’-OH-midazolam obtained after application of the 6-drug 
cocktail alone (blue curves), in presence of the inhibitors paroxetine, ciprofloxacin, and fluconazole (red curves) as well as in 
presence of the inducer rifampicin (green curves). Concentration-time profiles before (A) and after (B) treatment with β-
glucuronidase. 
 
The exposure to inhibitors and the inducer was checked by determining the AUCs of paroxetine, 
ciprofloxacin, fluconazole and rifampicin in each subject (Figure 31). Subject  number 1 was found to be 
non-compliant with rifampicin pre-treatment and was excluded from subsequent analyses of induction 
data.  
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Figure 31. Exposure of study subjects to inhibitors and inducers. Plasma AUC0-24h of Paroxetine (A), Ciprofloxacin (B), 
Fluconazole (C), and Rifampicin (D). 
 
The extent of inhibition and induction was graded following FDA guidelines. A drug was considered a 
weak, moderate or strong inhibitor of a CYP isoform when a 1.25 to 2-fold, 2 to 5-fold or more than 5-
fold increase in the AUC of the CYP specific substrate was observed, respectively. It was considered a 
weak, moderate or strong inducer of a CYP isoform when a 20-50%, 50-80% or more than 80% decrease 
in AUC of the CYP specific substrate was observed, respectively. 
In our study varying degrees of inhibition (Table 18, Figure 32) and induction (Table 19, Figure 33) of the 
different CYPs involved were observed for each individual study subject. Despite using three different 
inhibitors we were not able to achieve adequate inhibition of CYP 2B6 in all subjects and in up to one 
third of the subjects no inhibition was achieved for CYP1A2 and CYP2C9. For CYP2C19 in contrast, most 
subjects showed a strong level of inhibition, while for the remaining CYP isoforms weak to moderate 
inhibition was reached. Using rifampicin, weak to moderate induction was seen for CYP2B6 and CYP2C9. 
The highest effect was observed for CYP2C19 and CYP3A4. For CYP1A2 and CYP2D6 on the other hand, 
no induction was observed in more than half of the subjects. 
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Table 18. Degree of inhibition (n=16) estimated using plasma AUC0-24h of parent drugs. AUC0-24h fold change (AUC0-24h after 
administration of inhibitors / AUC0-24h baseline) for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6,  and CYP3A4. 
INHIBITION no inhibition weak moderate strong 
CYP1A2 4 (25%) 9 (56%) 3 (19%) - 
CYP2B6 16 (100%) - - - 
CYP2C9 6 (37%) 10 (63%) - - 
CYP2C19 - 1 (6%)  15 (94%) 
CYP2D6 - 9 (56%) 7 (64%) - 
CYP3A4 - - 13 (81%) 3 (19%) 
 
 
Table 19. Degree of induction (n=15, subject 1 excluded from the evaluation) estimated using plasma AUC0-24h of parent drugs. 
AUC0-24h % decrease (100-AUC0-24h after administration of inducer / AUC0-24h  baseline x 100) for CYP1A2, CYP2B6, CYP2C9, 
CYP2C19, CYP2D6, and CYP3A4. 
INDUCTION no induction weak moderate strong 
CYP1A2 8 (53%) 7 (47%) - - 
CYP2B6 - 14 (93%) 1 (7%) - 
CYP2C9 - 6 (40%) 9 (60%) - 
CYP2C19 - - 1 (7%) 14 (93%) 
CYP2D6 10 (67%) 5 (33%)   
CYP3A4 - - 8 (53%) 7 (47%) 
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Figure 32. Effect of inhibitors on plasma AUC0-24h of parent drugs. AUC0-24h fold change (AUC0-24h after administration of 
inhibitors / AUC0-24h) for CYP1A2 (A), CYP2B6 (B), CYP2C9 (C), CYP2C19 (D), CYP2D6 (E), and CYP3A4 (F). 
 
 
 
 Page 92 
 
 
Figure 33. Effect of rifampicin on plasma AUC0-24h of parent drugs. AUC0-24h % decrease (100-AUC0-24h after administration of 
inducer / AUC0-24h X100) for CYP1A2 (A), CYP2B6 (B), CYP2C9 (C), CYP2C19 (D), CYP2D6 (E), and CYP3A4 (F). 
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7.3.3. Genotyping  
Fifteen study participants gave their consent for genotype testing for altered function alleles (Fehler! 
Verweisquelle konnte nicht gefunden werden.). CYP2D6 genotyping identified one intermediate (IM), 
14 extensive (EM) and no ultrarapid metabolizers. The IM subject (n. 10) showed the highest metabolic 
ratio at 8h after treatment A and C in plasma (9.0 and 8.0, respectively) and saliva (18.1 and 17.6, 
respectively). Therefore additional genotype testing was performed and a combination of a loss-of-
function and a diminished-function allele (CYP2D6*4/*41) was observed.  
For CYP2B6 and CYP2C9 no poor metabolizers were identified. Nine subjects were heterozygous for 
diminished-function alleles of CYP2B6 (CYP2B6*6, n=6) and/or CYP2C9 (CYP2C9*2, n=1 and CYP2C9*3, 
n=5). CYP2C19 genotyping identified four heterozygous subjects for a diminished-function allele 
(CYP2C19*2) and one poor metabolizer (CYP2C19 *2/*2). This subject (n. 15) showed the highest 
metabolic ratio at 2h in plasma (5.8) after treatment with rifampicin.  
Genotyping of CYP1A2 identified four homozygous and ten heterozygous subjects for the *1F allele, 
which is associated with increased inducibility.  
Data obtained from the CYP2D6 IM (subject 10) and the CYP2C19 PM (subject 15) were not included in 
the statistical analysis of metabolic ratios for CYP2D6 and CYP2C19, respectively. 
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Table 20: Results of genotyping analysis (Basel cocktail study II). WT, wildtype; HT, heterozygous; HO, homozygous; neg,  gene 
deletion or duplication not observed. Subject 8 did not give consent for genotype testing. CYP2D6*41 was only tested in subject 
10. 
 
 
 
  
CYP Allele Subject    1
Subject            
2
Subject    
3
Subject    
4
  Subject 
5
  Subject 
6
Subject   
7
  Subject 
9
1A2 CYP1A2*1F HT HT HO HT WT HT HT HO
2B6 CYP2B6*6 HT WT WT HT WT HT HT HT
2C9 CYP2C9*2 WT WT WT WT WT WT WT WT
CYP2C9*3 WT WT WT HT HT WT HT WT
2C19 CYP2C19*2 WT WT WT WT WT HT WT HT
CYP2C19*3 WT WT WT WT WT WT WT WT
2D6 CYP2D6*3 WT WT WT WT WT WT WT WT
CYP2D6*4 WT HT HT HT HT WT WT WT
CYP2D6*5 neg neg neg neg neg neg neg neg
CYP2D6*6 WT WT WT WT WT WT WT WT
CYP2D6*XN neg neg neg neg neg neg neg neg
CYP2D6*41
CYP Allele Subject 10
Subject 
11
Subject 
12
Subject 
13
Subject 
14
Subject 
15
Subject 
16
1A2 CYP1A2*1F HO HT HT HT HT HT HO
2B6 CYP2B6*6 WT HT HT HT HT WT WT
2C9 CYP2C9*2 WT WT WT WT HT WT WT
CYP2C9*3 WT WT HT HT WT WT WT
2C19 CYP2C19*2 HT WT WT HT WT HO WT
CYP2C19*3 WT WT WT WT WT WT WT
2D6 CYP2D6*3 WT WT WT WT WT WT WT
CYP2D6*4 HT WT HT WT WT WT HT
CYP2D6*5 neg neg neg neg neg neg neg
CYP2D6*6 WT WT WT WT WT WT WT
CYP2D6*XN neg neg neg neg neg neg neg
CYP2D6*41 HT
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7.3.4. Effects of induction and inhibition on single point metabolic ratios 
in plasma 
In the first Basel cocktail study metabolic ratios were proposed 2 h after dosing for CYP2C19 and 
CYP3A4, and 8 h after dosing for CYP1A2, CYP2B6, CYP2C9, and CYP2D6. We determined metabolic 
ratios at the same time-points in the second study. All study samples were analyzed using sensitive high 
performance liquid chromatography tandem mass spectrometry. Despite the high sensitivity of our 
analytical method, concentrations of metabolite or parent compound were not detectable in a number 
of subjects after pre-treatment with inhibitors or the inducer. Since non-detectability of the parent or of 
the metabolite is a consequence of strong inhibition or induction, we decided to substitute a 
concentration corresponding to the lower limit of quantification (e.g. 0.5 or 1 ng/mL) of the bioanalytical 
method for undetectable parent or metabolite concentrations. Substituting  the LLOQ  for non-
detectable parent or metabolite concentrations allowed us to calculate an “artificial” metabolic ratio, 
representing the most cautious estimate of the true metabolic ratio that could be obtained if a more 
sensitive analytical method would be available. 
The correlations of individual single point metabolic ratios with their corresponding AUC ratios for the 2 
hour and 8 hour time-points are shown in Figure 34. In the first study the coefficients of determination 
were >0.8 for all correlations except for losartan, which had an R2 of 0.59. For the second study the 
coefficients of determination after administration of the Basel cocktail were also >0.8 for all correlations 
except for omeprazole, which had an R2 of 0.698. 
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Figure 34. Effect of CYP-inhibitors (treatment B) and the CYP-inducer rifampicin (treatment C) on the correlation between AUC0-
24h ratios and single time-point concentration ratios of specific CYP substrates and their main metabolites in plasma for CYP1A2 
(paraxanthine/caffeine at 8 hours, Figure 34A) , CYP2B6 (efavirenz/8-OH-efavirenz at 8 hours,Figure 34B), CYP2C9 (losartan / 
E3174 at 8 hours,Figure 34C), CYP2C19 (omeprazole /5-OH-omeprazole  at 2 hours, Figure 34D), CYP2D6 (metoprolol/OH-
metoprolol at 8 hours, Figure 34E), and CYP3A4 (midazolam/1’-OH-midazolam at 2 hours, Figure 34F). 
 
Rifampicin is known to induce enzymes involved not only in phase I but also in phase II reactions. 
Considering only the concentration of the phase I metabolite (e.g. 1’-OH-midazolam) in cases where it is 
further metabolized by an inducible phase II reaction (e.g. glucuronidation), will result in metabolic 
ratios that do not adequately reflect the extent of induction. For a reasonable estimate of induction, all 
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induction products, i.e. phase I and phase II metabolites have to be taken into account. This can be done 
either by direct determination of the concentrations of the phase II metabolites (i.e. glucuronides) or 
indirectly by reverting the phase II reaction e.g. by incubating the samples with glucuronidase. For the 
cocktail probe drugs this indirect procedure was used for the metabolic ratios of CYP2B6 and CYP3A4 
resulting in an improved separation of the metabolic ratios obtained after induction compared to 
baseline conditions (Figure 35). No glucuronidation products of other metabolites, indirectly assessed by 
a lacking increase of the phase I metabolite after treatment with β-glucuronidase, were observed. 
 
Figure 35. Effect of inhibitors (treatment B) and inducer (treatment C) on the correlation between AUC0-24h ratios and single 
time-point concentration ratios of specific CYP substrates and metabolites in plasma after treatment with glucuronidase for 
CYP2B6 (efavirenz/total 8-OH-efavirenz at 8 hours,Figure 35 A) and CYP3A4 (midazolam/total 1’-OH-midazolam at 2 
hours,Figure 35 B). 
 
Considering the total 8-OH-efavirenz (CYP2B6) and 1’-OH-midazolam (CYP3A4) results in a better 
separation of the metabolic ratios between treatment A and treatment C. 
The effect of inhibition and induction on metabolic ratios was visualized using box plots (Figure 36 and 
Figure 37) and individual changes of metabolic ratios using line series graphs (Figure 38-Figure 44). 
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Figure 36. Box plot comparing the effect of inhibitors (treatment B) and inducer (treatment C) on the metabolic plasma ratio for 
CYP1A2 (Figure 36A) , CYP2B6 (Figure 36B), CYP2C9 (Figure 36C), CYP2C19 (Figure 36D), CYP2D6 (Figure 36E), and CYP3A4 
(Figure 36F).  
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Figure 37. Box plot comparing the metabolic plasma ratios for CYP2B6 (A) and CYP3A4 (B) in the different treatments after 
enzymatic hydrolysis with glucuronidase. 
 
The individual metabolic ratios of all subjects treated with inhibitors increased compared to baseline. 
Post hoc analysis confirmed a statistically significant difference between A and B for all CYPs. 
Comparison between treatment A and C, showed a non-significant difference between A and C for 
CYP1A2, CYP2C9 and CYP3A4. However, for CYP3A4 the difference between A and C treatment did 
become significant when the total deglucuronized OH-midazolam was used to calculate the metabolic 
ratio. 
 
Table 21. Mean plasma metabolic ratios (MR) of the different CYP isoforms under study. Evaluation of the MR difference 
between treatment A and B and between treatment A and C by post hoc analysis. 
CYP 
Treatment A 
(baseline) 
Treatment B 
(inhibition) 
Treatment C 
(induction) 
n MR mean (range) SD n 
MR mean 
(range) SD n 
MR mean 
(range) SD 
1A2 16 0.842 (0.38-1.64) 0.300 16 
0.421**** 
(0.21-0.92) 0.171 15 
1.00  
(0.55-1.55) 0.277 
2B6 16 55.2 (31.5-105) 16.9 16 
93.8*** 
(56.3-150) 32.4 15 
28.4**** 
(17.0-35.4) 5.24 
2B6 
(deglucuronidation) 16 
3.54 
(2.1-6.1) 0.994 16 
5.55*** 
(3.05-8.19) 1.70 15 
2.04**** 
(1.4-2.6) 0.434 
2C9 16 0.0543 (0.02-0.18) 0.0425 16 
0.308*** 
(0.1-0.9) 0.245 14 
0.0550 
(0.04-0.13) 0.0247 
2C19  15 1.18 (0.61-3.1) 0.613 15 
28.0**** 
(10-52.2) 11.5 14 
0.284**** 
(0.11-0.6) 0.141 
2D6  15 2.16 (1.2-3.3) 0.579 15 
10.2**** 
(5.4-14.9) 2.55 14 
1.71* 
(1.2-2.5) 0.445 
3A4 16 1.46 (0.48-3.36) 0.697 16 
3.69**** 
(1.62-6.78) 1.35 15 
1.83 
(0.81-2.93) 0.625 
3A4 
(deglucuronidation) 16 
0.196 
(0.04-0.56) 0.114 16 
0.702**** 
(0.29-1.3) 0.333 15 
0.0689*** 
(0.024-0.13) 0.0299 
 
*, P<0.05  ***, P<0.001 ****, P<0.0001 
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7.3.5. Intra-individual changes of metabolic ratios under inhibition or 
induction 
Line series graphs were used to visualize the intra-individual changes of the metabolic ratios in the three 
different conditions (CYP1A2 Figure 38, CYP2B6 Figure 39, CYP2C9 Figure 40, CYP2C19 Figure 41, 
CYP2D6 Figure 42, CYP3A4 Figure 43, CYP2B6 and CYP3A4 after treatment with glucuronidase Figure 
44). The treatment with inhibitors resulted in a clear increase of MR (or decrease in the case of CYP1A2 
due to the “inverse” metabolic ratio) in each subject. The pretreatment with the inducer did not change 
the CYP1A2, CYP2C9 or the CYP2D6 metabolic ratios. However, a clear reduction of the metabolic ratio 
in each subject was observed for CYP2B6 and for CYP2C19. CYP3A4 line series graphs showed a clear 
trend when the total OH-midazolam (i.e. after de-glucuronidation) was considered.  
 
Figure 38. Comparison of the plasma MR of CYP1A2 after administration of the cocktail alone (treatment A) versus the cocktail 
co-administered with inhibitors (treatment B) or co-administered with inducer (treatment C). 
 
 
Figure 39. Comparison of the plasma MR of CYP2B6 after administration of the cocktail alone (treatment A) versus the cocktail 
co-administered with inhibitors (treatment B) or co-administered with inducer (treatment C). 
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Figure 40. Comparison of the plasma MR of CYP2C9 after administration of the cocktail alone (treatment A) versus the cocktail 
co-administered with inhibitors (treatment B) or co-administered with inducer (treatment C). 
 
 
Figure 41. Comparison of the plasma MR of CYP2C19 after administration of the cocktail alone (treatment A) versus the cocktail 
co-administered with inhibitors (treatment B) or co-administered with inducer (treatment C). The subject with the highest MR 
after treatment A and C had a poor metabolizer genotype. 
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Figure 42. Comparison of the plasma MR of CYP2D6 after administration of the cocktail alone (treatment A) versus the cocktail 
co-administered with inhibitors (treatment B) or co-administered with inducer (treatment C). The subject with the highest MR 
after treatment A and C had an intermediate metabolizer genotype. 
 
 
Figure 43. Comparison of the plasma MR of CYP3A4 after administration of the cocktail alone (treatment A) versus the cocktail 
co-administered with inhibitors (treatment B) or co-administered with inducer (treatment C). 
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Figure 44. Comparison of the plasma MR of CYP2B6 and CYP3A4 after administration of the cocktail alone (treatment A) versus 
the cocktail co-administered with inducer (treatment C) after treatment with glucuronidase. 
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7.3.6. Effect of induction and inhibition on single point metabolic ratios 
in oral fluid and DBS 
In saliva, the concentrations of all analytes except caffeine, paraxanthine, omeprazole, 5-hydroxy-
omeprazole, metoprolol and hydroxy-metoprolol were too low to allow reliable quantification (LLOQ 
between 0.5 and 5 ng/ml, Table 8). Non-detectable concentrations of metabolite or parent compound 
were therefore replaced with the appropriate LLOQs to estimate the metabolic ratios in saliva.  
In saliva the glucuronidation products present in plasma were not detected.  
 
 
Figure 45. Effect of inhibitors (treatment B) and inducer (treatment C) on the correlation between AUC0-24h ratios and single 
time-point concentration ratios of specific CYP substrates and metabolites in saliva for CYP1A2 (paraxanthine/caffeine at 8 
hours, Figure 45A) , CYP2C19 (omeprazole /5-OH-omeprazole  at 2 hours, Figure 45B), and CYP2D6 (metoprolol/OH-metoprolol 
at 8 hours, Figure 45C). 
 
 
Box plot and line series graphs of saliva metabolic ratios showed the same trend as observed in plasma 
(Figure 46, Figure 47, Figure 48, and Figure 49). In saliva the difference between the metabolic ratio A 
and C for CYP1A2 and CYP2C19 was not significant (Table 22).  
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Figure 46. Box plot comparing the effect of inhibitors (treatment B) and inducer (treatment C) on the metabolic saliva ratio for 
CYP1A2 (Figure 46A), CYP2C19 (Figure 46B), and CYP2D6 (Figure 46C).  
 
Table 22. Mean saliva metabolic ratios (MR) of the CYPs under study. Evaluation of the MR difference between treatment A 
and B and between treatment A and C by post hoc analysis. 
CYP 
Treatment A 
(baseline) 
Treatment B 
(inhibition) 
Treatment C 
(induction) 
n MR mean SD n MR mean SD n MR mean SD 
1A2 16 0.783 0.275 16 0.362**** 0.158 15 0.953 0.336 
2C19  14 0.315 0.245 14 8.75**** 3.72 13 0.173 0.0954 
2D6  15 3.25 1.34 15 55.8**** 26.6 14 2.043** 1.06 
 
**, P<0.01  ****, P<0.0001 
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Figure 47. Comparison of the saliva MR of CYP1A2 after administration of the cocktail alone (treatment A) versus the cocktail 
co-administered with inhibitors (treatment B) or co-administered with inducer (treatment C). 
 
 
 
Figure 48. Comparison of the saliva MR of CYP2C19 after administration of the cocktail alone (treatment A) versus the cocktail 
co-administered with inhibitors (treatment B) or co-administered with inducer (treatment C). The subject with the poor 
metabolizer genotype showed non-detectable concentrations of omeprazole and OH-omeprazole in saliva 2h after 
administration of treatment A and B. 
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Figure 49. Comparison of the saliva MR of CYP2D6 after administration of the cocktail alone (treatment A) versus the cocktail 
co-administered with inhibitors (treatment B) or co-administered with inducer (treatment C). The subject with the highest MR 
after treatment A and C had an intermediate metabolizer genotype. 
 
 
DBS samples were also analysed. The LLOQ for losartan, E-3174, and OH-efavirenz was not low enough 
to quantify these analytes in DBS. Analysis will need to be repeated with a more sensitive method 
specifically adapted to DBS applications. 
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7.3.7. Reproducibility of single point plasma metabolic ratios measured 
in the two Basel cocktail studies  
The metabolic ratios measured in the first and the second Basel cocktail studies are displayed in a box-
plot (Figure 50). For the first cocktail study not only the metabolic ratios measured in treatment E were 
considered, but also the MRs from the safe 3-drug combination. For the second study, only the MRs 
after treatment A are reported. Four subjects participated in both studies. Their MRs measured in the 
first (October-December 2010) and in the second study (October-December 2011) are reported in Figure 
51. 
 
Figure 50. Metabolic ratios measured in the first and the second Basel cocktail study 
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Figure 51. Metabolic ratios of the four subjects that took part in both studies. 
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7.4. Discussion 
In the first Basel cocktail study we showed that a new probe drug combination can be used 
simultaneously without mutual interactions. We demonstrated that single point metabolic ratios (MRs) 
collected 2 and 8h after administration of the phenotyping drugs correlate with the AUC ratios and 
therefore we proposed these single timepoint determinations to simplify the sampling procedure. In the 
second Basel cocktail study we have performed additional validation steps and evaluated the effects of 
inducers and inhibitors. According to FDA guidelines the increase or decrease of AUC of the phenotyping 
drug before and after the administration of the potential inhibitor or inducer of a drug metabolizing 
enzyme should be measured to determine whether a drug acts as an inducer or inhibitor. The choice of 
inhibitors and inducers for the second study was based on the criteria mentioned in paragraphs 3.5. 
According to literature data, paroxetine is a potent inhibitor of CYP2D6 and a weak inhibitor of CYP2B6, 
whereas fluconazole inhibits CYP2C9, CYP2C19, and CYP3A4, while ciprofloxacin is a weak inhibitor of 
CYP1A2. Rifampicin is a well-documented inducer of CYP2B6, CYP2C9, CYP2C19, and CYP3A4. In our 
study, when considering AUC fold increase, we observed no inhibition of CYP2B6 and weak to strong 
inhibition of the others CYPs (Table 18, Figure 32), while when considering AUC decrease after 
administration of rifampicin, we measured a weak induction of CYP1A2 and CYP2B6 and a weak to 
strong induction of the other CYPs (Table 19, Figure 33). For most of the cocktails published so far no 
data about the change of the phenotyping metric under conditions of induction or inhibition is available. 
The only exception is the Karolinska cocktail which has been tested after pretreatment with rifampicin 
[69]. Using the same probe substrates and MRs as in our study for CYP1A2, CYP2C9 and CYP2C19, the 
authors showed the MRs to be sensitive to rifampicin induction (500mg during 14 days). Unlike that 
study, we used plasma to quantify the CYP2C9 MR instead of urine. Moreover the induction of CYP3A4 
was already observed after pretreatment with a low dose of rifampicin (20 mg) using both quinine/3’-
hydroxyquinine and 4β-hydroxycholesterol MRs as phenotyping indexes. Despite the CYP2C9 MR 
variation after induction being statistically significant, a relevant intra-subject change was only observed 
in a few subjects.  
The use of MRs instead of full pharmacokinetic profiles considerably simplifies sample collection for 
phenotyping, e.g. for clinical applications, and has already been extensively documented in previous 
studies [16,104]. In the present study we confirmed the high correlation between plasma MRs and AUC 
ratios of the phenotyping drugs under baseline conditions. In the first study the R2 for all correlations 
were higher than 0.592, while in the second study all R2 were higher than 0.698. 
One of the objectives of the second Basel cocktail study was to evaluate whether the effect of inducers 
and inhibitor on AUC, the reference procedure suggested by FDA, could be observed to a same extent 
using MRs. After pre-treatment with a specific CYP inhibitor, a clear separation of the MRs compared to 
baseline was observed for CYP2C19 and CYP2D6. This becomes apparent by the non-overlapping 
boxplots and the clearly different ranges of MRs (Table 21). Subjects with a CYP2C19 EM genotype had 
baseline MRs between 0.61 and 3.1, while after pre-treatment with the inhibitor their MRs were 
between 10.0 and 52.2. Subjects with a CYP2D6 EM genotype showed baseline MRs between 1.2 and 
3.3, while after inhibition their MRs moved to a range between 5.4 and 14.9. Considering intra-subject 
variations, MRs were just as sensitive indicators of inhibition as the extent of AUC increase, the 
reference approach. In all subjects an increase of MR (decrease for CYP1A2) was observed between 
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basal concentrations and post-inhibition concentrations with statistically significant differences for all 
the CYPs. 
Compared to inhibition, the effects of induction were less evident in changes of AUCs and MRs. A 
significant within-subject decrease of MRs was observed for CYP2B6, CYP2C19, and CYP3A4 (p<0.001 
when total OH-midazolam was considered). For CYP1A2, metabolic ratios after pre-treatment with 
rifampicin did not show significant differences compared to baseline. This can be explained by the fact 
that rifampicin is not an ideal inducer of CYP1A2. Potent inducers of CYP1A2 are halogenated or 
polycyclic aromatic hydrocarbons (e.g. present in cigarette smoke) that act via the aryl hydrocarbon 
receptor, which is not activated by rifampicin [105]. Therefore, induction studies on CYP1A2 are 
generally performed by comparing cigarette smokers with non-smokers, a strategy that was not feasible 
for our cocktail study due to logistical reasons.  
We introduced the use of LLOQs to calculate the MRs for cases where the concentrations of parent 
compound or metabolite were below the limit of quantification of the analytical method. This approach 
takes into consideration that the non-detectability of the parent or the metabolite also provides 
relevant information regarding induction or inhibition.  
CYP2D6 is regarded as a non-inducible CYP isoform. In this study, five subjects showed an AUC decrease 
between 20 and 50%, formally corresponding to weak induction while the other subjects showed a non-
relevant AUC decrease lower than 20%. A small but statistically significant decrease of MRs (p<0.05) was 
observed. In 1982 Bennet et al [106] reported a decrease of 30% in metoprolol AUC after the 
administration of 600 mg of rifampicin for 13 days. Our findings show a less pronounced decrease of 
AUC. Induction of other metabolic pathways of metoprolol could explain such an effect. However, a 
search of the literature did not reveal any studies confirming Bennet’s findings or supporting the 
hypothesis of alternative metabolic pathways. Metoprolol appears to be a good probe drug for 
phenotyping itself and in the presence of inhibitors, but is probably not the best choice when 
performing induction studies. The hypothesis of alternative CYP isoforms involved in metoprolol 
metabolism after induction with rifampicin should be followed up e.g. with in vitro experiments using 
supersomes expressing specific CYP isoforms. 
Induction of CYP2C9 using rifampicin was weak to moderate when estimated by extent of AUC decrease, 
while decrease of losartan/E3174 plasma ratios was not significant. In 2012, during completion of our 
study, Daali et al suggested the use of flurbiprofen to phenotype CYP2C9 measuring 4'-hydroxy-
flurbiprofen/flurbiprofen metabolic ratio in plasma and dried blood spots 2h after administration of 50 
mg of flurbiprofen [17]. The authors showed that the proposed metabolic ratios were sensitive to 
fluconazole inhibition and to rifampicin induction. Flurbiprofen seems to be a valuable alternative to the 
use of losartan to perform the phenotyping CYP2C9.  
During the evaluation of our data, Jiang et al [39] published a study proposing the use 8,14-dihydroxy-
efavirenz and efavirenz AUC 0-120h ratio for CYP2B6 phenotyping. We adapted the analytical method to 
include 8,14-dihydroxy-efavirenz and repeated the analysis of plasma and saliva samples. The 
concentrations of 8,14-dihydroxy-efavirenz 8 hours after cocktail administration were, however, below 
the limit of quantification before enzymatic hydrolysis, and lower than 6 ng/ml after treatment with 
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glucuronidase. Overall, the observed concentrations of 8,14-dihydroxy-efavirenz were negligible 
compared to the measured concentrations of 8-hydroxy-efavirenz. We therefore decided to not further 
consider the di-hydroxy metabolite in our data analysis. 
MRs appear to be less suited than AUCs to monitor induction, if sequential enzymes of the metabolic 
cascade are involved. If induction affects enzymes responsible for the decrease of both parent 
compound and phase I metabolite concentration, the ratio may not change. This phenomenon was 
observed with midazolam and efavirenz. Rifampicin is an inducer of phase I but also of phase II UGT 
mediated metabolism. After treatment with β-glucuronidase, we observed an increase of the 
concentrations of 1'- OH-midazolam and 8-OH-efavirenz, showing that phase II metabolism concerns 
only the isoforms CYP3A4 and CYP2B6 in our cocktail. The total amount of metabolites (i.e. the sum of 
phase I and phase II metabolites) has to be taken into account for the calculation of MRs of these two 
CYPisoforms [16].  
While the AUC fold increase or % decrease is a quantitative measure of inhibition and induction (weak, 
moderate, or strong), MRs can only give qualitative information. A quantitative evaluation of MR change 
as for AUC was explored but the correlation results were not satisfactory. AUCs that depend on parent 
compound should not be compared with MR ratios, which consider parent and metabolite.  
The metabolic ratios measured for baseline treatment in the first and in the second Basel cocktail study 
were collected and compared. The mean MR values for all the CYPs were comparable. In four subjects 
that participated in both studies, an intra-subject comparison was performed. Reproducibility of MRs is 
fundamental for clinical applications of phenotyping, that requires MRs to be stable if no external 
factors cause a change of the phenotype. Despite these limited set of data, we observed a systematic 
MR decrease after one year, that was more pronounced for CYP2B6 and CYP2D6. Attributing such a 
decrease to external causes for all subjects to a same extent does not seem likely. The more sensitive 
analytical method used for the analysis of the second study may be the cause of the observed 
discrepancies. 
The possibility of performing less invasive samplings by measuring the phenotyping drugs in oral fluid 
and DBS was also investigated in this study. In saliva, MRs could be calculated for CYP1A2, CYP2C19 and 
CYP2D6. The correlation of saliva metabolic ratios for CYP1A2 at 8 hours with the corresponding plasma 
AUC ratios was lower than previously observed (previous study R2=0.812, actual study R2=0.582) 
whereas the saliva metabolic ratios at 2 hours for CYP2C19 were good (previous study R2=0.473, actual 
study R2=0.895). For CYP2D6 the correlation between the MRs in saliva and plasma AUC ratio was 0.470. 
Comparison of the saliva MR between treatment A and B by post hoc analysis confirmed the findings 
observed in plasma. Comparison of the saliva MR between treatment A and C by post hoc analysis 
produced the same results observed in plasma only for CYP1A2 and CYP2D6. In saliva CYP2C19 
metabolic ratio did not decrease significantly after rifampicin treatment.  
A considerable effort was devoted to improve the analytical method used in the first study for DBS 
analysis. The analytical method used for the second study had improved sensitivity but still not enough 
to quantify the low metabolite concentrations after inhibition or the low parent concentrations after 
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induction. Before being able to perform phenotyping using DBS for all major CYP isoforms and different 
levels of CYP activity the sensitivity needs be considerably improved.  
 
7.5. Conclusions 
We compared the pharmacokinetics profiles and metabolic ratios of the Basel phenotyping drugs at 
baseline levels, after co-administration of inhibitors, and a broad CYP inducer. We showed that plasma 
metabolic ratios provide valuable qualitative information on the activity of relevant drug metabolizing 
CYP isoforms and constitute a valuable alternative to the reference method based on AUC 
measurements. So far, for the majority of the published phenotyping cocktail, no validation data under 
conditions of CYP inhibition or induction has been published. Induction of CYP1A2 was not effective, 
therefore we were not able to estimate if the MR for this CYP is suitable to detect induction. Losartan, 
the drug used to phenotype CYP2C9, produced metabolic ratios that did not reflect induction. For all the 
other CYPs plasma MRs were highly correlated with changes of AUC ratios. Ranges of the chosen 
phenotyping metrics under conditions of induction and inhibition have been presented. As more data 
will be collected in the future, these ranges can be expected to gain sufficient validity to allow 
sufficiently accurate phenotype determination. Suitability of saliva sampling has been shown for 
phenotyping of CYP1A2, CYP2C19, and CYP2D6. However, also for this non-invasive sampling method 
additional validation data will have to be collected. 
 
 
 

 Page 115 
 
8. Ongoing projects 
 
8.1. Currently running applications: the Combi-pill 
 
8.1.1. Introduction 
 
In both Basel cocktail studies, marketed formulations of caffeine, efavirenz, losartan, omeprazole, 
metoprolol and a low-dose midazolam formulation, prepared by the hospital pharmacy, were 
administered. The lowest available doses were selected and applied. The dosing as well as the release 
mechanisms of commercially available formulations were developed and approved for a specific 
therapeutic application, not for phenotyping applications. For example, we used a 12.5 mg metoprolol 
prolonged release formulation, which is the only one available in Switzerland or in the EU, to perform 
the phenotyping of CYP2D6. An oral low- dose oral formulation of midazolam was not available, 
therefore a formulation provided by the Basel hospital pharmacy was used for the cocktail studies. It 
becomes apparent that a single tablet containing all the Basel cocktail components at a dose and in a 
formulation adapted to be used for phenotyping, would be an important step forward in the 
development of a phenotyping cocktail which could be used routinely as a diagnostic tool in clinical 
practice. 
Several drugs included in the same formulation are known as combination drugs and are already used in 
clinical practice medicine. Typical examples are combinations of anti-infective drugs (e.g. amoxicillin+ 
clavulanic acid, antiretroviral drug combinations) or antihypertensive drugs (e.g. ACE-inhibitors + 
thiazide). Augmentin is a preparation of clavulanic acid and amoxicillin, HIV treatment Truvada, a 
combination of tenofovir and emtricitabine or Atripla (efavirenz, tenofovir and emtricitabine), just to 
mention the most important.  
The main advantages related with combi-pills are improved medication compliance in subjects that 
already received several medications, a modulated and adapted pharmacokinetic profile, an improved 
pharmacodynamic effects and consequently ideally a reduction of side effects of the drugs combination. 
The Basel University Pharmaceutical Technology Department has developed, to make these advantages 
available for phenotyping, a prototype of a single pill containing the six Basel cocktail substrates. 
After preliminary testing (dissolution tests, content uniformity and drug-drug compatibility tests) the 
combi-pill prototype was administered in a pilot clinical trial to one healthy volunteer. The plasma PK 
profiles generated with the new formulation were compared with the profiles measured after intake of 
the individual probe drug formulations used in the two Basel phenotyping cocktail studies. 
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8.1.2. Results and discussion 
 
An immediate release formulation containing metoprolol (10 mg, Sigma), S-omeprazole (10 mg, NEXUIM 
pellets), caffeine (10 mg, Sigma), efavirenz  (50 mg, Stocrin tablets), losartan (12.5 mg, Cosaar tablets) 
and midazolam (2 mg, Dormicum tablets) was prepared by Puckov et al (Figure 52). 
 
 
Figure 52. Layering and composition of the Combi-pill prototype 
 
Prior to the in vivo study, an in vitro comparative dissolution and content uniformity test was 
performed. The dissolution patterns of the new and the reference formulation were comparable and 
the results of the content uniformity test fulfilled the requirements (data not shown).  
The combi-pill prototype was tested in one healthy volunteer in an exploratory in vivo bioequivalence 
study. 
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 Cosaar Combi-pill  Antramups Combi-pill 
AUC 96 74 AUC 253 195 
Cmax 59 24 Cmax 184 86 
Tmax 0.25 0.5 Tmax 2 1.5 
T1/2  λz 1.9 2.2 T1/2  λz 0.7 0.7 
λ 0.36 0.32 λ 1.02 0.95 
 
Figure 53 (A-D). Plasma concentration time-profiles and PK parameters of the cocktail probe drugs obtained after application of 
marketed formulations of caffeine (A), efavirenz (B), losartan (C), omeprazole (D), metoprolol (E), midazolam (F, formulation 
prepared by the hospital pharmacy) and the same phenotyping drugs in the combi-pill. 
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 Belok Zok Combi-pill  USB 
formulation 
Combi-pill 
AUC 263 146 AUC 28.9 12.5 
Cmax 10.2 33.3 Cmax 12.4 6.3 
Tmax 2.5 1.0 Tmax 0.75 0.5 
T1/2  λz 16.4 2.5 T1/2  λz 2.1 1.3 
λ 0.04 0.28 λ 0.33 0.54 
 
Figure 53 (E-F). Plasma concentration time-profiles and PK parameters of the cocktail probe drugs obtained after application of 
marketed formulations of caffeine (A), efavirenz (B), losartan (C), omeprazole (D), metoprolol (E) , midazolam (F, formulation 
prepared by the hospital pharmacy) and the same phenotyping drugs in the combi-pill. 
 
 
To determine whether a new formulation has the same rate and extent of absorption as a reference 
drug, an in-vitro dissolution test followed by an in-vivo bioequivalence study is required. According to 
FDA guidelines, peak drug concentration (Cmax) is used to estimate drug rate absorption while the area 
under the curve (AUC) reflects the extent of absorption. Two treatments or formulations are equivalent 
if the 90% confidence interval of the geometric mean test/reference ratio for Cmax and AUC fall within 
the standard bioequivalence limits of 0.8 to 1.25. If the intra-subject variability of the PK parameters is 
higher than 30%, the drug is considered as highly variable and wider acceptance limits, e.g. 0.7 to 1.43 
may be applied. However, as shown in the first Basel cocktail study, none of the probe drugs showed 
high variability and thus the acceptance limits for the planned bioequivalence study with the combi-pill 
will also be the standard 0.8-1.25. 
Pharmacokinetic profiles and PK parameters after administration of Coffeinum (caffeine, 100 mg) and 
the combi-pill (caffeine, 10 mg) were comparable (Figure 53 A). AUC and Cmax were as expected 10 fold 
lower. Efavirenz administered as Stocrin® and as combi-pill showed comparable AUC and Cmax. Tmax 
was shorter for the combi-pill (Figure 53 B). Losartan AUC and particularly Cmax were higher after 
Cosaar® compared to the combi-pill, indicating a slower release from the combi-pill (Figure 53 C). 
The combi-pill was formulated using only (S)-omeprazole, while Antramups administered in the Basel 
cocktail studies is a 1:1 mixture of (R)- and (S)-omeprazole. The two isomers have different metabolic 
pathways, therefore the omeprazole and OH-omeprazole PK profiles of the combi-pill differ from the PK 
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profile of the racemate. (S)-omeprazole is metabolized by CYP2C19 to 5-O-desmethyl omeprazole (46%) 
and 5-hydroxy-omeprazole (27%), but an important role is also played by CYP3A4 that is responsible for 
the formation of the sulphone (27%). The (R)-isomer is a specific substrate for CYP2C19, responsible for 
the production of the main metabolite 5-hydroxy-omeprazole (94%). Only negligible amount of 5-O-
desmethyl omeprazole and sulphone are produced. As expected, the OH-omeprazole AUC of the combi-
pill was lower than the OH-omeprazole AUC measured when the racemate was administered (Figure 53 
D and Figure 54). Therefore, the combi-pill that will be used for the third Basel cocktail study has been 
reformulated, replacing (S)-omeprazole with the racemate to obtain PK profiles comparable to the ones 
after intake of the racemate. 
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Figure 54. Plasma concentration time-profiles of omeprazole and 5-OH-omeprazole after administration of omeprazole 
racemate and S-omeprazole.  
 
The PK profiles of metoprolol are not directly comparable because in the combi-pill immediate release 
metoprolol was used which is not available as a commercial formulation for clinical use (Figure 53 E). For 
midazolam a liquid low-dose formulation produced by the local hospital pharmacy was used for the 
Basel cocktail studies while the combi-pill contained the same dose as solid formulation, which was less 
well absorbed than the liquid formulation (Figure 53 F). 
 
8.1.3. Conclusions 
 
These results showed that combination of six low-dose phenotyping probe drugs with diverse physico-
chemical properties into one single combi-pill is feasible and that comparable PK characteristics can be 
observed when the formulation of the compound is not altered. The presence of enantiomeric forms or 
modified release mechanisms will cause differences that have to be taken into account when planning 
the Basel cocktail III bioequivalence study. On the other hand, the combi-pill also offers the opportunity 
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to optimize PK characteristics for the specific purpose of phenotyping. These aspects will be explored in 
future clinical projects. 
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8.2. Phenotyping of CYP1A2, CYP3A4 and quantification of erlotinib, OSI-
420, sunitinib, SU-12662, and pazopanib in plasma, blood and DBS in 
cancer patients 
 
8.2.1. Introduction 
 
Tyrosine kinases (TK) are enzymes that catalyze the transfer of phosphate groups from adenosine-
triphosphates (ATP) to tyrosine residues of target proteins and activate them. TKs control various 
processes in normal cells, and are also involved in oncogenesis [107, 108]. Thus, the inhibition of TKs by 
TK inhibitors (TKI) is used in targeted cancer treatment. TKIs such as sunitinib, erlotinib, and pazopanib 
are used to treat non-small-cell lung cancer and renal cell carcinoma. Due to their more selective nature, 
the respective side effects of TKI are less pronounced in comparison to adverse reactions caused by 
conventional unspecific cytotoxic chemotherapies. Nevertheless, therapeutic effect and toxicity are 
determined by patient exposure, which shows considerable variation after standard doses. Sunitinib and 
pazopanib are metabolized by CYP3A4 while erlotinib is additionally metabolized by CYP1A2. Activity of 
these metabolizing enzymes shows large inter-individual variability due to multiple factors (genetic and 
environmental), therefore adapted dosing according to the phenotype of the patient could result in 
improved clinical effect and/or tolerability.  
The main objective of the ongoing clinical study conducted together with the department of oncology at 
the Kantonsspital St. Gallen is to show that the individual CYP3A4 and CYP1A2 phenotype predicts drug 
exposure of sunitinib, pazopanib or erlotinib. 
A secondary objective is to test the feasibility of using dried blood spots (DBS) instead of conventional 
venous blood samples for drug analysis of these TKIs. Based on these results, an integrated covariate 
model on sunitinib, pazopanib, and erlotinib pharmacokinetics will be built and a dosing algorithm 
based on the individual CYP-phenotype will be proposed.  
Since the clinical study is still recruiting patients, only a small number of samples have so far been 
available for phenotyping and determination of drug concentrations. The following chapters describe 
the development and optimization of the analytical tools used to reach the objectives mentioned above, 
with special attention to DBS, a technique that facilitates blood sampling for both patients and medical 
staff, and could increase acceptance of therapeutic drug monitoring and phenotype testing. 
DBS collection is a micro-sampling technique. After a finger or heel prick, drops of blood are transferred 
onto blood collection cards and dried for 2 hours at room temperature. While conventional blood or 
plasma sampling requires volumes of at least 0.5 mL [109, 110], only 10-15 µL of capillary blood are 
sufficient for DBS. DBS has the potential to be a useful tool for TDM, as for instance the samples can be 
collected by the patients at home, without the support of medical personnel and be shipped by regular 
mail to the analytical laboratory. However, before replacing conventional wet sampling with DBS, the 
feasibility of reliable quantification of the drug of interest within the DBS, as well as the correlation 
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between concentrations measured in DBS and plasma or whole blood has to be assessed. Additional 
validation steps are required, to evaluate effects of hematocrit and blood volume.  
Although DBS sample collection is easier, the manual processing of DBS is more time consuming and 
laborious compared to conventional wet sampling. Thus the sample work-up automation and the use of 
a sensitive detection system were fundamental requirements to accomplish this project. We therefore 
established a collaboration with industry and academic partners. Camag, a Swiss company and world 
leader in thin-layer chromatography, supplied a newly developed autosampler which can be used for 
on-line DBS extraction. Shimadzu Switzerland, a key-player in chromatography and more recently also in 
MS equipment, supplied a UHPLC system coupled with a high end triple quadrupole mass spectrometer. 
The Division of Pharmaceutical Technology of Prof. Jörg Huwyler and Dr. Maxim Puchkov agreed to 
house the equipment in one of their laboratories, whilst providing logistical as well as scientific support.  
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8.2.2. Results and discussion 
 
A UHPLC-MS/MS method for the simultaneous quantitative analysis in plasma, blood and DBS of 
caffeine, paraxanthine, midazolam, 1’-OH-midazolam, sunitinib, SU12662, erlotinib, and OSI-420 was 
initially validated. Online DBS analysis was performed using a CAMAG DBS 500 autosampler coupled to a 
Shimadzu LCMS 8040 (Figure 55).  
 
  
 
Figure 55. Camag DBS-MS 500 and Shimadzu UHPLC and MS8040 (A). Camag DBS-MS 500, detail view of the automatized cards 
handler (B) and of the online extraction head (C).  
 
In plasma the method was specific, selective and linear in the range of 5-1250 ng/mL for sunitinib, 12.5-
5000 ng/mL for erlotinib, 1-250 ng/mL for midazolam and 1’OH-midazolam, and 50-5000 ng/mL for 
caffeine and paraxanthine. Intra assay CV% was lower than 8.1%, while inter assay CV% was lower than 
6.7% for all analytes. The total run time was 2.3 min.  
An additional TKI, pazopanib, was subsequently introduced in the study. A second UHPLC-MS/MS 
method was developed and validated for the quantification of pazopanib, sunitinib, SU12662, erlotinib, 
A 
B C 
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and OSI-420 in plasma, blood and DBS. The DBS method was specific, selective and linear in the range of 
350-70’000 ng/mL for pazopanib, 25-5000 ng/mL for erlotinib, 2.5-500 ng/mL for sunitinib, 5-
1000 ng/mL for OSI-420, and 1.5-100 ng/mL for SU12662. Intra assay CV% was lower than 9.7% (11.9% 
for LLOQ), while inter assay CV% was lower than 7.6% (10.5% for LLOQ) for all analytes. Total run time 
was 2 min.  
A representative chromatogram is reported in Figure 56. 
 
Figure 56. Chromatogram of a DBS sample containing 50 ng/mL of pazopanib, erlotinib, sunitinib, and 10 ng/mL SU12662, and 
OSI-420. 
 
DBS analysis was performed online by means of a DBS autosampler developed and produced by Camag. 
The entire process was automated and did not require any manual intervention. Up to 500 DBS cards 
can be stored, sequentially transferred to the extraction head, sprayed with the internal standard and 
extracted.  
Several additional parameters need to be validated when DBS rather than traditional blood samples are 
analyzed. Factors that need to be evaluated are: inter/intra-card variability, hematocrit, venous versus 
capillary blood sampling, anticoagulant, sample and spot homogeneity, internal standard addition, 
extraction recovery, sample dilution procedures, spotting technique and volume, punched spot size, 
sample stability and storage of cards (pre- and post-spotting) [111]. 
Of these parameters the effect of hematocrit, sample stability, and extraction recovery were considered 
to be of greatest importance and were therefore evaluated in this study. 
Hematocrit effect on TKIs and metabolites was investigated for a hematocrit range between 20 and 
60%. No significant changes of accuracy were observed for spots made by spiking 15 μL of blood. 
Sunitinib-d10 
Sunitinib 
OSI-420 
Erlotinib 
    Erlotinib-d6 
                      Pazopanib 
    Pazopanib-d3 SU12662 
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Accuracy deviation compared to the reference hematocrit value of 40% was between -21.8% and 15.1% 
(Table 23). For the phenotyping drugs and metabolites, the hematocrit effect was not evaluated. We 
assumed that if there was to be a hematocrit effect, its extent would be the same for parent compounds 
and their metabolites. Since metabolic ratios are used as phenotyping metric, a possible hematocrit 
effect would be cancelled out of the calculation. 
 
Table 23. Accuracy deviation compared to the haematocrit 40%  
  Hematocrit 
Analyte Concentration 
20 30 40 50 60 
Deviation compared to hematocrit 40% 
ng/mL % % % % % 
Pazopanib 1050 -10.9 -8.4 reference 6.3 15.1 5200 -9.9 11.6 7.0 12.4 
Erlotinib 75 -10.3 -0.6 reference 7.4 7.9 3750 -8.0 3.7 6.4 1.8 
Sunitinib 7.5 -21.8 -8.2 reference -2.3 -17.2 375 -7.8 3.0 1.0 -1.4 
OSI-420 15 -9.2 -2.5 reference -0.8 5.3 750 -4.6 5.0 7.3 0.9 
SU12662 1.5 -15.6 -10.0 reference -13.2 -14.4 75 -3.8 9.3 2.6 0.5 
 
An alternative procedure to avoid hematocrit effects is to analyze the entire spot. This implies to exactly 
measure the volume of blood used to create the spot. Accurate pipetting and spotting of small blood 
volume constitutes a routine procedure for a lab technician or a nurse but if the sample has to be 
collected directly by the patient or by non-trained personnel an acceptable reproducibility could not be 
assured.  
DBS stability in different conditions was evaluated. All analytes were stable for at least 24 days at -20°C, 
+4°C, and at room temperature (Table 24). 
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Table 24. DBS stability for at 24 days at -20°C, +4°C, and at room temperature 
  Change of concentration after 24 days  
Analyte Concentration RT protected from light 
RT exposed to 
light +4°C -20°C 
 ng/mL % % % % 
 1050 5.0 5.7 0.5 -5 
Pazopanib 5250 8.7 1.8 1.4 -0.4 
 52200 -0.5 2.8 -0.4 -0.6 
 75 2.0 0.9 2.6 -2.2 
Erlotinib 375 3.8 -2.5 -0.8 -1.1 
 3750 0.7 -0.5 1.8 0.5 
 7.5 2.2 -2.0 8.0 -0.6 
Sunitinib 37.5 -2.7 -3.5 -2.3 3.4 
 375 1.7 0.0 0.5 5.1 
 15 6.4 9.8 5.2 -3.3 
OSI-420 75 11.3 10.9 2.5 -1.7 
 750 3.4 3.9 1.8 -0.2 
 1.5 5.8 3.6 9.1 -9.8 
SU12662 7.5 12.3 6.6 10.9 6.9 
 75 -0.5 -0.8 -0.8 7.3 
 
The addition of the internal standard through an automated spraying process greatly improves accuracy 
and precision, as already shown by Zimmer et al [112]. 
Quantification of substances in different concentration ranges within the same sample could be a 
challenge, which is especially of interest in the analysis of DBS. Whilst low abundant compounds are 
difficult to detect in a small blood volume, too high concentrations samples have to be diluted. For this 
study, a sensitive triple quadrupole MS detector enabled us to balance out the sensitivity issue. DBS 
samples with a too high concentration can be diluted with DBS blank extract. However, with the DBS 
MS-500 on-line extraction system this approach is not possible. Therefore MS parameters, in particular 
collision energy, were optimized to reduce too high signals and avoid overloading of the photomultiplier 
of the mass spectrometer. 
The correlation between venous and capillary concentrations (DBS) of TKIs is currently under 
investigation in patient samples. These results will be used to evaluate the application of DBS for 
therapeutic drug monitoring of TKIs. 
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8.2.3. Conclusions 
 
Before a meaningful analysis of the correlation between individual CYP1A2 and CYP3A4 phenotypes and 
TKI exposure can be performed, a sufficient number of patients have to be recruited. Patient 
recruitment is expected to be completed by the end of 2013. The developed method will then facilitate 
the fast and reliable analysis of all patient samples of this clinical trial. 
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9. Final Conclusions and Outlook 
 
At the beginning of this project, our main goal was to develop and validate a new diagnostic tool for 
phenotyping of phase I drug metabolizing enzymes that would be easy to use and thus suited also for 
clinical applications. We imagined a phenotyping kit containing a pill, a collection tool for saliva or blood, 
a simple patient instruction sheet, and an envelope for shipping the sample to the phenotyping 
laboratory.  
During the last years several cocktails have been described. In general, they were well characterized in 
terms of mutual interactions between the probe drugs used and for few cocktails the analytical methods 
proposed were designed and validated for phenotype testing. Sampling simplification has been 
considered by several authors that proposed saliva or DBS sample collection for phenotyping of few CYP 
isoforms. However, despite some improvement, none of the already proposed cocktails has received 
general acceptance in clinical practice so far.  
With our studies, we showed that low doses of the phenotyping drugs of the Basel cocktail did not 
interfere with each other and did not provoke adverse effects. We proposed a simplified sampling 
procedure using metabolic ratios in plasma 2 hours after administration of omeprazole and midazolam 
for CYP2C19 and CYP3A4 or after 8 hours administration of caffeine, efavirenz, losartan, and metoprolol 
for CYP1A2, CYP2B6, CYP2C9, and CYP2D6 respectively. Although not generally accepted for all CYP 
isoforms (e.g. midazolam), our data showed that MRs obtained at a single time point showed high 
correlations with AUC ratios both under baseline conditions as in conditions with induced or inhibited 
CYP activity.  
We compared the pharmacokinetics profiles and metabolic ratios of the Basel phenotyping drugs at 
baseline levels, after co-administration of inhibitors, and a broad CYP inducer. We showed that plasma 
metabolic ratios provide valuable qualitative information on the activity of relevant drug metabolizing 
CYP isoforms and can be considered as a valuable alternative to the reference method based on AUC 
measurements. Induction of CYP1A2 was not effective, therefore we were not able to estimate if the 
MR for this CYP was responsive to induction. Losartan, the drug used to phenotype CYP2C9, produced 
metabolic ratios that were not sensitive to induction. For all the other CYPs plasma MRs could replace 
AUC estimation for induction monitoring. 
Alternative sampling procedures such as saliva and DBS would facilitate phenotyping and were explored 
in both clinical studies. The MRs in saliva and DBS for CYP1A2, and CYP2C19 are potential alternatives to 
MRs determined in plasma as they reproduced the results observed in plasma.  
The six low-dose phenotyping probe drugs used in the Basel cocktail were formulated into one single, 
three-layered combi-pill and tested in one healthy volunteer in a pilot study. Comparable PK 
characteristics were observed after intake of the combi-pill compared to the simultaneous intake of the 
probe drugs as separate formulations. The combi-pill offers the opportunity to optimize dose, 
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absorption, and release properties for the specific purpose of phenotyping. These possibilities will be 
explored in future clinical projects. 
The possibility of using phenotype information of CYP1A2 and CYP3A4 for dose individualization of TKIs 
is currently investigated in an ongoing a clinical study in collaboration with PD Dr. Jörger (department of 
oncology at the Kantonsspital St. Gallen, Switzerland) with a special focus on minimally invasive DBS 
sampling. The development of on-line DBS extraction for quantification of phenotyping drugs and TKIs 
has been performed. This method will facilitate the fast and reliable analysis of all patient samples. A 
meaningful analysis of the correlation between individual CYP1A2 and CYP3A4 phenotypes and TKI 
exposure will be performed as soon as the clinical study is completed (end of 2013).  
Development and validation of sensitive analytical LC-MS methods were fundamental for the evaluation 
of the considerable amount of samples generated in the first and second Basel cocktail study, in the 
combi-pill pilot and TKIs studies. In addition to high sensitivity, a short run time and the capability to 
measure the phenotyping drugs and their metabolites within the same analytical run using the same 
conditions, were fundamental requirements that are fulfilled by the method presented.  
The Basel cocktail is a promising tool for phenotyping of CYP1A2, CYP2B6, CYP2C9 and CYP3A4 using 
single point plasma measurement and for phenotyping of relevant polymorphic CYPs such as CYP2C19 
and CYP2D6 using both single point plasma or non-invasive oral fluid measurements. Beside the “solo” 
phenotyping application, administration of our cocktail in concomitance with a new drug in drug-
interaction studies, would simultaneously evaluate inhibitory or inducing potential on CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 
The phenotyping procedure proposed in this dissertation needs further validation and has not yet the 
format of a commercial kit. The acquisition of more reference data and the development of the combi-
pill, already planned, will be the next steps in this direction. 
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13. Poster presentations 
 
Poster 1, presented at the EBF conference (Barcelona, December 2009) 
Simultaneous quantification of Posaconazole, Voriconazole and Fluconazole in human 
serum by liquid chromatography–tandem mass spectrometry using on-line extraction
Donzelli M, Vetter B, Krähenbühl S , Haschke M
Analytical Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Switzerland
Introduction
Posaconazole and voriconazole are extended-spectrum
triazoles used for prophylaxis and treatment of invasive
fungal infections.
Increasing evidence suggests a relevant correlation of
drug-exposure with clinical effect and toxicity.
Dosing is complicated by large interindividual
pharmacokinetic variability and/or non-linear pharmaco-
kinetics (voriconazole).
Although there are no generally accepted target
concentration ranges, therapeutic drug monitoring
represents an important tool to optimize drug therapy,
especially in immunocompromised patients.
We describe a highly sensitive analytical method for the
simultaneous analysis of three frequently used triazoles
in human serum. The short run-time and online-sample
extraction make this method useful for routine
application.
Methods
.
Results
Our method fulfills all pre-specified validation criteria. It is specific, selective and
linear over the concentration range of 10 to 5000 ng/mL for posaconazole (R2
>0.998), voriconazole (R2 >0.997) and fluconazole (R2 >0.998).
Inter-assay precision for calibration samples were ≤7.1% for Posaconazole, ≤9.8%
for Voriconazole and ≤6.0% for Fluconazole.
Inter-assay precision for quality control samples were ≤7.9% for Posaconazole,
≤7.0% for Voriconazole and ≤6.4% for Fluconazole.
Recovery rates at concentrations of 50 ng/ml and 500 ng/ml were 76.7% and 70.0%
for Posaconazole, 96.5% and 92.2% for Voriconazole, and 101.6% and 94.5% for
Fluconazole, respectively.
The three analytes were stable in human serum after three freeze/thaw cycles and
for at least eight hours at room temperature.
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Comment: ""    Annotation: ""
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Mass Spectrometry Conditions
A triple quadrupole mass spectrom         
with a ESI source with the followin      
Ion Spray voltage: 5500 eV. Temp   
The selected mass-to-charge (m/z          
standard ions [M +H]+ used in the       
Posaconazole: m/z 701–m/z 683          
Voriconazole: m/z 350–m/z 281          
Fluconazole: m/z 307–m/z 238          
The dwell times are set at 50 ms fo     
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Poster 2, presented at the EBF conference (Barcelona, December 2010) 
New applications for an old technique: Clinical Validation of Dried Blood Spot 
(DBS) sampling for CYP1A2 phenotyping
M Donzelli, B Berger, S Krähenbühl, M Haschke
Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Switzerland
Results
Conclusions
Concentrations of caffeine and paraxanthine measured in DBS are highly correlated with concentrations in venous blood. The correlation between the concentration of an analyte in venous blood and
DBS can not be assumed a priori as already shown by several authors and by our group for Efavirenz. The reported procedure is an indirect clinical validation of DBS using analysis of caffeine and
paraxanthine in venous blood as reference.
DBS seems to be suited as minimally invasive sample collection technique for CYP1A2 phenotyping. Suitability of DBS for phenotyping probes of other CYP isoforms remains to be shown.
Methods
Figure 2. Linear regression analysis: DBS versus venous blood 
paraxanthine levels before and after caffeine administration.
Extensive efforts have been directed towards developing genotyping methods for detecting specific DNA mutations that determine individual drug metabolizing capacity. However, genotyping is not able 
to monitor changes of phenotype caused by non-genetic factors, e.g. drug-drug or drug-food interactions. Phenotyping provides a measure of the activity of a given drug-metabolizing enzyme taking into 
account not only genetic but also non-genetic and environmental factors.
Phenotyping involves the administration of an appropriate substrate that is selectively metabolized to a known metabolite by a given CYP isoform. Caffeine (CAF) is the probe substrate for CYP1A2 
phenotyping and the ratio between CAF and paraxanthine (PAR) is commonly used as phenotype measure.
Methods using dried blood spot sampling require formal testing of specific validation parameters (effect of blood spot sampling location, the sort of sampling paper, and the effect of blood volume 
spotted). Before replacing traditional venous sampling by DBS sampling cross validation using a sufficient number of subjects should be performed. We have investigated feasibility of DBS sampling for 
CYP1A2 phenotyping compared to venous blood sampling.
Background
In a clinical study that involved 46 healthy volunteers, we compared  concentrations of CAF and PAR in DBS samples and venous blood samples after dietary caffeine intake. After 2h of drying, blood 
spots were ready for further manual work-up and analysis by LC-MS/MS or storage. 
The method applied for caffeine and paraxanthine quantitation was sensitive (LLOQ 50 ng/mL), linear within the range 50-20000 ng/mL and inter-run precision and accuracy where within the 
recommended specifications. The correlation between caffeine and paraxanthine concentrations measured in DBS samples with the corresponding concentrations measured in venous blood 
evaluated by linear regression analysis showed a significant correlation between concentrations in DBS and venous blood samples.
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Figure 4. Bland Altman analysis: paraxanthine venous blood 
minus DBS level versus mean paraxanthine level
    
           
          
           
      
 
                 
               
                  
              
     
  
            
        
   
                 
            
           
            
    
Figure3 . Bland Altman analysis: caffeine venous blood minus 
DBS level versus mean caffeine level
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Poster 3, presented at the EBF conference (Barcelona, December 2010)
Pharmacokinetic profile of efavirenz in dried blood spot (DBS) samples. Comparison of manual 
sample preparation and automated on-line extraction with the CAMAG DBS-MS device
M Donzelli1, M Loppacher2, L Nezic1, S Krähenbühl1, M Haschke1
1 Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Switzerland
2 CAMAG, Sonnenmattstrasse 11, 4132 Muttenz, Switzerland 
Conclusions
EFV concentrations can be monitored even after a subtherapeutic dose using DBS samples. Use of the CAMAG DBS-MS autosampler increased precision compared to the manual DBS sample work-
up. Four collection cards (4 DBS per card, totally 16 samples) can be analyzed without manual handling. More than 130 DBS were analyzed without any system failure. The optimization of the
extraction conditions, method qualification, and sample analysis was performed in approx. four workdays. Carry-over and inter-day accuracy were not systematically evaluated but preliminary results do
not suggest presence of any systematic challenges.
To optimize therapeutic effect of certain drugs, therapy has to be individualized based on a patient’s genotype and/or phenotype. Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor for the
treatment of human HIV type 1 infection. Genetic polymorphism of CYP2B6 markedly influences metabolism of EFV and pharmacokinetic monitoring can help to avoid treatment failure or CNS toxicity.
Monitoring of EFV concentrations in DBS samples would facilitate outpatient management. Our goal was to test feasibility of analyzing EFV in DBS samples using the automated CAMAG DBS-MS
extraction device.
Background
Methods
After a subtherapeutic oral dose of 50mg, venous blood and DBS samples were collected from a healthy male volunteer for 96 hours. DBS samples were dried for 2h before conventional manual work-
up or automated extraction on a CAMAG DBS-MS autosampler. All samples were analyzed with a fully validated LC-MS/MS method using online-solid phase extraction, either using an external 
switchvalve or by integrating an extraction column into the CAMAG DBS-MS autosampler. 
DBS analysis – manual sample preparation
A disc with a diameter of 3 mm was cut out of the centre of the dried 
blood spot using a manual hole punching device. Each disc was mixed 
with 150 μl ISTD working solution (Efavirenz 100 ng/mL in MeOH). After 
vortexing and centrifugation, aliquots of 20 μl were injected into the LC-
MS/MS system.
Three discs per sample were punched, manually extracted and 
analyzed.
DBS-CAMAG analysis – automated sample work-up
Four collection cards were positioned in the autosampler. 
Each DBS was loaded on a trapping column integrated in the 
autosampler with extraction eluent (water/MeOH 1/1, Efavirenz 100 
ng/mL ). 
After 1.5 min the valve was switched and the analytes were eluted in 
back flush mode to the analytical column. Three spots per sample were 
analyzed.
Results
Figure 1: concentration-time profiles  of 
EFV analyzed in manually prepared DBS 
samples (A) and DBS samples extracted 
with the CAMAG autosampler (B).
Linear regression analysis showed a highly significant correlation for EFV concentrations 
obtained by the manual and the automated approach (R2=0.996). Bland-Altman 
correlation analysis did not show a difference between the two methods (bias :-1.21 ng/ml, 
all data points within the acceptance limits of -13.1 to 10.7 ng/ml). The mean precision 
estimated as CV% of triplicate analysis was 9.2% (range 1.7-28.7) for the manual work-up 
and 4.4% (range 0.2-6.6 %) for the CAMAG DBS-MS autosampler.
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Conclusions
The method fulfils the requested conditions concerning speed and reliability. It is suitable for TDM and will be expanded to analyze other tyrosine kinase inhibitors. Before a meaningful
analysis of the correlation between individual CYP1A2 and CYP3A4 phenotypes and TKI exposure can be performed, a sufficient number of patients have to be recruited. Patient
recruitment is expected to be complete by the end of 2013. The developed method will then be used for fast and reliable analysis of all patient samples of this clinical trial.
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Liquid chromatography
An Acquity UPLC HSS T3 column (2.1x50 mm, 1.8 mm,
Waters, Switzerland) was used for the separation of the
analytes. Eluent A (0.1% formic acid in water) and eluent B
(0.1% formic acid in methanol) were used with the following
gradient: 100% A from 0 to 0.1 min, 15% B from 0.1 to 0.3 min,
50% to 98% B from 0.3 to 1.4, 98% B from 1.4 to 1.75 min,
100% A from 1.75 to 2.3 min. The mobile phases were
delivered at a constant flow of 1 mL/min. Total run time was
2.3 min. The thermostated column oven was set to 55°C.
Mass spectrometry conditions
Mass spectrometric detection was performed using a triple
quadrupole mass spectrometer operating in electrospray-
ionization positive-ion mode. Samples were quantified using
peak area ratios.
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Fast UHPLC-MS/MS method to simultaneously quantify erlotinib, OSI-420, sunitinib, 
SU-12662, and pazopanib in dried blood spots (DBS)
D. Winogradova 1, B. Berger 1, B. Erxleben 2, U. Burger 3, M. Swiderska 4, M. Loppacher 4, M. Joerger 5, S. Krähenbühl 1, M. Haschke 1, M. Donzelli 1
Conclusions
Our method fulfills the requirements concerning speed and reliability. Online DBS analysis considerably reduces sample work up compared to manual punching. DBS samples were 
stable for 24 days at room temperature, at 4°C and -20°C. Hematocrit  values between 20 and 60 % did not influence accuracy. The correlation between venous and capillary 
concentrations (DBS) of TKIs is currently under investigation in patient samples. These results will be used to evaluate the use of DBS for therapeutic drug monitoring of TKIs.
Background
Sunitinib, erlotinib and pazopanib are tyrosine kinase inhibitors (TKI) used to treat non-small-cell lung 
cancer and renal cell carcinoma. Individualizing TKI doses may optimize drug treatment by avoiding 
subtherapeutic levels or toxicity. The method, previously validated according to the EMEA guidelines for 
plasma samples, was also validated for blood and dried blood spots (DBS). Additional DBS validation 
steps such as stability and the effect of the hematocrit were also evaluated.
DBS sample collection can facilitate blood sampling for both patients and medical staff.
From a technical perspective, conventional analysis of DBS is a challenging task. Each DBS spot is 
manually processed using a manual puncher, transferred into a test tube and extracted with a suitable 
solvent. Handling of a high number of DBS cards following the manual procedure is time consuming and 
error prone. In this study, automated on-line DBS extraction was performed using an on-line extraction 
system.
Results
The method was specific, selective and linear in the range of 350-70’000 ng/mL for
pazopanib (R2>0.989), 25-5000 ng/mL for erlotinib (R2>0.998), 2.5-500 ng/mL for
sunitinib (R2>0.998), 5-1000 ng/mL for OSI-420 (R2>0.998), and 1.5-100 for
SU12662 (R2>0.994). Intra assay CV% was lower than 9.7% (11.9% for LLOQ),
while inter assay CV% was lower than 7.6% (10.5% for LLOQ) for all analytes. Total
run time was 2 min.
DBS stability at three different concentrations up to 24 days at room temperature 
(exposed and protected from light), at +4 °C and at -20°C was tested (Table 1).
The effect of different hematocrit values was also estimated (Table 2).
All analytes were stable for 24 days at room temperature and were not sensitive to
light.
For all analytes accuracy was not affected by hematocrit values between 20% and
60%.
The method is currently being used in a clinical study investigating the correlation
between DBS and plasma concentrations of pazopanib, sunitinib, and erlotinib in
cancer patients.
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Pazopanib
  Hematocrit 
Analyte Concentration 
20 30 40 50 60 
Deviation to hematocrit 40 
ng/mL % % % % % 
Pazopanib 1050 -10.9 -8.4 0.0 6.3 15.1 5200 -9.9 11.6 0.0 7.0 12.4 
Erlotinib 75 -10.3 -0.6 0.0 7.4 7.9 3750 -8.0 3.7 0.0 6.4 1.8 
Sunitinib 7.5 -21.8 -8.2 0.0 -2.3 -17.2 375 -7.8 3.0 0.0 1.0 -1.4 
OSI-420 15 -9.2 -2.5 0.0 -0.8 5.3 750 -4.6 5.0 0.0 7.3 0.9 
SU12662 1.5 -15.6 -10.0 0.0 -13.2 -14.4 75 -3.8 9.3 0.0 2.6 0.5 
 
Table 2. Effect of different hematocrit values on D
  Change of concentration after 24 days  
Analyte Concentration RT protected from light 
RT exposed to 
light +4°C -20°C 
 ng/mL % % % % 
 1050 5.0 5.7 0.5 -5 
Pazopanib 5250 8.7 1.8 1.4 -0.4 
 52200 -0.5 2.8 -0.4 -0.6 
 75 2.0 0.9 2.6 -2.2 
Erlotinib 375 3.8 -2.5 -0.8 -1.1 
 3750 0.7 -0.5 1.8 0.5 
 7.5 2.2 -2.0 8.0 -0.6 
Sunitinib 37.5 -2.7 -3.5 -2.3 3.4 
 375 1.7 0.0 0.5 5.1 
 15 6.4 9.8 5.2 -3.3 
OSI-420 75 11.3 10.9 2.5 -1.7 
 750 3.4 3.9 1.8 -0.2 
 1.5 5.8 3.6 9.1 -9.8 
SU12662 7.5 12.3 6.6 10.9 6.9 
 75 -0.5 -0.8 -0.8 7.3 
 
         
    
 
